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1.1 Overture 
The skeletal muscle is a very adaptable organ responding evidently to the level of stress, or lack of 
stress, under which it is put. One of the most classic examples that reflects the degree of which the 
skeletal muscle adapts concerns its response to exercise-training. With the stress load of exercise, 
the ‘normal’ non-exercise physiological equilibrium, homeostasis, of various systems in the body, 
are tipped off balance. A sufficient long-term level of exercise would then shift or optimise these 
systems to be in balance with the ‘new’ normal, which means that adaptation is in progress 
(Kraemer, Fleck and Evans, 1996; Lambert and Borresen, 2006). During this process, regardless of 
how relatively short or long it may be, the performing individual is potentially subject to some level 
of skeletal muscle injury. 
The cause of the injury can be a combination of many different factors, some of which, differentiate 
between conditions, within which either elite athletes or recreational athletes are training or 
competing. One could say the training conditions, referring to the environment, the equipment, 
the trainer, the choice and setup of exercise programme, the periodic goals, etc. are more 
controlled and optimised for the elite athlete. Meanwhile, the recreational athlete whose drive 
might be principally of interest, enthusiasm and health benefits has less controlled training 
conditions and less optimised support system for guidance and prevention. Whilst these are 
relative parameters, it is quite reasonable to consider that the population of recreational athletes is 
more susceptible to a skeletal muscle injury in comparison with the population of elite athletes. 
Although the scope of this text is not to address the difference between these two groups per se, 
it is necessary to bear in mind the individual variability of performance along with different levels 
of what would be classified as a skeletal muscle injury. The optimisation or the lack of optimisation 
of the aforementioned training conditions also has its influence on how the variability is reflected 
within these two populations, even if the groups could be supposedly similar. These wide 
differences in muscle injuries amongst athletes (the degree of damage, the anatomical localisation, 
and the functional consequences) make it difficult to reach conclusive results from an 
epidemiological analysis. 
In the following chapters of the introduction, we will start with looking at the physiology of the 
skeletal muscle, its exercise-training, injury and regeneration, but most importantly, the application 
of hypoxia in the recovery of a tissue damage. We will then later look at the practical aspects of 
using plasma markers, gene expression profiles and simple weight measurements to trace a 
recovery profile. Throughout the text and to conclude the introduction, we will consider various 
angles to raise experimental integrity, most of which can be employed via internal quality control 
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by the investigative team itself. The dissertation may seem to touch upon various topics; still, an 
experimental strategy in physiological research that utilises various scientific techniques needs to 
successfully orchestrate all aspects in a harmonised manner. — On those musical notes, this pretext 
is titled ‘overture’ and summaries that conceptualise bigger sections are titled ‘coda’.  
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1.2 The Skeletal Muscle: From Injury to Recovery 
1.2.1 The Skeletal Muscle and Its Physiology in Brief 
1.2.1.1 The Macro- and the Microscopic Anatomy of the Skeletal Muscle Contraction 
The skeletal muscles are the contractile portions of an organism, attached through the fascia via 
tendons to the periosteum of bones and voluntarily produce movements or exert forces. The 
muscle structure is surrounded by different layers of the fascia, with the outermost layer being the 
epimysium encircling the organ as a whole and perimysium surrounding bundles (or fascicles) of 
several muscle fibres (or muscle cells), each composed of fused myocytes. Within the fascicles, 
endomysium separates individual cells and connects to the basement membrane which is closest 
to the cell membrane (or the sarcolemma) and acts as a supporting network. It carries capillaries 
that bring fresh blood with oxygenated haemoglobin and nutrients, etc. to the muscle fibres, which 
are left (to some extent) with waste products and deoxygenated haemoglobin molecules. It, 
furthermore, carries nerves with motor neurons that transmit action potentials to the fibres via 
synapses on the motor end-plate, and sensory neurons informing about the organ’s postural and 
contractile status. The motor end-plate on the sarcolemma is optimised with receptors to react to 
the acetylcholine neurotransmitter, diffusing from the synaptic bulb of the neurone axon terminal 
and across the synaptic cleft. The receptors alter electrolyte composition of the immediate 
environment on both sides of the sarcolemma, the exosol and the cytosol, through the opening of 
specific ion channels, resulting in a depolarised membrane potential with the action potential 
propagating along the membrane.  
The sarcolemma has dents of tubular network that extends the extracellular surface in contact with 
the cytosol (or the sarcoplasm) (Huxley and Taylor, 1958). The sarcoplasm contains glycogen (in 
glycogen granules), myoglobin to store and transport oxygen, creatine kinase to mobilise energy 
supplies, organelles such as the mitochondria, eccentrically localised nuclei and the Ca2+-containing 
sarcoplasmic reticulum encircling the contractile organelles (the myofibrils). The myofibrils extend 
throughout the length of the muscle cell/fibre linked to the sarcolemma via dystrophin (a structural 
protein). Moreover, the myofibrils have interactive and highly organised protein compartments 
called sarcomeres arranged between the polarised ends of the myofibrils, within each organised 
filament protein structures lie, called myofilaments. Opposite ends of each sarcomere are marked 
by a dense protein plate called Z-discs. From both sides contractile proteins (the thin filaments), 
extend towards the middle of the sarcomere, though bluntly ending, supported and linked to the 
Z-disc by the structural proteins nebulin and α-actinin. Actin has binding sites for the other 
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contractile protein filament, myosin (the thick filaments), which is continuous through the middle 
of a sarcomere without extending the entire length from Z-disc to Z-disc. The repetitive hexagonal 
arrangement of actin filaments surrounding each myosin filament can be seen in a transverse 
section where the filament structures overlap within the sarcomere (Huxley, 1953). The myosin 
filaments are centrally linked and held in place via myomesin which forms the M-line of a sarcomere 
— in the middle where myosin is not overlapped with actin. The M-line is linked to both Z-discs 
with titin, which also stabilises the myosin filaments and, furthermore, attaches to α-actinin.  
The interactions between the contractile proteins, actin and myosin, are the mechanical basis of a 
contraction occurring when myosin heads of the myosin filaments are linked to the binding sites 
on actin. These binding sites are mechanically regulated by tropomyosin which is regulated by the 
troponin complex (better explained in chapter 1.4.3.3) which, in turn, are regulated by Ca2+. — Recall 
the existence of Ca2+-containing sarcoplasmic reticulum. — The sarcolemma’s action potential 
activates a voltage-dependent release of Ca2+ from the sarcoplasmic reticulum allowing it to bind 
to the troponin complex. The Ca2+-binding facilitates the movement of tropomyosin away from 
the binding sites on actin for myosin. At this stage we have now coupled the cellular excitation (via 
the action potential) with the contractile properties; referred to as the excitation-contraction 
coupling (Ríos, Ma and González, 1991; Franzini-Armstrong and Jorgensen, 1994). The myosin 
head structure of myosin contains an ATPase and can bind ATP that is immediately hydrolysed 
(ADP + Pi) but hanging on to the phosphate, leaving the structure energised. When the myosin 
heads can bind to actin, forming the cross-bridges, they release the phosphate group, perform the 
power stroke, a ‘forward’ movement of the myosin head, which structurally opens and releases the 
ADP. The cross-bridges remain linked until another ATP molecule binds to the myosin heads, at 
which point, they detach from actin. In a structurally favourable position, the energised myosin 
head binds to the next binding site along the actin filament (Page and Huxley, 1963; Huxley and 
Simmons, 1971; Rayment et al., 1993). The cross-bridges generate force as the movement cycle 
slides actin past myosin, on both ends, towards the centre of the sarcomere, bringing the Z-discs 
closer together, and the sarcomere shortens. For all these actions a sarcomere is called the basic 
functional unit of a myofibril.  
1.2.1.2 The Contractile Attributes of the Skeletal Muscle 
In a simplified manner, the muscle contractile function can be described with two variables, one 
that describes its length or the change in length and the other that describes the tension or the 
change in tension. The tension in the muscle is equal to the force it is generating which, in turn, is 
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proportional to the number of myofibrils and the contractile filaments overlapping length that are 
partaking in the contraction work (Huxley and Niedergerke, 1954; Gordon, Huxley and Julian, 1966). 
If the length of the whole muscle, or isolated myofibril, is kept constant during a contraction, that 
is, the contraction does not alter the immediate size, we are perceiving an isometric contraction 
which produces static muscle work. On the contrary, if the tension is kept constant during a 
contraction (via applied stable load) throughout a length-change, we perceive an isotonic 
contraction which produces dynamic muscle work. This behaviour is due to the presence of a series 
of elastic components (such as tendons) with a great mechanical compliance. The skeletal muscle, 
in addition to its contractile (plastic) components, namely the sarcomeres, is endorsed with both 
elastic and viscous components due to the physical properties of the other tissues surrounding the 
myofibrils. The elastic components are connected in series or parallel to the contractile apparatus. 
The parallel elastic elements provide the muscle with passive elastic properties derived from their 
membranous components (from sarcolemma to fascia), whereas, the series elastic components 
give it a passive elasticity derived from the action of contractile elements on tendons when the 
muscle is stretched. The viscous components (nervous tissue, capillaries) hinder the movement of 
the muscle but are still essential for a correct function of the system. These structural arrangements 
combined render the muscle with remarkable biomechanical properties (Levin and Wyman, 1927; 
Mathur et al., 2001).   
The dynamic range of a striated muscle is quite straight forward (or backwards, for that matter). We 
can produce a concentric action, where the sarcomeres are shortening, and the fibres are 
producing a force that overcomes an external resistance. Alternatively, the opposite occurs with an 
eccentric action, where the fibres are producing force but the external resistance, moving in the 
opposite direction of the shortening of the sarcomeres (Rivera-Brown and Frontera, 2012) slows 
down or prevent the lengthening of muscle fibres. The fibres, furthermore, contract and relax at 
different speeds due to different cellular composition and how quickly the ATPase in the myosin 
heads hydrolyses ATP (Karp, 2001). Red fibres are more capillarised, with a higher concentration of 
myoglobin and have more and larger mitochondria; thus, mainly generate ATP via aerobic cellular 
respiration. The combination of these factors, along with generally smaller cellular diameter, makes 
the fibres more fatigue-resistant. Their myosin head-ATPase rate is relatively slow, resulting in a 
slower paced contraction cycle, hence, bear the name of slow oxidative fibres (type I). Fast oxidative-
glycolytic fibres (type IIa) are also red in their appearance as they have similar properties as the type 
I fibres, apart from being slightly larger in diameter and having high intracellular glycogen content 
meaning that they, furthermore, generate ATP via anaerobic glycolysis. Moreover, the myosin 
heads have an ATPase that hydrolyses ATP at a greater rate in comparison with type I fibres 
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(Bottinelli et al., 1994; Capitanio et al., 2006), making type IIa contract at higher speed. Lastly, in 
contrast to fibre types I and IIa, fast glycolytic fibres (type IIb) are white in colour and sparsely 
capillarised. They have high intracellular glycogen levels and form ATP via glycolysis as their main 
metabolic route, having simultaneously low myoglobin content and few mitochondria, thus, 
adapted for intense anaerobic work but fatigue quickly. These fibres are the largest in diameter, 
containing many myofibrils which endorse them with more powerful contractions in comparison 
with the other fibre types, and a fast contraction as the myosin head-ATPase hydrolyses ATP even 
quicker than in fibre type IIa (Bottinelli et al., 1994). The majority of skeletal muscles are 
heterogeneous because they contain all of these three main types of fibres and, furthermore, hybrid 
fibre types (for example, type IIx between type IIa and IIb). The proportions between the fibre types 
reflect the general action carried out by the muscle as a whole (Pette and Staron, 2000). The postural 
muscles are rich in slow fibres, whereas muscles recruited only for quick and potent actions usually 
have a large portion of the fast contracting fibres. 
1.2.2 Exercise-Training and Skeletal Muscle Injury 
1.2.2.1 Different Types of Skeletal Muscle Exercise-Training 
Skeletal muscle can be markedly affected by exercise training reflected in both structural and 
biochemical changes along with other physiological characteristics such as: altered blood flow; 
increased heart rate, breathing rate and sweat rate; secretion of stress hormones and increased 
body temperature; and increased oxygen consumption and glycolytic flux (Lambert and Borresen, 
2006). The nature of the exercise, regarding duration and intensity, conducts the level of different 
changes, potentially occurring as an adaptation to different types of physical stress (Coyle, 2000; 
Garber et al., 2011), making the end goal a key factor in determining the structure of the exercise-
training. Still, in the work of Häkkinen et al. (2003), whilst the authors reiterate the divergent nature 
between the two variables, duration and intensity, for endurance-focused training or strength-
focused training respectively; they also emphasise that they do not have to be worked on entirely 
separately. The preferred parameter to evaluate endurance training is generally the maximum 
oxygen uptake, V̇O2,max. In the work of Bassett and Howley (2000), the authors review the limiting 
factors for V̇O2,max, which are indeed the central and peripheral training-related changes (mentioned 
above). The central factors concern the pulmonary system’s diffusing capacity to saturate the 
arterial blood with O2; the maximal cardiac output via the stroke volume and the velocity of the 
blood flow; and the oxygen carrying capacity of the blood via the concentration of haemoglobin 
(Hb) which carries the O2. The peripheral factors concern the characteristics of the skeletal muscle 
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in terms of the PO2 diffusion gradient over the surface of the O2-delivering red blood cells and the 
sarcolemma facilitated by the mitochondrial O2 uptake (Honig, Connett and Gayeski, 1992) which, 
in turn, is influenced by the increased mitochondrial mass by means of exercise (Essig, 1996). 
Furthermore, the surface area and the transit time is augmented with increased capillary density as 
a response to training (Saltin, 1985). 
Continuous or repeated eccentric work of a muscle that is generally unaccustomed to the work is 
likely to be felt weak as a primary consequence of a muscle damage. Whilst pain, tenderness, 
swelling and stiffness ‘may be secondary manifestations of acute inflammation triggered by some 
aspect of the muscle damage’ (Armstrong, Warren and Warren, 1991 and Smith, 1991 cited in 
Allen, 2001, p. 311). 
1.2.3 The Physical Damage in Exercise-Induced Skeletal Muscle Injury 
A clear definition of what accounts for skeletal muscle injury is somewhat still a debate. In their 
review, Brancaccio, Lippi and Maffulli (2010) divide the types of injury into two groups: indirect and 
direct damage. Whilst the authors generally assign the indirect type as the result of clinical and 
pathological conditions, such as drug use, hyperthermia, electrolyte alterations or pathogenic 
infections; they classify the direct muscle injury as more trauma and exercise related. The direct 
muscle injury is, in turn, defined as a loss of muscle function caused by the physical disruption of 
muscle structures involved in producing or transmitting force (Proske and Allen, 2005; Slater et al., 
2005; Tiidus et al., 2008). With a focus on the exercise-induced injuries, the physical disruption of 
the skeletal muscle fibre can be defined even further depending on where the damage takes place 
in the macro- or the microstructure. Although this is also true for trauma-induced injuries, we will 
leave those for more macro-level disruptions whilst the exercise-induced damage is often 
recognised to be more subtle.  
When considering the microstructure, or the cell structure, the spotlight is naturally directed 
towards disruption within the functional units of the contraction, the sarcomeres, or proximal 
disruptions that cause relaying effects. The notion of sarcomere disruption is certainly not a new 
one. Embedded within normal units, displaced sarcomeres have been observed along with 
disrupted Z-disks and half-disrupted sarcomeres, reported in the work of Newham et al. (1983) — 
and throughout the years, the increased mechanical loading and longer muscle fibre length have 
been linked to a higher sarcomere disruption in a single eccentric-contraction studies (Brown and 
Hill, 1991; Talbot and Morgan, 1998). Furthermore, damages to other cytoskeletal elements also 
facilitate the disruption of the sarcomeres, given that they contribute to the integrity of the 
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myofibrillar structure, for example, the disruption of desmin (Lieber, Thornell and Fridén, 1996) and 
dystrophin (Komulainen et al., 1998). The sarcolemma is also likely to get disrupted, potentially 
allowing the intracellular components to seep into the blood which can be detected as markers of 
injury, as further discussed in Chapter 1.4. Studies have, furthermore, revealed that fast glycolytic 
fibres (type IIb) are more easily disrupted in comparison with slow fibres (type Ia) in particular. The 
reason relates to both the rigorous effects in fast fibres from metabolic inability to regenerate ATP 
and perhaps more cytoskeletal structural support within the slow muscle fibres (Friden, Sjostrom 
and Ekblom, 1983, cited in Patel et al., 1998; Patel et al., 1998). 
Research started to focus on eccentric-contraction induced injury once studies revealed that the 
damages it causes were greater in comparison with concentric-contraction induced injury (Davies 
and White, 1981; Friden, Sjostrom and Ekblom, 1983, cited in McCully and Faulkner, 1985). McCully 
and Faulkner (1985), further established this notion when they demonstrated the link between the 
higher level of force loss and histological damage to eccentric contraction in comparison with 
concentric and isometric contraction. Since then, the mechanical properties of eccentric contraction 
have been found to play the key role in injuries (Warren et al., 1993) and, as an experimental model, 
are now considered particularly injurious for skeletal muscle.  
Given that the disruption of parts of the skeletal muscle fibres appears to be fairly scattered, even 
when the eccentric-contraction model is used, it seems quite puzzling that relatively more 
decreased force measures do not seem to be proportional to the overall structural damage. 
Investigators have observed that the eccentric-contraction model also alters the structure of the T-
tubules (Takekura et al., 2001; Yeung et al., 2002), which in turn might impair the excitation-
contraction coupling. This might, moreover, contribute to loss of calcium homeostasis, given that 
the ‘coupling lies in the junctions between the T-tubules and the sarcoplasmic reticulum’ (Ingalls et 
al., 1998). With a focus on the coupling alterations, Warren et al. (2001) claim they are indicative of 
playing a key role in strength loss with an injury. 
1.2.3.1 Repairing the Damaged Skeletal Muscle Fibre 
As mentioned above, when skeletal muscle suffers an exercise-induced injurious event some 
muscle fibres lose part of their internal structural integrity and the sarcolemma can be disrupted. 
Local nuclei die as part of the fibre’s localised necrosis, leaving a ‘gap’ filled up with haematoma 
initiating inflammatory reaction (Carlson and Faulkner, 1983; Hurme et al., 1991). Neutrophils enter 
the injured area releasing free radicals, that target the cellular debris for phagocytosis, and secrete 
pro-inflammatory cytokineases, promoting the inflammation (Wiedow and Meyer-Hoffert, 2005). 
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Migrating macrophages release digestive enzymes that break down extracellular matrix and debris, 
which is also aided by the fibre’s own lysosomes. The disrupted sarcolemma activates satellite cells, 
which are myogenic precursor cells, located between the sarcolemma and the basal lamina, and 
they start to differentiate into myoblasts. The cells align themselves on the basal lamina and fuse 
into myotubes and continue to differentiate and synthesise myofibrillar proteins (Hawke and Garry, 
2001; Chargé and Rudnicki, 2004). With time the nuclei start to get pushed towards the periphery 
and will start to appear like a mature skeletal muscle fibre. To begin with, the fibre will not be able 
to contribute to the contraction force as before damage, still, as mentioned earlier, it is very 
adaptable, and Donovan and Faulkner (1987) discovered that regenerating fibres adapt even more 
rapidly in comparison with the already existing ones. 
Some biochemical pathways of inflammation, in relation to regenerating muscle fibre, are specific 
to the general actions of leukocytes, for example, in common with their ‘actions’ in wound healing. 
In Chapter 1.5.2, these processes behind the regeneration of a skeletal muscle fibre and the 
inflammation will be revisited in relation to their gene expression profiles. 
1.2.4 Hypoxia and Exercise as Rehabilitation to Actively Improve Skeletal 
Muscle Fibre Regeneration 
Active rehabilitation via exercise has been backed up with experimental evidence (Kannus et al., 
2003; Järvinen et al., 2005), to be beneficial to the regeneration of the injured skeletal muscle. 
Although immediate immobilisation is necessary after injury, mobilisation should start as soon as 
possible, refraining from high-intensity exercise to avoid re-rupture. The early onset of exercise is 
crucial to the induction of the appropriate molecules and the correct orientation of the 
regenerating myofibres (Kääriäinen et al., 2001; Kannus et al., 2003; Järvinen et al., 2005) along with 
augmented mobilisation of progenitor cells with exercise (Möbius-Winkler et al., 2009). Hence, 
totally passive rehabilitation is therefore not recommended (Hurme and Kalimo, 1992; Kääriäinen 
et al., 2000) although immobility will not impede the cell from regenerating. 
Furthermore, intermittent hypoxia exposure has been observed to augment the angiogenic effects 
(Panisello et al., 2008) and to increase mobilisation of circulating stem cells (Serebrovskaya et al., 
2011). However, Viscor et al. (2009) demonstrated that circulating stem cells count could be 
improved significantly after acute hypoxia in combination with muscle electrostimulation. These 
findings point towards the potential benefits of the aforementioned factors which could improve 
the regeneration process of an injured skeletal muscle. Let us have a closer look at what is meant 
by hypoxia and what that entails. 
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1.2.4.1 Hypoxia 
Hypobaric Hypoxia and Normobaric Hypoxia 
Starting with atmospheric pressure and how altitude and temperature affect it in comparison with 
a sea level reference (normobaria); one needs to consider that with altitude the atmosphere gets 
thinner and, therefore, the overall pressure exerted by the gas molecules is, in turn, reduced 
(hypobaria). This means that atmospheric pressure decreases as a function of increased altitude. 
Furthermore, as the gas molecules weigh down on and compress the ones beneath them, the 
change in the atmospheric pressure with altitude is steeper closer to the surface of the earth. 
Moreover, as pressure decreases with lowering temperature, the decreasing rate of atmospheric 
pressure with altitude is enhanced even further as temperatures drop with altitude as well. These 
variables are described in the ideal gas law incorporating the classic Boule’s and Charles’ laws 
regarding the relationship between pressure, volume and temperature. The atmosphere, being a 
mixture of several molecules, has its proportion of oxygen (O2) at about 20.95% and, apart from 
the water vapour, its gas composition is remarkably stable with altitude. Thus, with respect to the 
gases of physiological importance (oxygen, carbon dioxide and nitrogen) the concentration is 
uniformly decreasing but not the fractional concentration between these molecules. The 
atmospheric pressure is the sum of the partial pressures exerted by these individual gases, each 
exerting pressure in relation to its own concentration (as per Dalton’s law). (Schmidt-Nielsen and 
Duke, 1997; West, Schoene and Milledge, 2007).  
In general terms, hypoxia refers to a low quantity (or concentration, for a more relative reference) 
of O2, that is, a reduced partial pressure of O2. With altitude, as the barometric pressure decreases 
(hypobaria) reflecting the reduced total atmospheric pressure, the partial pressure of O2 has 
simultaneously decreased, that is, hypobaric hypoxia. Normobaric hypoxia is essentially a play on 
lowering the O2 concentration on a sea level atmospheric pressure. The consequence of either 
application would be reduced inspired pressure of oxygen resulting in hypoxemia within the body, 
meaning, less oxygenated arterial blood delivered to tissues, therefore, less oxygen for cellular 
respiration. An experimental analogue for hypobaric hypoxia requires reducing the total barometric 
pressure with air suction of a confined space with regulated vacuum pumps. The concentration of 
each gas molecule is equally reduced, hence the partial pressure of O2 is reduced. The analogue 
setup for normobaric hypoxia would aim to reduce the concentration of O2 alone (resulting in the 
drop of its partial pressure) but replacing it with an inert gas (for example nitrogen) to maintain the 
total barometric pressure at normobaric levels. Exposure to these conditions, natural or 
experimental (simulated), just as when performing exercise, is an exposure to a physiological stress 
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and a cascade of reactions which take place with the intention to keep homeostasis. The nature 
and the level of the response are dependent on the duration and the intensity of the exposure, 
where here, the intensity refers to the O2 partial pressure difference with reference to a normoxic 
value of about 150 mm Hg (Conkin and Wessel, 2008). 
The Types and the Effects of Hypoxia Exposure 
A short one-time exposure is normally classified as acute hypoxia and triggers immediate 
physiological responses. A chronic hypoxia exposure is a prolonged exposure (and as long as it 
does not induce pathological effects) promotes acclimatisation in natural circumstances. The 
corresponding adaptation in laboratory condition is referred to as acclimation (Schmidt-Nielsen 
and Duke, 1997; Hochachka and Somero, 2002). An intermittent hypoxia exposure refers to 
alternating between hypoxic and normoxic conditions, and in controlled settings, seeking the 
benefits of favourable adaptations to the hypoxic environment with exposures that are short but 
relatively intense (Beidleman et al., 2004). It is, furthermore, necessary to consider non-atmospheric 
related types of hypoxia experiences on a tissular level, even though those can be caused or in 
combination with external factors (such as atmospheric pressure change). Let us consider, for 
example, reduced or restricted blood flow (ischemia) causing insufficient delivery of O2 to tissues. 
Restricted blood flow due to contracting big muscle groups can create a hypoxic environment for 
smaller tissues during exercise, and furthermore, the metabolic need for O2, enforced by high-
intensity exercise, can also be considered a form of hypoxic stress. Moreover, tissues that are 
relatively poorly capillarised also have a hypoxic gradient towards the cells furthest away from the 
capillaries. 
The systemic effects of hypoxia exposure are several. The cardiac output increases, mainly due to 
increased heart rate, which is a physiological adjustment driven by a remarkable autonomic 
sympathetic response, accompanied by increased ventilatory exchange (Jouett et al., 2015). This 
sympathetic drive also leads to increased haemoconcentration due to both the evaporative water 
loss caused by increased ventilation and the augmented diuresis. Although the most prominent 
effects are tachycardia and hyperventilation, increased haemoconcentration also helps to maintain 
the oxygen delivery to tissues by increasing the oxygen transport capacity of the blood (Grover, 
Weil and Reeves, 1986).  
After this ‘emergency’ responses onset, if hypoxia exposure persists, several responses are initiated 
at endocrine level and also as a consequence of the hypoxia direct effects on the cells through a 
complex cascade of intracellular signalling pathways. These pathways are elicited by the hypoxia-
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inducible factor (HIF) that acts as a master switching molecule in order to modify the gene 
expression of the cell if hypoxia conditions persist. 
Furthermore, in conditions of an altitude around and higher than 2500 m, the condition of acute 
mountain sickness can develop in humans (Harrison et al., 2013). This is the reason for which most 
of the altitude training centres around the world are sited between 2000-2500 m above sea level. 
1.2.4.2 Intermittent Hypoxia Exposure 
The adaptive physiological responses of the training method of live high-train low are becoming 
increasingly renowned for enhancing endurance performance by athletes (Wilber, 2001; Richalet 
and Gore, 2008; Millet et al., 2010). The analogues to simulate the altitude for performers are either 
via normobaric hypoxia exposure or hypobaric hypoxia exposure.  
It is still under debate whether the two analogues elicit the same physiological responses given that 
the fundamental stimulus is presumed to be the partial pressure of oxygen (Self et al., 2011). 
Although, there is growing evidence suggesting that tissues might be under more oxidative stress 
in hypobaric hypoxia (Faiss et al., 2013; Coppel et al., 2015). However, the duration and the hypoxic 
level of exposure that should comprise the intermittency has not been standardised and varies 
somewhat between studies (Coppel et al., 2015). Nevertheless, other studies focusing on the effects 
of intermittent hypoxia exposure on the myocardium and skeletal muscles demonstrated 
capillarisation increase (Panisello et al., 2007) and oxidative metabolism shift of active fibres (Esteva 
et al., 2009). These results make the idea of potential benefits of intermittent hypoxia exposure 
programs during skeletal muscle injury recovery a favourable application. 
1.2.5 Rodents as Experimental Models for Exercise-Induced Injury 
In order to either study the type or level of skeletal muscle injury and subsequent regeneration with 
or without rehabilitation interventions, one needs to start by acquiring the occurrence of the injury 
itself. The experimental setup with humans running downhill on a treadmill, considers the 
performer to eccentrically contract the muscles that brake off the running movement to avoid 
falling over. Above, we have established that the eccentric-contraction model results in more 
injured muscle tissue and in their work Newham et al. (1983) have also demonstrated that 
concentric contraction resulted in minimal injury. This is useful to bear in mind when intending to 
implement active rehabilitation, as the concentric contraction of the injured muscle will potentially 
aid the regeneration whilst minimising possible re-rupture.  
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Rodent models are popular for investigating skeletal muscle injury. Whilst rabbits are more used 
for trauma injury-models, mice and rats are popular for exercise-contraction injuries, having them 
running on a treadmill. The damage induction with rats (and mice) have been demonstrated to 
occur both during downhill and uphill running for 60-200 min and at speed between 0.25 and 0.42 
m/s (Armstrong, Ogilvie and Schwane, 1983; Kasperek and Snider, 1985; Peeze et al., 1989; Van der 
Meulen et al., 1993; Kasuga et al., 1999; Tiidus et al., 2001). However, Taylor, Caldwell and Rowntree's 
(1972) study support the fact that downhill running is a more energy-efficient eccentric contraction. 
Notably, m. soleus seems to suffer tissue damage during both of these types running, still, not the 
only muscle. Nevertheless, there are contradictory speculations as to why the muscle responds in 
both conditions with respect to its stretched length in the hind limbs whilst a rat runs (Newham et 
al., 1988; Komulainen, Kytola and Vihko, 1994; Gosselin, 2000). 
1.2.6 Coda 
The physiological groundwork has been laid down, and it is now time to look at an experimental 
model and how one can recreate recreational athletes. Whilst it is a loose term for an investigation, 
‘recreational’ athlete, the conditioning needs to be stable and repeatable, or at the very least, be 
known. After all, the effect of a specific induction of muscle damage is likely to be different based 
on the previous condition of the ‘wounded’. Still, irrespective of the different level of skeletal muscle 
injury occurring in everyday athletes or intentionally induced in experimental models, the 
subsequent chapters will address how the damage is assessed or measured indirectly. The meaning 
of indirect measuring is not to be confused with the above-explained difference between direct 
and indirect injury, as the assessment will indeed involve direct injuries.  
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1.3 Training Conditioning 
1.3.1 Run-training for Rats 
Rats are relatively intelligent in comparison with other, smaller rodents. As runners, they are prone 
to short voluntary bursts of discontinuous running (Squibb, Collier and Squibb, 1977). Perhaps, 
unless there is a continuous threatening reason, their proneness reflects a natural tendency of 
stopping and checking if there is anything to run away from. Smaller rodents are likely to evaluate 
their environment differently, and the difference is reflected in different types of treadmills designed 
for rats versus those designed for mice, for example, when carrying out run-training. Whilst a 
moving treadmill belt beneath the mice is, perhaps, stimulant enough to keep them running, rats 
do need an additional stimulus to keep them on the moving belt. 
The majority of treadmills designed for rats rely on mild electric shock to keep them running. The 
electric shock is mediated via a metal grid (Fig. 1-1), located just behind the treadmill belt, and a 
shock is received every time the grid is touched. The word ‘shock’ in this context, might come across 
as quite harsh. However, the intensity of the stimulus is relatively low and of accepted level, and 
perhaps should rather be considered as ‘uncomfortable’ than ‘harmful’. Although that would refer 
to physical implications, whilst emotional stress linked to the shock might mirror a different reaction 
pattern. Nevertheless, the intensity should, in theory, serve the purpose of making the rats 
recognise what they should be avoiding doing. Then, given that the treadmill belt and the metal 
grid are walled off, a rat will, therefore, either touch the grid and receive electric shocks or stay on 
the moving belt and run.  
 
Fig. 1-1. Schematic drawing of a treadmill for rats based on Harvard Apparatus (USA). 
Some manufacturers also design the treadmill apparatus with a controlling hardware that counts 
the number of shocks and the duration of each shock. These parameters can then be used to 
evaluate how a rat has been running considering how many electric shocks it has received and for 
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how long time.  The logic is extremely straight forward. A rat that is a good runner might receive 
the occasional electric shock, still, will have a relatively low electric shock count summing up to a 
short duration. In contrast, a rat that has not been running well and is continually touching the 
metal grids will have a higher shock count with an accumulating duration reflecting that count. A 
duration of an electric shock is normally a question of a fraction of a second — unless the rat can 
withstand the intensity and decides to stay on the grids for a bit. 
1.3.1.1 The Training Sessions 
Naturally, there is no one way of constructing a training session on a treadmill. The design simply 
has to fit its purpose. Although, it is fair to say that the use of the word ‘simply’ in the context of 
designing a series of training sessions, can mean ‘a wild stab in the dark’. It is relatively easy to judge 
if a rat is a really good runner or a terribly bad runner, and by that measure, if a protocol is 
appropriate or not. However, unless one could speak the squeaky language of rats, that is as far as 
reliability goes in terms of estimating the success of a training session. Clearly, it is not ethically 
sound, when working with laboratory animals, to base the design on a simple trial and error. 
Furthermore, what do we do with rats that are between being good and bad runners? Do we 
consider them as outliers? — If so, where do we draw the line of acceptance? 
When looking through the literature it is safe to say that the majority reports sparsely on the training 
setup, and any comments on selecting the rats based on their success as runners is even poorer. 
Therefore, one could easily make the assumption that either throughout or by the end of the 
training period all the rats in a given study, pretty much ran with identical success. In Table 1-1 a 
comparison of training session on treadmill is listed. Although the parameters have been adjusted 
to the same units and all calculated parameters are demonstrated, although not specifically 
reported in this by each author, the information is still fairly fenestrated, especially with the mindset 
of inter-laboratory reproducibility. Nevertheless, published references like these are the only once 
available for one to be able to create a new protocol. 
1.3.2 The Problems with Treadmill-Running 
The treadmills for rats are normally not just walled off to the sides but rather boxed in, with air 
ventilation holes, in order to prevent the rat from potentially jumping away. As such, a closed 
system, the electric shock is the only direct implementation to make sure that the rat runs properly 
on the belt, without opening the encasing. A rat that is very stressed out by the combination of 
running and receiving electric shock, might momentarily ‘freeze’ on top of the grid. Increasing the 
intensity might work to get the rat to pop of the grid, but not necessarily, and some the rat needs  
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Table 1-1. An example of studies with rats running on treadmill and the provided protocol information. 
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to be manually pushed off. To push a rat of the grids, requires opening the encasing, and at that 
point rats can potentially escape. Furthermore, especially when rats are stressed, the leave faeces 
and urine on the treadmill belt, whilst running, which if touches the metal grids will be accounted 
for as an electric shock by the apparatus. To take that even further, droplet or solids stuck on the 
metal grid, will come across in the resulting electric shock parameters as if the rat in question was 
staying on the metal grid for considerable time. All of these actions reduce the reliability of the 
shock count parameters for the usage of estimating successful running — especially this runs 
through without any observations.  
Up until now, there does not seem to be any ultimate solution. Some of the design elements of the 
treadmill have been approved, whereas older features gave the rats opportunity to clutch on and 
hang on to the walls, in order to avoid running. However, those improvements only address part 
of the problem. Other issues are related to the metal grids specifically; the counting apparatus does 
not differentiate between a rat that is continually touching the bar, or a piece of faeces, stuck on 
the bar. Addressing that can be troublesome without disturbing the running rat or affecting the 
session, if the access to and around the metal grids is not made easy.   
1.3.3 Coda 
It is technically difficult to implement a solution that fully replaces or addresses the problems. Some 
of the issues are not really problems that can be fixed, and therefore require continuous attention 
if the electric shock counts, from the basis of determine how well the rat has been running during 
a session. It is necessary to have tools that allow us to get the most out of what we have, especially 
when it comes to using experimental animals. It is easy to say to discard rats that run, but aren’t 
really good runners – in order to have a more selective subject group. However, the reality is that 
unless the rats are specifically bread to fit the group, it certainly becomes an ethical issue if the 
selection of subject rats relies on discarding them, rather than refining the number of rats in the 
experiment from the onset. 
 
  
 Introduction 
20 
 
1.4 Plasma Marker Assay 
1.4.1 The General Concept of Plasma Markers in Relation to Muscle 
Damage 
The general idea of plasma markers is to recognise molecules present in the blood stream that 
reflect distinct biological conditions, sometimes referred to as biomarkers in plasma. The reference 
to plasma per se is in which part of the whole blood the markers are located. Although, plasma is 
formally described as the separate blood liquid part in a separated anticoagulated whole blood 
whilst serum would refer to the same blood liquid of separated whole blood but after coagulation 
— hence serum does not contain fibrinogen (a protein that assists in the blood clot making).  
When defining skeletal muscle damage, one needs to be aware of the fact that the level of damage 
can be of various extent. On a cellular level, one could define it as tares or ruptures of the skeletal 
muscle fibres. Depending on the degree of the skeletal muscle damage, it is then related to how 
many tared or ruptured fibres are involved, and if localised or not, which might also depend on the 
skeletal muscle as an organ, i.e. its anatomical position and function. A damaged skeletal muscle 
fibre that is tared will have part or fractions of its intracellular components seeping into the 
interstitial compartment and then entering the blood tissue network surrounding it. The 
intracellular compounds can now be found in the blood stream for some time relative to their size, 
and the degree of the muscle damage, until they are cleared by the kidneys or gradually broken 
down in the liver. It is, therefore, logical that if the blood is sampled after a skeletal muscle damage 
has been induced, its analysis will reveal some quantity of some of the fibre’s intracellular 
components in the plasma. These components, from now on and throughout the dissertation, 
denominated as plasma markers, can be isolated from a plasma sample, identified and quantified. 
The quantity found in the blood will then depend on the degree of the damage, both on an 
individual fibre level and how many fibres are involved, and furthermore, which point in time after 
the damage, the blood sample is reflecting. Depending on the muscle fibre compound in question, 
its outbound flow is reflective of it being ‘free’, adhering, or as part of the structural elements of the 
fibre. If the severity of the damage is not adverse or catastrophic, a decreasing quantity in blood 
over time can then be used as an indirect measure of the recuperation process of the damaged 
structure. 
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1.4.2 Selecting the Appropriate Plasma Markers for Skeletal Muscle 
Damage 
Logically, the blood will contain whatever needs to be transferred in it, irrespective of the occurrence 
of skeletal muscle damage. Therefore, any accompanying action with the muscle damage is also 
likely to be reflected in the blood in a similar way. Thus, it is necessary to select plasma markers that 
are unique to the tissue type of the muscle in question. If the actions that lead to the damage of 
skeletal muscle expectedly (or unexpectedly) caused some sort of damage to the cardiac or the 
smooth muscle cells; any marker common to muscle cells, in general, would give misleading 
quantity when judging the effects on skeletal muscle alone. Both being striated, skeletal and cardiac 
muscle cells have more intracellular components in common (structural, mechanical or metabolic) 
in comparison with smooth muscle cells. Thus in the process of selecting a marker, specificity is, 
therefore, key, although, not necessarily realistic in assay production.   
In the case of skeletal muscle damage, the simplest scenario would be that the selected marker (or 
the component) is usually not found extracellular to the skeletal muscle fibre, i.e. a blood sample 
would not contain it until the tares involved in a skeletal muscle damage would then make it 
detectable via proceeding samples. Therefore, a clear indication of a skeletal muscle damage, until 
the liver would eventually have broken down these components, and after that not be detectable 
in blood anymore. Another clear indication that the damage has been repaired. Still, one needs to 
consider that tissues go under regeneration as part of normal biological maintenance. A growing 
individual has higher cell turnover frequency. These and other basal processes, which in our simple 
scenario we consider normal (or not damaged or non-healthy cell) also return components into 
the blood with regularity to be broken down. Depending on the component in question (role and 
‘normal’ intracellular quantity) it both could or could not be detected in a plasma assay which, in 
turn, depends on the timing and the sensitivity of the assay. One can logically assume that the 
quantity released into the blood after damage is higher in comparison with what happens in 
normal cell turnover. Hence understanding the role of the marker chosen is necessary to be able 
to give the interpretation of the analysis any proper meaning. 
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1.4.3 Myoglobin, Creatine Kinase and Troponin-I in Plasma to Detect 
Skeletal Muscle Damage 
In the following, the three components; myoglobin, creatine kinase and troponin-I; will be defined 
as muscle injury markers, and are indeed commonly relied on as plasma markers for the indication 
of muscle damage. Myoglobin and troponin-I are specific to striated muscle tissue. Whilst 
myoglobin is generally speaking non-specific for this purpose; troponin-I is expressed in different 
isoforms whether it is in skeletal or cardiac muscle cells. Creatine kinase is expressed in various 
tissues in general, where different isozymes are expressed in skeletal or cardiac muscle cells.  
1.4.3.1 Myoglobin 
Myoglobin (Mb) is a relatively small cytoplasmic globular protein made of 153-aminoacyl residue 
with the molecular weight of approximately 17 kDa. Two main isoforms have been identified, Mb1 
and Mb2, with additional three in humans (Mb3, Mb4, Mb5), although none of them appears 
strictly specific to striated or skeletal muscle tissue (Rossi-Fanelli and Antonini, 1956; Fraser et al., 
2006; Perkoff et al., 1962 in Gussoni et al., 2011). Having ancestral relations with haemoglobin and 
both containing the O2-binding haem ring, Mb is classically known to store and facilitate oxygen 
diffusion in the cardiac muscle cells and the oxidative myofibres of skeletal muscle (fibre types I, IIa 
and IIx, specifically) (Wittenberg, 1970; Ordway and Garry, 2004). Still, Frauenfelder et al. (2001) 
suggested the role of Mb to be of an allosteric enzyme due to its other functions of binding and 
reacting to CO and NO2
–. The structural properties of Mb make its O2 affinity much stronger than 
that of haemoglobin which underpins its role as oxygen carrier (Garry and Mammen, 2007), as, 
without it, O2 diffusion inside the muscle cells is not enforced by an intracellular gradient sufficient 
for an adequate delivery to the mitochondria. After observing electron micrographs of gold-
labelled Mb in rat cardiac cells, Hochachka (1999) postulated that a random intracellular distribution 
of Mb is ‘to assure a similar [O2] everywhere in the cytosol (and simultaneously to minimize or even 
destroy intracellular O2 gradients)’ (p. 669). Although, he does recognise and underline the fact that 
skeletal muscle cells might demonstrate different Mb recruitment in relation to different fibre types 
and their muscle’s overall workload whilst cardiac cells are biochemically more homogenous 
(Hochachka, 2000). Meanwhile, ultrastructural immunohistochemical techniques have positioned 
Mb in concentration near the A-band and the I-band in skeletal muscle fibres (Mitsui et al., 1994); 
bands which define the interdigitating thick and thin protein filaments, respectively, of the 
functional units (sarcomeres) within the fibres. 
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1.4.3.2 Creatine Kinase 
Creatine Kinase (CK) is an enzyme the size of about 40-43 kDa in molecular weight, with three 
tissue-specific isozymic forms; MM, BB, and MB (a heterodimeric between MM and BB) (Grossman 
and Mollo, 1979; West et al., 1984; Pickering et al., 1985), as well as two mitochondrial isoforms 
(Eder et al., 1999). The CK-MM isoform is found in muscle; both skeletal and cardiac, associated 
with the M-line structure of the myofibril (Wallimann, Turner and Eppenberger, 1977) the CK-MB 
is exclusive to myocardial tissue. 
The CK-BB isoform is designated to brain tissue, where it is mainly found, although, it could be 
designated as the non-muscle isoform (Grossman, 1983; Eder et al., 1999). CK catalysis the 
rephosphorylation of ADP, using phosphocreatine, to maintain the ATP energy requirements 
within the cell (West et al., 1984; Grossman, 1990; Wallimann et al., 1992), which Hochachka (1999) 
refers to as ‘buffering’ the ATP concentration, e.g. as ‘during large-scale changes in muscle work’  
(p. 662) necessary for the ATP-hydrolysis in the cross-bridge cycle. 
1.4.3.3 Troponin-I 
Troponin-I (TnI) is a striated muscle-specific structural protein with the molecular weight of about 
20-23 kDa. The TnI is known to have three isoforms ‘encoded by three distinct genes that are 
differentially expressed in cardiomyocytes, fast skeletal muscle fibers, and slow skeletal muscle 
fibers’ (Hastings, 1997, p. 206). Regarding peptide count, the cardiac isoform is about 30-60 units 
longer than the other two, which only demonstrate minor structural differences (Wilkinson and 
Grand, 1978; Brotto et al., 2006). As part of a 3-polypeptide troponin complex, when the complex 
does not have Ca2+ bound to it, the TnI inhibits the actomyosin interaction which is the fundamental 
mechanical link needed for the cross-bridge cycle of a contraction (Farah and Reinach, 1995; 
Hastings, 1997). When the muscle cell action potential triggers the Ca2+-release from the 
sarcoplasmic reticulum and its cytosolic concentration subsequently increases; Ca2+ binds to the 
TnC, the calcium-binding unit of the troponin complex. This binding leads to conformational 
changes in TnI and together with TnT, the 3rd part of the complex, pushes linked tropomyosin 
away from the myosin binding sites on actin, freeing the way for myosin to interact (Reinach et al., 
1997; Perry, 1998). 
  
 Introduction 
24 
 
Table 1-2. The Charactersitics of Myoglobin, Creatine Kinase and Troponin-I. 
Molecule 
Size 
(kDa) 
Type 
Skeletal 
muscle 
isozyme 
Cardiac 
muscle 
isozyme 
Other 
important 
isozymes 
Reference 
Myoglobin 
(Mb) 
≈17 Cytoplasmic 
globular 
protein 
Mb1 (non-
specific) 
Mb1 (non-
specific) 
Mb2 (brain-
specific)  
Rossi-Fanelli and Antonini, 1956; 
Hochachka, 1999, 2000;  
Fraser et al., 2006 
Creatine 
Kinase 
(CK) 
40-43 Enzyme CK-MM CK-MB and 
CK-MM 
CK-BB (in 
non-muscle 
tissue) 
Walliman, Turner and 
Eppenberger, 1977;  
Grossman and Mollo, 1979 
Troponin-I 
(TnI) 
20-23 Structural 
protein 
Fast-TnI 
and Slow-
TnI 
Cardiac-TnI 
(maybe 
slow-TnI) 
Not specific 
for striated 
muscle tissue. 
Wilkinson and Grand, 1978; 
Hastings, 1997;  
Brotto et al., 2006 
1.4.4 Detecting Markers in a Sample 
The identification and quantification of compounds in a solution can be carried out in many ways, 
and for biomarkers, the use of chromatographic analysis and mass spectroscopy are relatively 
standard. However, carrying simple assays such as ELISA is both straight forward and easily 
applicable in routine physiological laboratories, both for the confirmation of a markers existence in 
the given sample and for quantification. As much as an ELISA can be designed in several ways, it 
can be carried out in several manners as well. Between different variations and combinations of 
direct and indirect with sandwich, competition and inhibition types of ELISA, the general setups are 
not within the scope of this text. However, as a reference, the direct sandwich ELISA will be 
introduced. 
1.4.4.1 Direct sandwich ELISA 
The general description is based on a monoclonal antibody of the compound of interest being 
incubated to a hard plastic surface. The monoclonal aspect marks the specificity needed to 
distinguish the particular compound from the potential mixture of others in the subsequent 
acquisition of a sample. With the addition of a sample solution, the compound will bind to the 
antibody on the plastic during incubation. All unbound and other sample matrix material is, at this 
point, washed away. A second batch of the compound’s antibody is now added. These antibodies 
normally have the following two characteristics: (i) The antibody is polyclonal, which is still specific 
to the compound but recognises multiple epitopes on the compound to ensure that each 
compound has a bound antibody during incubation. Furthermore, (ii) this polyclonal antibody is 
enzyme-linked. The enzyme plays the key part in subsequent recognition of the antibody-
compound links. Then, another washing away of all unbound and excess material is carried out. At 
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this stage, the compound of interest, in the original sample, that has bound to the monoclonal 
antibody on the plate, has now also an enzyme-linked antibody bound to it, or, to reference the 
technical terminology (Aydin, 2015)— the compound is sandwiched in between the two types of 
antibodies. A substrate solution, specific for the enzyme linked to the antibody, is now added to 
the plate. A by-product of the substrate-enzyme reaction is a compound that gives off colour, 
which can be colourimetrically recognised. The incubation time needed for this step needs to take 
two factors into consideration; (i) the amount of substrate needs to be sufficient for any potential 
maximal Antibody-Compound-Antibody Sandwich on the surface area of each well. Also the 
amount of substrate has to be in sufficient excess quantity, to make sure that there is no 
competition for the amount of substrate, and that the substrate has reached or covered all potential 
areas where an enzyme might be available. (ii) At the same time, as the enzyme continually leaves 
of the coloured by-product with mildly excess substrate available; the reaction needs to be stopped 
as well for the colour emerging to be representative and proportional. A stop solution is added, 
which reacts with the substrate and the substrate by-product, leaving the unbroken substrate not 
available for the enzyme to react with, and changes the colour of coloured by-product. This new 
colour can also be recognised colourimetrically, and its amount can be quantified as the involved 
reaction is in proportion to the existence of the antibody. 
1.4.4.2 Technical Considerations for Colorimetric Assays 
The colourimetric identification is based on a wavelength absorption for the compound in 
question. However, the compound in question for the absorbance measurement is not the same 
as for the compound of interest in the sample. The existence can be back traced in a way that the 
compound in question only exists if elements in the stop solution have formed it with the by-
product from the enzyme reaction. The enzyme reaction only takes place if the enzyme is available. 
In turn, the enzyme is only available if the enzyme-linked antibody is bound to the compound of 
interest from the sample. Moreover, the compound of interest from the sample is only there if it 
has bound to the antibody on the plastic surface of the well plate. However, we still do not know 
the quantitative relationship between one compound of interest with one active enzyme on its 
enzyme-linked antibody, and how many by-product compounds the one enzyme has formed that 
are simultaneously and unavoidably measured. If the enzyme was inactivated after one reaction, 
the relationship would be fairly straight forward. All these factors lead us to how a calibration curve 
is needed to reflect on this relationship between the concentration of the compound and its 
absorption. On a specific range, one can find a linear relationship, and define the limits of linearity. 
However, both because of matrix effects on the well plate and as the quantity of substrate is in 
excess; the relationship might become curved. Instrumental detector saturation can also be 
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reflected in a non-linear relationship; in either case, it is necessary to dilute the samples so it falls 
within the range of quantification of the calibration curve. The relationship between the limits of 
linearity and range of quantification are explained below. 
1.4.4.3 The Calibration Curve 
The key parameters to define the calibration curve and how it can be used for quantification are 
expressed in the following: The limit of detection (LoD), the limit of quantification (LoQ), the limit of 
linearity (LoL) and the range of quantification (RoQ). The LoD is where the measurement response 
can be said to be due to the compound of interest (Hayashi et al., 2004). Consider an absorbance 
reading of a blank sample that is always fairly similar, still, slightly variable. If the background, the 
blank, has high variation, it becomes problematic to decide what one is truly measuring in a sample 
with a very diluted concentration of the compound of interest, that has an absorbance really close 
to the blank. Therefore, the limit is usually determined by the absorbance variation from the 
repeated measurements of the blank sample as a reference; more precisely, the value of 3-times 
its standard deviation. If the blank is chemically simple, and the measured volume is as constant as 
it can be between different repetitions, the LoD becomes an indication of the instrumental 
precision; however, in practice, it is likely that variations in the volumetric procedure play an over-
shadowing role. Once the LoD has been established, we objectively need to decide at what point 
it can be said that we have detected the compound of interest, with a small absorbance value, 
though higher than that of the blank, and when possible we can relate the amount absorbed to 
the quantity of the compound. The quantification can be troublesome in diluted samples if one is 
supposed to deduct the absorbance value of an extremely varying blank for the rest to represent 
the compound of interest. The LoQ is also determined by the absorbance variation of the blank, 
still, 10-times its standard deviation, and formally determines at what point the smallest 
measurement response can be quantified with some certainty (Proctor, 2008). When a calibration 
curve is constructed with several known but distinct levels of concentration of the compound of 
interest, the absorbance-concentration relationship is usually limited to linearity. Between the 
different concentration points, the linearity is usually determined by the best fit with a linear slope 
using least mean square, where the acceptance mark is referenced to where the R² is higher than 
0.999. The outermost concentration points of the curve that give this for determining LoL. Whilst 
the lower end of the range of quantification starts with the determined LoQ, the upper end is 
usually determined as 10% RSD from the upper LoL. In practice, this means that although several 
concentration points are used to make up the calibration curve, the LoQ and LoL define which of 
them can ultimately be used for reference which is the RoQ. 
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1.4.5 The Sample-Matrix Effect 
The matrix effect of a sample on a well plate array is usually dealt with by a sample-blank. Still, a 
blank only estimates the general effects that the matrix may have on the absorption. The effect 
might be visible in a different manner especially in the lowest range of the compound 
concentration; affecting the readability, to put it simply (Hibbert, 2007). The reading is typically 
represented in a different linear relationship (less steep slope) in the lowest concentration points in 
comparison with the higher concentration points where the linear relationship is most evident; and, 
furthermore, being in many cases denoted as the initial curve before the linearity, or below the 
lower limit of linearity. Although, classically, this initial linear relationship is considered as outside 
linearity and therefore discarding any quantification of samples that fall within these ranges of 
concentration; the way to discard them is more formal, and, in fact, this initial relationship can be 
used, and only seems curved in comparison with the rest due to the matrix effect. However, what 
marks which low-concentration sample can be quantified is the LoQ. The definition of the LoQ is 
also debatable, but is a clearer reference point, and perhaps more realistic, than only the lower limit 
of linearity based on the middle linear relationship (the evident bit on a graph). Another type of the 
matrix effect is how the medium affects the measurability of the compound of interest in general 
(even if the blank is determined). This measurability can be determined by spiking a sample that is 
without any compound of interest and compare it with a calibration curve, which normally does 
not have the initial sample matrix involved. The yield calculation between the two then determines 
how the initial sample matrix, affecting the first steps of the assay, might be involved in the results. 
1.4.6 Coda 
As it is evident regarding the experimental environment, any application (physiological or 
otherwise) set up with the intention to cause skeletal muscle damage supposedly to be detected 
via plasma marker assay, will have several barriers to overcome in its procedural design. The 
analytical aspect of it will depend on practical skills, the equipment accuracy and, of course, the 
sensitivity of the assay itself. Still, even if these aspects would greatly affect the downstream results, 
they would generally only be viewed as part of the systematic error. The true complex factor 
involves the underlying biology in terms of its validity and variability. If for arguments sake, we 
assume that a given plasma marker is valid to reflect muscle damage and its quantification 
measures are correctly representative for the level of the damage; the plasma marker alone could 
only confirm the existence of a muscle damage in general. The identification of which muscle or 
muscles are involved could not be truly confirmed even if we could guesstimate it by the physical 
setup of the experiment. Similarly, as many skeletal muscle damage plasma markers are the same 
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as for cardiac muscle damage, one needs somehow to eliminate the existence of the latter in the 
results. One method of doing this is to select more than one plasma marker. This, indeed, is a 
commonly used strategy simply to ensure the probability of detecting the muscle damage, as a 
reason for the appearance of different markers in the blood stream is still not fully clear. However, 
the same strategy could logically be used simultaneously to measure the existence of cardiac 
muscle damage, as some markers are more specific to cardiac muscles cells, to either rule that 
possibility out or in. Of course, in practice, the rationale behind the experimental setup along with 
financial limits might suggest rather focusing on additional and different skeletal muscle damage 
measurements; some of which are introduced in the following chapters. 
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1.5 DNA Microarray Gene Expression 
1.5.1 The Central Dogma of Molecular Biology 
Changes in physiological circumstances require molecular responses on a cellular level. These 
molecular alterations can further promote the gene transcription for the synthesis of a protein that, 
further on, plays its part in the response. These molecular alterations affect the gene transcription 
by facilitating the bond of transcription factors to their specific regions on the DNA. These regions 
are promoters and are located upstream of a protein-coding gene. The transcription factor can act 
as an activator or repressor that respectively enhances or suppresses the transcription of the 
downstream gene. The same type of transcription factor can affect several genes, perhaps, 
enhancing the transcription of some and suppressing others. When the transcription factor is an 
activator, it can bind RNA polymerase II, forming the transcription initiation complex. If the 
transcription factor is a repressor, this complex will not form. The transcription takes place when 
the RNA polymerase II catalyses the formation of a pre-mRNA (pre-messenger RNA) by opening 
and unwinding a small portion of the double-stranded DNA, using the 3‘-to-5‘-direction strand as 
a template along the DNA, to from a pre-mRNA strand in the 5‘-to-3‘-direction. The transcription 
ceases with an end code of the gene region in the DNA itself. Any non-protein-coding portions of 
the pre-mRNA are now spliced away, forming the mRNA (messenger RNA). The mRNA is 
transported out of the nucleus and to the ribosomes. It is in the ribosomes that the mRNA strand 
is translated to a protein chain with the help of tRNAs (transfer RNA) that match representative 
amino acids, coded by every 3-base pairs in the mRNA strand. As with the transcription, the 
translation ceases with a stop code in the mRNA strand. The protein, either by itself, modified or as 
part of a bigger protein structure, relatively directly or indirectly participates in a biochemical 
process or processes in response to the molecular action it serves. The synthesised protein is what 
we can consider a functional gene product, and up until this point, from the commencing point of 
transcription, we say that the protein-coded gene has been expressed. 
1.5.2 Gene Expression Profiles 
With the accumulated scientific knowledge, many protein-coding genes in vertebrate species have 
been identified, via the measurements of the resulting corresponding up- or downregulated 
protein, as part of molecular pathways. The set of genes that can potentially express mRNA as part 
of a particular pathway, or a set of parallel pathways, can be referred to as the representing gene 
expression profile. A gene expression profile can also refer to the changes in the expression of a 
particular gene as a function of time. For an experimental setup involving exercise-induced skeletal 
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muscle damage and its recovery, perhaps with hypoxia, one could consider four different profiles: 
genes that are expressed as a response to skeletal muscle damage, hypoxia signalling, vascular 
endothelial growth factor signalling, and, perhaps, wound healing. 
1.5.2.1 Skeletal Muscle Pathway 
Skeletal muscle’s role in voluntary movement contributes greatly to energy metabolism and its 
regulation via glucose uptake and storage by insulin. Complications from aging and metabolic 
diseases like diabetes and metabolic syndrome contribute to muscle wasting (atrophy). However, 
recent research hypothesises that metabolic defects in skeletal muscle contribute to the aetiology 
of diabetes and metabolic syndrome, suggesting that skeletal muscle has a larger role in these 
disease states than initially expected. Large heterogeneous protein complexes including titin or 
dystrophin facilitate muscle contraction by connecting the skeletal muscle cytoskeleton to the 
extracellular matrix (Conover, Henderson and Gregorio, 2009). Muscular dystrophies arise from 
inherited mutations in the genes encoding components of these complexes, and gene expression 
changes disrupting their normal contractile function dysregulate signalling pathways that control 
muscle growth. Potential therapies for muscle wasting include generation of new muscle cells 
(myogenesis) or increasing the mass of current muscle cells (hypertrophy). Thus, muscle-specific 
biological and pathophysiological processes are interrelated and cannot be studied in an isolated 
manner. 
1.5.2.2 Hypoxia Signalling Pathway 
Oxygen is required for aerobic energy metabolism processes such as oxidative phosphorylation. 
Low oxygen conditions activate the hypoxia signalling pathway in eukaryotic cells, primarily via the 
hypoxia inducible factor (HIF) (Bunn and Poyton, 1996). HIF heterodimers consist of a constitutively-
expressed beta subunit and one of 3 alpha subunit isoforms whose expression is tightly regulated. 
The presence of oxygen activates prolyl hydroxylases to hydroxylate HIF, leading to its 
polyubiquitination and degradation. Under low oxygen conditions, prolyl hydroxylase inactivity 
allows the HIF to accumulate in the cytoplasm until translocation to the cell nucleus and there 
initiating target gene expression (Chi et al., 2006). Hypoxia-inducible target genes mediate multiple 
biological functions, such as angiogenesis, haematopoiesis, and the maintenance of vascular tone 
to provide or replenish tissues with blood and oxygen.  
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1.5.2.3 Vascular Endothelial Growth Factor (VEGF) Signalling Pathway 
Genes involved in signal transduction and cell signalling downstream of vascular endothelial 
growth factors and their receptors are critical for regulating new blood vessel formation, also 
known as angiogenesis, arteriogenesis, or vasculogenesis (Lyons et al., 2010). Angiogenesis and 
VEGF Signalling go hand-in-hand with sprouting and splitting (intussusception) angiogenesis, 
vascularization, neovascularization, revascularization, pruning and vascular remodelling in response 
to the developmental and hypoxia or ischemic signalling pathways. 
1.5.2.4 Wound Healing Pathway 
Wound healing progresses via three overlapping phases: inflammation, granulation and tissue 
remodelling. After mechanical injury, a blood clot forms and inflammatory cells infiltrate the wound, 
secreting cytokines and growth factors to promote the inflammation phase (Gordon, 2003). During 
the granulation phase, fibroblasts and other cells differentiate into myofibroblasts, which deposit 
extracellular matrix proteins. Simultaneously, angiogenesis occurs, and keratinocytes proliferate 
and migrate to close the wound (Hoffmann, Gloe and Pohl, 2001). In the final tissue remodelling 
phase, apoptosis eliminates myofibroblasts and extraneous blood vessels, and the extracellular 
matrix is remodelled to resemble the original tissue. Dysregulation of this last tissue remodelling 
phase leads to fibrosis. 
1.5.3 Gene Expression Analysis with Probe Arrays 
In order to measure representative changes in gene expression for a specific moment in time, one 
needs to acquire a sample from a tissue of interest and process the mRNA transcribed by the cells 
in the tissue. The mRNA material is prepped to be potentially hybridised to single-stranded bits of 
DNA (called probes), each representative of a different gene of interest. The mRNA material needs 
to be properly extracted from the sample to avoid any interferences in the subsequent analysis. 
With a reverse transcriptase, the mRNA is converted to its complementary DNA (cDNA) which is 
also single stranded. The extracted mRNA is in relatively low quantity due to a small processing-
sample size; hence, the corresponding amount of cDNA needs to be amplified with a PCR and is 
done so in a presence of a label (usually a fluorescent dye). The amplification process is necessary 
for the subsequent step. Remember, that the labelled cDNA molecules are of many kinds (as many 
as different mRNA were expressed in the sampled tissue), but are still all amplified. A lot of these 
different but representative labelled cDNA molecules are incubated with an amplified probe of 
interest (each separately) to allow hybridisation to take place and then unbound materials are 
washed away. If the labelled cDNA hybridises to a probe, we know that the corresponding gene 
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has been expressed in the sample. Furthermore, the intensity of the label (for example, the intensity 
of the fluorescent light emitted) can be measured and is proportional to the quantity of labelled-
cDNA bound to the same type of probe. As various expressed mRNAs from the sample are in 
different quantity to start with, their labelled cDNA molecules after amplification will maintain these 
type-proportional differences and the amplified amount is proportional to the label intensity. This 
relationship is fundamental to the quantification used in quantitative real-time PCR (both qPCR and 
RT-qPCR).  
PCR arrays are prepared to have as many different probes needed to represent a gene expression 
profile. For example, the number of different genes can be just under 96 or 384 to fit standard well 
plate capacity. However, the number of genes in a profile is not limited by a well plate per se, rather, 
it is a matter of practicality. Ultimately, depending on the genes used to make up that particular 
profile to fit on a well plate; if no hybridisation does take place, the chosen profile (and its 
composition) is not prominent in the physiological condition of the tissue from which the sample 
was taken – which, in turn, could make it a limiting assay with that respect. DNA microarrays have 
a much larger number capacity for different genes/probes and can mount up to as many as to 
represent the entire genome of an organism (20000-50000 probes per array, for example). 
Therefore, once the label intensity measure for each gene is obtained, selected genes can be 
collectively evaluated with reference to any known gene expression profiles if so desired. However, 
both of these technical applications to measure the gene expression mentioned here, only provide 
a relative level of expression for each gene, but not the initial concentration of the corresponding 
mRNA. Still, the difference in the expression level can be used to interpret the effect on different 
genes and also between the various experimental conditions.  
1.5.4 Data processing for Differential Gene Expression 
Many applications for the DNA microarray setup offer different cDNA labels for different samples 
to be compared. The ‘classic’ setup applies the two-colour detection, where one sample contains 
cDNA molecules labelled with fluorescent dye Cy3 (green) and the cDNA molecules from the 
compared sample are labelled with the fluorescent dye Cy5 (red). Each colour corresponds to a 
different wavelength and can, therefore, be measured separately. When the intensity of the two 
colours have been normalised, the comparison can be made numerically, and furthermore, visually, 
by overlying an image scan for each colour with each other. Each probe-type location on the array 
will appear in the colour of the labelling dye of the sample that dominates the hybridisation. If both 
samples are present, the resulting colour will be yellow. 
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However, to formally process these data, we need a more sophisticated approach. Applying t-
statistics is the most straightforward with the objective of comparison, especially when looking at 
the differential expression on a gene-to-gene basis. Between two groups, the difference in the 
average expressions of each (for example, experimental group versus control group; control being 
the reference group) is presented in a log2-scale and is called the fold change (log2(FC)). If the value 
of the fold change is negative, the expression has been downregulated in comparison to the 
reference group, whereas the value of the fold change being positive, the expression has been up-
regulated. The t-test provides the ratio of the difference between the groups’ average expression 
and the variability of the groups. However, to normalise the variability between individual genes, a 
modified version of the t-test, called moderate t-test, furthermore, replaces any gene-specific 
variance by a common variance that represents all the genes analysed. Finally, the p-value of the t-
test hypothetically determines how likely the same t-value is to be observed if the gene was not 
differentially expressed between the two groups. One can use the p-value as an arbitrary level of 
significance; for example, a p-value≤0.05 indicating that the difference is significant in 95% of the 
cases. 
There are many different ways to represent the data of relative changes in gene expression. Some 
of them complement each other. However, the choice ultimately depends on the setup and the 
purpose of the experimental study and which type of interpretation is needed. With the focus on 
differential expression and correspondence with gene expression profiles, which means both 
wanting to look at many groups and many genes at a time; the volcano scatter plot and the gene 
list plot (in particular) are useful. 
1.5.4.1 Practical Use of the Gene List Plot 
When looking at groups of genes, for example, a gene expression profile, where the focus is on the 
differential expression and not on the absolute values, the gene list plot is very straightforward. The 
plot can be constructed in many ways. The fold change values can be presented per each gene, 
typically listed in rows, and per each comparison of groups in columns. The fold change is usually 
visually expressed by bars (with pooled standard deviations as error bars) heading towards the right 
in a positive direction if reflecting an up-regulation and heading towards the left in a negative 
direction of reflecting a down-regulation. Reference lines to mark certain fold change values are 
used as a visual aid to ease a general estimation. 
1.5.4.2 Genome Overview with the Volcano Scatter Plot 
A volcano plot is visually very appealing to guesstimate the number or the layout of the expression 
of many genes with reference to their p-value. Each dot in the graph represents one gene and is 
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plotted as its log10-transformed p-value as a function of the fold change (logFC) landing the gene 
either on the down- or up-regulated section of the x-scale. The y-axis, the p-values, are in reverse 
order where one can conveniently mark the significance threshold value horizontally. If the majority 
of the expression values are not significant, they will be clustered below the horizontal threshold, 
whilst the significant range stretches upwards scattering the significantly expressed genes that are 
generally marked with the gene symbol if far from the main cluster. This plot can be used to rank 
the genes in their order of significance. However, for complex experimental setup, it has its limits, 
as one graph only compares two sample groups at a time, and is therefore perhaps more useful 
for intermediate data analytical steps. 
1.5.5 Experimental Interferences 
Gene expression analysis is very sensitive to all sorts of variability and deviations that can potentially 
take place during the entire experimental process. One of the fundamental factors that represents 
biological variability is evident when comparing the use of in vivo tissue samples vs in vitro cell 
cultures. When using experimental animals, an intention to the onset of biological differences is 
reduced by using genetically similar strains. However, the ‘unwanted’ biological difference can take 
rise from the difference in handling and living conditions, nutritive conditions, gender and age, and 
even different anaesthetic agents have been demonstrated to have their effects (Champy et al., 
2004). Although, some of the factors are more pronounced depending on the tissue sample of 
interest, standardising the experimental protocols becomes essential, especially if the experiment 
runs for a considerable time. 
It is, furthermore, crucial to consider the tissue heterogeneity, especially if the experimentally 
affected cells are relatively localised within the organ, in which case a ‘global’ homogenised sample 
from the tissue can easily dilute any difference in the gene expression between the cells. Still, even 
if all these factors are controlled or managed, the practical aspects of the sampling itself have a big 
role in the quality of the sample. Samples can be processed immediately after tissue dissection, but 
in large experiments that is rarely practical and the samples need to be frozen. The length of the 
period from the time the fresh sample is acquired until it is snap frozen is critical regarding 
degradation of the mRNA and also for cross contamination with other samples via laboratory 
material. It is recommended that samples stay fresh no longer than 30 minutes (if to be frozen) and 
should be stored at −80 ºC reducing any freeze-thaw cycles. These factors are also very prominent 
in the RNA extraction itself, and it is important that the quantity of any isolated RNA be of high 
quality. The type of tissue can be a factor in the RNA yield, with fibrous tissue like skeletal muscle 
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having expected yield of 1-2 µg per 1 mg of sample, in comparison with 4 µg per 1 mg of cardiac 
muscle and 5-10 µg of 1 mg of liver tissue. Factors like these play a significant role in isolation, and 
it becomes a question of judgement whether the processed sample should be run through its 
extraction filters fewer times for higher yield or more times for higher purity as there is a minimum 
working quantity for the downstream microarray preparations. Therefore, the quantity and quality 
of the RNA is systematically assessed, based on potential degradation (28S:18S rRNA test), purity 
(A260/280 and A260/230 tests), and used as a point of reference for normalisation for the 
subsequent analysis. 
1.5.6 Coda 
As with many types of samples, one needs to be aware of the fact that gene expression 
measurement with arrays is a snapshot. The timing of this snapshot is crucial in order to gain a real 
insight into the consequences of physiological changes on a cellular level thus the main question 
concerns when they occur. Recently, the timing has been challenged as research has demonstrated 
that genetically identical subjects can have very different and random fluctuations in the expression 
of individual genes, ultimately suggesting basal stochastic characteristics (Raj and Van 
Oudenaarden, 2008) and even chemical memory (Tian, 2013). Still, these characteristics seem to 
differ between genes as well, which underpins the need to recognise the genes for an in-depth 
gene expression analysis. For any given physiological experiment, the choice of pathways with its 
representative gene expression profile could be both more or less extensive. One needs to be 
reasonable concerning the definition of a pathway (or pathways) and the corresponding gene 
expression profiles and the physiological conditions they are supposedly reflecting. The definition 
of a pathway is far from being set in stone regarding which genes make up the expression profile. 
The profile can be dependent on the definition of the physiological condition as well. Many genes 
have now been accepted to be responsible for protein synthesis in a particular biochemical 
reaction. Still, many gene participations would need to be verified even further and probably others 
that are unrecognised. 
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The general aim of this thesis is to see if intermittent hypobaric hypoxia exposure, alone or followed 
by a short duration of low impact rehabilitation exercise, has any effect on the recovery profile of 
the skeletal muscle damage elicited in m. soleus by a downhill-eccentric exercise-induction in 
treadmill-trained rats. The recovery after the induction of muscle damage was monitored via 
indirect measurements at four different time points throughout a 2-week rehabilitation period with 
a passive recovery as the control condition. The exercise-training protocols modelled to simulate 
that of human recreational athletes. 
The indirect measurements used in the experimental work for this dissertation are: (a) Skeletal 
muscle damage-plasma markers; and (b) Differential expression of theoretically-representative 
gene expression profiles in the rat’s hind limb m. soleus, as the muscle downhill eccentric-injury 
model protocols are widely considered effective. 
Secondary measurements to ensure the experimental conditions are: (c) An intuitive treadmill-
running rat’s performance score (AEY-score), to estimate the quality of the treadmill training both 
before, during and after the exercise-induction of skeletal muscle damage. (d) The rat body weight 
logs, the lung and heart weight fraction and the Fulton index, to differentiate between sedentary, 
hypoxic and exercising rats. Lastly, (e) the internal quality control actions for procedures and analysis 
to ensure the validity of the results. 
 
Given the following experimental conditions are true …  
(i) The rats are considered trained (as ‘recreational athletes’) before the induction of skeletal muscle 
damage.  
(ii) The downhill-running protocol is sufficiently effective to induce skeletal muscle damage (at least, 
noticeable in the rat’s soleus muscle).  
(iii) The intermittent hypobaric hypoxia exposure programme elicits physiological changes 
(acclimation) that improve the recovery of injured tissues.  
(iv) The hypoxia exposure followed by a light treadmill exercise is different from the hypoxia 
exposure alone. 
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The following general and simplified expectancy variables should be … 
(A) The AEY-score to demonstrate a consistent training performance allowing to discard a potential 
outlier affecting subject variability during and after training periods — Or, on the contrary, providing 
a tool that estimates the exercise-implication (individual behaviour) of animals on the treadmill.  
(B) The skeletal muscle damage plasma markers could be detectable just after the training period 
(indicating muscle turnover), still, be markedly increased after the injury-induction protocol and be 
gradually reduced over the recovery period in the case of passive recovery. The intermittent hypoxia 
exposure should have some form of reduced plasma marker profile. If the addition of rehabilitation 
exercise favours the recovery, the plasma marker profile should be more reduced. However, there 
is a possibility of counteractive injury is some, in which case, the plasma-marker profile should have 
a differing pattern. 
(C) The differential expression within the chosen gene profiles for the m. soleus, should be reflected 
in upregulated or downregulated genes, in response to exercise, tissue damage, hypoxia and 
hypoxia followed with exercise, and tissue regeneration or reparation. Different types of gradual 
changes should be visible throughout the injury-recovery period with reference to a passive 
recovery. 
(D) The body weight log should reflect leaner rats if trained, in comparison with sedentary rats. The 
effect of the intermittent hypoxia exposure is not expected to have considerable effects on the 
weight due to the frequency and the duration of the sessions. 
(E) Exercise is expected to slightly increase the Fulton index, with reference to sedentary subjects. 
Hypoxia is considered to be more effective than exercise to increase the index. After becoming 
‘recreational athletes’, it is possible, to a certain extent, that the physiological changes are reflected 
in a higher index. Skeletal muscle damage alone is not considered to have any effect on this 
parameter. The intermittent hypoxia sessions might increase the index but likely to be only visible 
at the end of the measured recovery period. As the addition of rehabilitation exercise is not 
designed for endurance purposes, it is not likely to have any additional effects on the index during 
the recovery period. 
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3.1 The Experimental Pretext 
The funded research project, bearing the translated name ‘Effect of intermittent hypobaric hypoxia 
on induced muscle injury repair in laboratory rats’, makes the foundation for the work accounted 
in this dissertation. Several practical issues arose during the commencement of the project, 
requiring execution modifications regarding some parts of the experimental foci. The initial setup 
aimed to test an equal count of both male and female treadmill-trained Sprague-Dawley rats, 
divided into two experimental groups, and one control group, with each gender contributing 15 
rats in each group (NRat=45×2gender). After inducing skeletal muscle damage with downhill treadmill 
running, the tissue recovery would be monitored for two weeks. During the recovery period, four 
sampling days would be included, [1, 3, 7, 14] days after the injury induction and one sampling day 
prior as a reference.  
The main sample types of interest would be blood samples, to measure plasma markers with ELISA 
and blood cells with cell counting, and skeletal muscle tissue, for immunohistochemical and 
biochemical and quantitative gene expression levels (qRT-PCR) with interest in four different gene 
profiles. Acquiring the muscle tissue samples would mean sacrificing the animal in question. 
Therefore, apart from the reference day (prior to damage-induction), from the 1st post injury 
sampling (day 1) to the 4th post injury sampling (day 14), 3 male and 3 female rats would be 
sacrificed for the muscle tissue sampling; gradually decreasing the number of rats throughout the 
period. The blood sampling was planned to be acquired from every rat during each sampling day 
until it was sacrificed for the other sample acquisition.  
3.1.1 The Experimental Caveats 
When establishing the most appropriate blood sampling routine, regarding a specific sample 
volume or an invasive technique that would not have any potential post-sampling physiological 
effects – the techniques tried were not sufficiently efficient, especially regarding the quantity 
needed for the downstream analysis. The minimum volume needed would involve more invasive 
techniques and would interfere with the rat’s normal physiology.  
The decision was made to sacrifice the rats at each sampling to acquire the sufficient blood sample, 
counting on plasma marker ELISAs as a quick way to establish the existence of skeletal muscle 
damage for further studies. As the rats would be sacrificed in each sampling, the compensation 
would be exploring the rats with acquiring more types of sample. Spreading the rats, 
NRat=45×2gender, equally between all sampling days for each group, would mean n=3 per gender. 
 Material and Methods 
44 
 
The results from this setup would be subject to little conclusive meaning, and to compensate, one 
gender was dropped (the female rats, keeping the more simplistic male rats), raising the count per 
sampling days and groups (subgroups) to n=6. The count would still stay within the approved 
NRat=90 (for the established protocols). To compensate for the extensive log of more samples per 
rat, the subgroup count was pushed to n=7, to raise statistical significance, simplifying the pre-
injury subgroups (explained in the following chapters). 
These changes are necessary to bear in mind, as to why only one gender was chosen, and more 
importantly, the expectancy of biological variability when looking at the overall picture, since from 
one point of view, the samples are discontinuous by nature. The focus, therefore, shifts to the 
necessity of rigorous technical integrity, to reduce the addition of other types of uncertainty. 
Furthermore, changes in the experimental setup altered the previous balance between more 
simple and advanced analytical techniques due to financial budgeting. The changes weighed down 
on the samples dedicated to qRT-PCR for four expression pathways; requiring the reduction of NRat 
or number of gene profiles. It was considered more valuable switching to whole genome 
expression analysis and pool data concerning any expression pathway of interest at the expense of 
reducing the subject number per subgroup. 
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3.2 The Experimental Backbone 
3.2.1 The Ethical Approval 
The relevant experimental procedures of the research project, DEP2010-22205-C02-01, were 
approved by the Experimental Animal Ethics Committee of the University of Barcelona (Comitè Ètic 
d’Experimentació Animal de la Universitat de Barcelona) (Appendix A.1, p. 167). The animals 
received humane treatment, fulfilling the Spaniard and European directives for the care of animal 
used for scientific purposes (Directive, 2010/63/EU). 
3.2.2 The Experimental Subjects 
3.2.2.1 The General Subject Accounting 
During the course of 2.5-3 years, overall 5 female and 152 male Sprague-Dawley rats (strain: 
RjHan:SD, Janvier Labs, France) went through the entire experimental process. These were outbred 
albino rats with the Tyrc/Tyrc genotype. The rats went through the process generally in lots of 10 
(min 5, max 13) to comply with the housing limitations and the experimental equipment availability. 
The experimental schedule was specifically constructed around general working days and other 
critical factors, to ensure repeatability between lots. Each lot always arrived on a Wednesday to the 
certified facility for experimental animals (Faculty of Biology, University of Barcelona) at the weight 
of 0.10 kg each (about 28 days old, Appendix A.2, p. 168). After six days in quarantine (the following 
Tuesday), the rats were moved to the experimental laboratory to immediately commence the first 
day of the experimental process, weighing 0.156(±0.009) kg. The first rats used were the 5 female 
rats and only served as a part of the trial tests (reasons explained in Chapter 3.1.1). From that point 
onwards, only male rats were used. Parts of the overall experimental project have a different subject 
count for logistical reasons, where ‘N’ will be symbolling an overall count for subjects, data sets or 
combined data sets; and where ‘n’ will be symbolling subgroup count or relevant partial count. 
3.2.2.2 The Subject Identification Integrity 
On their arrival to the experimental lab, each rat was numbered on the tail close to the base, with a 
marker; with the strategy in mind of using odd numbers for male rats and even numbers for female 
rats. These numbers were assigned in a logical order from 0-99 and then reused. This number, the 
working number, was remarked each week to avoid fading of the marks. The number was always 
written horizontally from the base towards the end of the tail, to secure a one-way-of-reading and 
avoiding potential ambiguity. The number was, furthermore, carefully registered and linked to the 
rat‘s home cage, along with the rat‘s unique ID number (a 9-digit code). The working number (on 
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the tail), used during the rat handling phase, was never used simultaneously with the ID number, 
which was applied at the moment of anaesthesia in the sampling procedure. The link registry 
between the two numbers was kept hidden and only used by two agents exclusively at the moment 
of anaesthesia. In this way, all agents that worked with the rats during the handling phase were 
only exposed to the working number; and from the moment of sampling and subsequent analysis, 
were only exposed to the 9-digit ID number without knowing the connection between the 
numbers until made accessible on the databases post all data analysis. The reason for this setup 
was to keep any biased opinion due to any given rat‘s behaviour separate from potentially affecting 
the downstream processes that took place during and after the sampling.  
3.2.2.3 Housing and Care of the Rats 
Throughout the entire run of the experimental project, the same protocol was used to monitor, 
maintain and clean the animal housing on a regular basis. The facility’s room temperature and 
relative humidity ranged between 20-25°C and 45-55% respectively. The rats were housed at 
maximum three rats per cage (dimensions [length ×width ×height]: [465×215×145] mm), were fed 
a standard diet (15-mm diameter granulates) and water ad libitum and were regularly checked for 
stress signs, judging from their physical appearance and body weight monitoring. The weight 
logging consisted of a 3-times/week registry, in addition to other one-time weight registries 
needed, for each animal, until its end in the experimental process. Results from the weight 
accounting are presented in Chapter 4.1. Furthermore, the rats were handled regularly following an 
in-house handling protocol to ensure a routine and calm environment, especially for the 
anaesthetic manoeuvring (Appendix B.1, p. 169). 
3.2.3 Instrumental 
3.2.3.1 The Rat Exercise Treadmill 
An encased five channel treadmill with an adjustable running plane (5°/ramp-setting from −15° to 
25°) and its accompanying treadmill controller (LE 8710, Harvard Apparatus, United States), were 
used for the run-training. The instrument allows the running to be stimulated with an adjustable 
light electric shock (ranging from 0.2-2 mA), received when touching metal grids, located behind 
the back end of the treadmill belt. The encasing of the treadmill separates the five channels/lanes. 
The lid of the encasing is located in the back, above the metal grids, and air holes on the walls 
behind the metal grids and at the front, for each lane, enable free flow of air inside the encasing. 
For each lane, the monitor on the treadmill controller displays: (i) the number of electric shocks 
generated, (ii) the accumulated time of electric shocks, and (iii) the calculated distance considering 
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the set velocity and the time lapsed with the time spent receiving the electric shock deducted. The 
velocity setting gives a range of 0.05-1.50 m/s (0.18-1.08 km/h), with changes made collectively for 
all lanes, controlled with a start/stop button. When the button is on start, all running recordings are 
continuously displayed on the monitor. When the button is pushed to stop, the last recordings 
remain onscreen until the button is hit again or the reset button is pushed. The system offers the 
ability to connect the controller to a PC to automatically acquire the recordings in digital form. 
However, this function was not available for the project. The detailed description of this instrument 
plays an important role in issues concerning handling and monitoring the rats whilst on the 
treadmill. 
3.2.3.2 The Hypobaric Chamber 
A steel based grid creating the interior space of [0.6×0.6×0.9] m (length × depth × height), encased 
in 5 cm thick plexiglass blocks on each side, forms the custom-made hypobaric chamber 
(constructed 2008, Dept. Physiology & Immunology, University of Barcelona). An additional exterior 
steel grid positions the plexi blocks and junctions are sealed with silicon. Three holes run through 
the plexi blocks, each on a different side: (1) for the tube connection to the rotary vane pump (Trivac 
D4B, Oerlikon Leybold Vacuum, Germany), a vacuum pump which lowers the chamber’s internal 
air pressure by suctioning the air out; (2) as an inlet for the passive pressure sensor (Penningvac 
PR25, Oerlikon Leybold Vacuum, Germany), which provides a continuous internal air pressure 
reading on the monitor operating unit (Combivac IT23, Oerlikon Leybold Vacuum, Germany); and 
(3) for the air valve (Vacuum lock valve DN16, Oerlikon Leybold Vacuum, Germany) with adjustable 
opening, enabling the manual control of the air flow. The vacuum pump, theoretically, can create 
a vacuum inside the chamber. However, the strength of the internal steel grid has only been tested 
to withstand an imploding force to the internal pressure of 526 hPa (395 torr), which simulates the 
altitude of slightly higher than 5000 m above sea level. Keeping the air valve closed during the 
running of the vacuum pump, allowing the internal pressure to decrease, until a reached set point. 
Opening the air valve slightly (which increases the internal pressure), with the pump running (which 
decreases the internal pressure), can be adjusted to maintain stabilised pressure, simultaneously 
allowing a steady influx of fresh air through the chamber.  
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3.2.4 The Experimental Strategy and Protocols 
3.2.4.1 The Experimental Strategy 
From the experimental point of view, the project was divided into two phases, connected by the 
point of sampling: (i) the rat handling phase, a pre-sampling phase which included the 
experimental protocols with the objective of creating the desired physiological conditions; and (ii) 
the analytical phase, a post-sampling phase, which included the sample analytical protocols and 
data handling procedure, to measure and interpret the resulting physiological conditions. 
The Rat Handling Phase 
 
Fig. 3-1. The rat handling phase of the experimental procedure commencing with a countdown, from Day −28 to Day −1, 
representing the preconditioning period until the day of the experimental critical point (Day 0). Thereafter, a count-up, from Day 1 
to Day 14, representing the recovery period. 
Fig. 3-1 shows the schematic setup of the rat handling phase of the experimental procedure. Each 
rat handling phase started on a Tuesday (Day −28), the first day of the preconditioning period, 
which was composed of two stages. First (i) the preparation stage of 10 working days (2 weeks, 
minus 1.5 weekends), with the objective of conditioning the rats to get used to the stress of being 
inside the encased treadmill and then to run continuously; and then (ii) the training stage, of 10 
working days (2 weeks, minus 2 weekends), ending with 1 additional relaxing day (always on a 
Monday), with the general objective of increasing stamina on the treadmill.  
The day marking the critical point of the experiment (Day 0, always on a Tuesday) reflected carrying 
out the eccentric exercise-induction of skeletal muscle damage on the treadmill. Lastly, the recovery 
period, lasting 1-14 days (2 weeks, minus 2 weekends), is where the rats were divided into the 
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experimental groups, where each reflected the different application of recovery methods to induce 
the experimental physiological conditions of interests, ending with sacrificing the rats on different 
days during the period.  
3.2.4.2 The Experimental Groups 
With the aim of investigating the effect of two physiological applications on trained rats with 
induced skeletal muscle damage, two experimental groups were planned out: (i) The group of 
hypoxia, [H]-group, subject to intermittent hypobaric hypoxia sessions during the working days in 
the recovery period; and (ii) the group of hypoxia+exercise, [E]-group, subject to the same hypoxia 
sessions as [H]-group, but, immediately followed by an additional light rehabilitation training on 
the treadmill. (iii) The positive control group, [C]-group, (positive to training followed by the 
induced muscle damage) experienced no additional physiological application, i.e., had a passive 
recovery during the recovery period. (See Chapter 3.2.4.3 for negative controls.)  
3.2.4.3 The Sampling Frequency 
For each experimental group, [C], [H] and [E]-groups, sampling took place on 4 different days 
throughout the recovery period; on Day 1, Day 3, Day 7 and Day 14. The subgroups with reference 
to the day count were identified as following: In the control [C]-group, C{01}, C{03}, C{07} and C{14}; 
in the hypoxia [H]-group, H{01}, H{03}, H{07} and H{14}; and in the hypoxia+exercise [E]-group, 
E{01}, E{03}, E{07} and E{14}. 
The Negative Controls 
For a physiological reference, an additional control subgroup was strategized, R{−1}, with rats that 
after having gone through the preconditioning period, training on the treadmill, were sacrificed on 
Day −1; before the induction of muscle damage on Day 0. This control group was relatively 
negative; negative to the induced muscle damage, still, positive to the preconditioning. 
For an analytical reference, another additional control subgroup was strategized, A{−1}, with 
sedentary rats throughout the preconditioning period and were sacrificed on Day −1, before the 
muscle damage induction. This control group was absolutely negative; negative both to the 
induced muscle damage and to the preconditioning. 
A detailed schedule, lining out the actions carried out for each subgroup, with reference to the 
name of periods, stages, weeks and days, is provided in Appendix C.1, p. 189. 
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3.2.4.4 The Experimental Subject Counting 
Rats were randomly allocated to the different scheduled subgroups throughout the entire duration 
of the research project, with the following accounting in mind: Each of the 14 subgroups 
(experimental and negative controls) consisted of n=7 male rats or NRat=98 in total for the study. 
(This count does not include n=4 rats that were discarded throughout the rat handling process).  
Over the preconditioning period, the NRat=98 weighed on average 0.156(±0.009) kg and 
0.24(±0.01) kg at the start and the end of the preparation stage, respectively, and then, 
0.27(±0.01) kg and 0.38(±0.02) kg at the start and the end of the training stage, respectively. The 
weekend between the stages bridged the weight gain. Of those rats, NRat=84 exercised according 
to the muscle damage protocol, on Day 0, weighing 0.39(±0.03) kg at the start of the day and 
0.36(±0.02) kg at the end of the day. These rats commenced the recovery period on Day 1 weighing 
0.37(±0.03) kg, with the average weight gain of 0.0063 kg/d throughout the period. 
3.2.4.5 The Experimental Protocols 
The General Structure of the Exercise Schedule 
During the preconditioning period, the rats generally did sessions of continuous exercise 5 days 
per week (d/week), but not on the weekends. From Week 1 to Week 4, they started with one session 
per day (1 Sess/d), always around 09:00 hours, from Day −28 to Day −25. During the rest of the 
period they did 2 Sess/d. On a day with two sessions, the former session was carried out around 
09:00 hours and the latter session around 17:00 hours, with the goal of minimum 6-h rest in 
between them. On Day 0, the day of muscle damage induction, they carried out two sessions with 
a 4-h rest in between. Lastly, during the 14-d recovery period, Week 5 and 6, the assigned rat group 
did 1 Sess/d (around 13:00 hours), but never on the weekends. 
The General Phases of a Treadmill Session  
All exercise protocols were generally divided into 5 phase-settings (from 0 to IV), as per Fig. 3-1, 
addressing the floor angle of the treadmill, θ, in °, the speed, v, in m/s, the acceleration, a, from one 
speed setting to another, in (m/s)/min, and the duration, t, in min. (0) Phase 0-setting involved no 
treadmill velocity, still, with an active electric shock function. (I) Phase I-setting consisted of a 5 min 
acceleration to a specific velocity mark. (II) Phase II-setting involved a 2-3 min lower acceleration to 
a higher velocity mark in comparison with phase I (this phase was only used in the preparation 
stage, see below). (III) Phase III-setting, the main exercise phase of each exercise session, where the 
set/objective velocity was kept stable. Lastly (IV) phase IV-setting, which included a 1-2 min rest at 
the end with no velocity, still, with the electric shock function active. A detailed qualitative registry 
 Material and Methods 
51 
  
of each rat’s performance, with specific analytical emphasis on phase III, makes up part of the result 
data in this dissertation (see Chapter 3.3).  
 
Fig. 3-2. The general phase-settings for one treadmill session reflected in velocity, v, as a function of time, t. A typical session initiating 
at t=i and ending at t=f with the velocity objective of v=x in phase III, starts and stops with no velocity in phases 0 and IV respectively. 
The velocity change from v=0 to v=x is carried out with acceleration rate aI on phase I and aII on phase II, where aI>aII. 
The Preconditioning Period — Treadmill Protocol During the Preparation Stage 
The formal day count for the preparation stage was between Day −28 and Day −16, covering Week 
1 and Week 2 of the experimental process. This stage had ten working days (days with sessions): 
Day −28 to −24 of Week 1, Tuesday to Saturday; and Day −22 to −18 of Week 2, Monday to Friday. 
The objective of this stage was to reduce stress by conditioning the rats to the environment of the 
treadmill and for that the rats would run continuously on a θ=0°-planar surface — preferably 
avoiding receiving electric shocks from the grids. Day −28 and −27 solely consisted of the rats 
being on the treadmill without running (phase 0-settings). From Day −26 onwards, the treadmill 
phase III-settings started at v=0.30 m/s, t=10 min/Sess and were gradually changed throughout 
the preparation stage with 2 Sess/d until the settings matched the training stage protocol (See 
protocol in Appendix B.2, p. 170). 
The Preconditioning Period — Treadmill Protocol During the Training Stage  
The formal day count for the training stage was between Day −15 and Day −1, covering Week 3 
and Week 4 of the experimental process. This stage had ten working days: Day −15 to −11 and 
Day −8 to −4, both from Monday to Friday Week 3 and 4 followed by an additional day of rest on 
Monday of the 5th week, Day −1. The rats always had two identical sessions per day with phase III-
settings at θ=0°, v=0.45 m/s, t=30 min, with a minimum of 6-h rest between the sessions on each 
day (See protocol in Appendix B.3, p. 172). 
The Muscle Damage Protocol on Day 0 
This protocol was specific on Day 0 (always a Tuesday) and represents the critical point of the 
experiment to induce skeletal muscle damage with eccentric exercise/running on the treadmill. The 
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protocol is carried out twice with a minimum of 4-h rest between the sessions. The rats ran downhill 
with a slope of θ=−15° declination, v=[0.50-0.70] m/s until exhaustion. Each rat was immediately 
removed from the treadmill if muscle damage became visible in the running style; and, if no signs 
were visible, removed from the treadmill at the point of exhaustion (See protocol in Appendix B.4, 
p. 174).  
The Recovery Period – Intermittent Hypobaric Hypoxia Sessions 
The recovery period had the formal day count of Day 1 to Day 14, covering Week 5 and Week 6, 
with overall ten working/session days, starting on a Wednesday and ending on a Tuesday, two 
weeks later. The rats allocated to the groups of hypoxia [H] and hypoxia+exercise [E], were placed 
inside their cages into the hypobaric chamber for 4-h sessions at a simulated altitude of 4000 m 
above sea level, i.e. at 616 hPa (462 torr). Each session started and ended with 12-15 min to adjust 
the pressure gradient in addition to the 4 hours. The sessions were carried out in the morning, 
starting at around 08:00-09:00 hours only on the working days. During each session, the rats were 
monitored closely, registering a qualitative status rapport for each rat every 30 min, to secure their 
wellbeing and on standby to terminate the session immediately if necessary. On a day of sampling, 
the rats always finished their session first (See protocol in Appendix B.5, p. 176). 
The Recovery Period – Treadmill Protocol 
The rats of the hypoxia+exercise [E] group, immediately (<30 min) after each hypoxia session 
(described above), continued with a light rehabilitation exercise on the treadmill. The rats ran uphill 
with θ=5°, inclination, at v=0.30 m/s for t=15 min in the treadmill phase III-settings. The idea was 
to imitate the condition of humans doing exercise inside a hypobaric chamber. However, as the rat 
treadmill did not have wireless control, the analogue setup was limited regarding those conditions 
(See protocol in Appendix B.6, p. 178). 
Running Encouragement Whilst on the Treadmill 
The mild electric shock (intensity range: I=[0.2–2] mA) that the rats received if lagging in the running 
and touching the metal grid was a useful stimulus to encourage running, still, also the most efficient 
resource for stimulus throughout all the weeks of training. Therefore, the use of the electric shock 
was regulated with gradually changing minimum and maximum intensity limits throughout the 
weeks. For the ten working days of the preconditioning stage, the intensity limits ranged from 
Imin=0.2 mA at the beginning to Imax=1.0 mA at the end of the stage. For the ten working days of 
the training stage, the intensity limits ranged from Imin=0.8 mA to Imax=1.8 mA. During the muscle 
damage protocol on Day 0, the intensity limits ranged from Imin=1.2 mA to Imax=1.8 mA. Lastly, for 
the light exercise protocol, used throughout the recovery period, intensity limits ranged from 
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Imin=1.0 mA to Imax=1.6 mA. A log was kept to monitor the changes made in the applied intensity, 
which was always adjusted to the worst performing rat in each training lot. Following the log, it was 
made sure that throughout all the exercise sessions, the intensity was never lower than the last 
change made (for the training lot in question), still, kept within the described minimum and 
maximum limits for each period/protocol. The training agents were, furthermore, instructed to 
knock on the back wall of the treadmill, or simply give the rats a little push (with their hands), to 
strategically reduce the use of the electric shock, hence, making the electric shock more effective if 
nothing else worked. At the end of each training session, the good rat performers (subjective-
qualitative estimate), always received a bit of chocolate as a reward linked with the sound of a bell. 
Each rats’ reaction to the chocolate was logged to possibly identify stress or tiredness (No data 
provided in this dissertation). 
The Control Group Protocol 
During the preconditioning period, the absolute negative control rats, A{−1} (n=7), always stayed 
in their cages close to the treadmill during sessions until Day −1. The relative negative control rats, 
R{−1} (n=7), were randomly allocated to the group on Day −1 after participating in the treadmill 
protocols like the other rats. The positive control rats, [C]-group (n=7 4 subgroups), randomly 
allocated to their group, participated in the treadmill training like the other rats until Day 1, at the 
start of the recovery period. The [C]-rats always waited in their cages on top of the hypobaric 
chamber, during the sessions, to reduce the difference in the stress stimulus provoked by the noise 
from the vacuum pump. 
3.2.5 The Sampling Procedure 
The project’s sampling procedure (The S33+ Sampling Process, in Appendix C.2, p. 190) intertwined 
the preparation stages of all provisional analytical assays, some of which that do not form part of 
this dissertation — however, the level of integrity and quality assurance still does. 
3.2.5.1 The Material used in the Sampling Procedure 
Chemicals 
0.05% (v/v) Chlorine solution for surface sterilisation; 0.5 M NaOH-solution and 70% (v/v) Ethanol-
solution for sterilisation of surgical material. 0.9 g/dL NaCl-solution for tissue bath; 30 g/dL 
Urethane solution, with a 0.9 g/dL NaCl as diluent, for irreversible anaesthesia (solution-batches 
older than 6 days were not used); Cocktail combination with 42.9% of 100 mg/mL Ketamine 
solution and 57.1% of 20 mg/mL Xylazine solution, for long reversible anaesthesia; Isolfurane as 
backup anaesthesia. Isopentane and liquid N2 for tissue storage. 
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Material 
Three-part (1-mL and 2.5-mL) syringes with 23 G needle (Blue) for the anaesthesia; 3-part (5.0-mL) 
syringe with 21 G needle (Green) for retrieving blood. 4-mL tubes to receive blood: K3-EDTA and 
Na-heparin treated. Surgical equipment: surgical blades (No. 10A and 21A) and handles, pincettes 
and scissors. Surgical gauzes for drying and plastic plates and bags for tissue storage.  
3.2.5.2 Maintaining the Subject Identification Integrity 
Just before initiating the sampling with anaesthesia, the working number on each rat in the 
sampling lot was hidden with its corresponding unique 9-digit ID (as a barcode), to ‘blind’ the 
agents carrying out the sampling procedure (see Chapter 3.2.2.2). Furthermore, within each lot, the 
rats in the sampling lot were put under anaesthesia in a random order. The 9-digit ID codes 
displayed during the sampling would therefore never appear in a logical order, to further confuse 
any preconceptions of which rat was in sampling. Moreover, during the sampling routine, 2-3 rats 
could coincide in the process as far as being in the sampling laboratory at the same time. To avoid 
any mix-up between the dedicated plastic and storage material for each rat, the random 
anaesthetic order (to confuse the 9-digit number logic) was given a logical Roman operating 
number (I-X, depending on the lot size) accompanying each rat throughout the sampling routine. 
Pre-sampling, each roman number was applied to a set of plastic and storage material dedicated 
to one rat in the sampling. This action, furthermore, controlled the identification of each pre-
weighed material and gave a clear separation as to which material should be in use for any given 
rat. 
3.2.5.3 The Anaesthesia and the Blood Sampling 
Rats were weighed about 1 hour before the sampling process to calculate the anaesthetic dose. To 
reduce the stress for each rat at the point of anaesthesia, the necessary handling, formed part of 
the regular handling protocol, used throughout the rat handling phase (see Chapter 3.2.2.3). 
Sacrificing each rat in its sampling, an irreversible anaesthetic agent (Urethane dose 1000 mg/kg 
rat body weight) was injected IP (right side) (Parasuraman, Raveendran and Kesavan, 2010). In the 
case of the solution seeming to end up in the fat tissue, thus not having sufficient anaesthetic effect, 
the additional dose was injected IP (left side) to the maximum of total Urethane dose of 1500 
mg/kg rat body weight. Signs of adequately deep anaesthesia was generally reached after around 
5 min, at which point the rat was re-identified (visually) with its registered ID code. The coded rat 
was moved into the operating laboratory and prepared for blood sampling via the vena cava, 
opening the abdominal area for further dissection (Parasuraman, Raveendran and Kesavan, 2010). 
About 3-4 mL of blood sample went into a pre-weighed syringe and was weighed to estimate the 
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density. The sample was distributed according to the estimated need of 1 mL into a heparin-treated 
test tube for rheological analysis (requiring the density measure) and the rest of the whole blood 
into an EDTA-treated test tube for a general blood cell count, plasma analysis and stem cell analysis. 
The plasma analysis with plasma markers makes up part of the result data in this dissertation (see 
Chapter 4.3). 
Reversible Anaesthesia 
As the original idea was to sample each rat for blood several times, the reversible anaesthesia 
needed to be used (until eventually sacrificed with an irreversible anaesthesia) with a combination 
of the dose of 60 mg/kg Ketamine and 16 mg/kg Xylazine (IP injection). In these trials, if a rat did 
not show sufficient level of anaesthesia after the expected amount of time, the anaesthetic level 
was assisted by having the rat inhale isoflurane. With this anaesthesia, the blood sampling was 
carried out via the saphenous vein or the tail vein (Parasuraman, Raveendran and Kesavan, 2010). 
3.2.5.4 The Dissection of Skeletal Muscle Tissue 
After the blood sample was acquired the dissection of the skeletal muscle started. From the rat’s 
left side: m. tibialis anterior, m. gastrocnemius, and m. soleus. Except for m. soleus, the muscles were 
cut into approximately even distal and proximal parts. All tissue samples were coded and weighed, 
and immersed in 1 mL of isopentane, and then stored in liquid N2 until the point of histochemical 
analysis (not part of this dissertation). From the rat’s right side: m. tibialis anterior, m. gastrocnemius, 
m. soleus, m. extensor digitorum longus, m. quadriceps femoris. The sampling objective focused 
on fractioning each muscle to the maximum of three ≈200-mg samples and the rest of the tissue 
in the fourth fraction (if applicable). Each tissue fraction was individually weighed and coded, put in 
a sampling bag, fast frozen in liquid N2 and stored at −80 °C until the point of biochemical analysis 
(on all muscles) and gene expression analysis (only on certain m. soleus samples). The gene 
expression analysis on m. soleus makes up part of the result data in this dissertation (see Chapter 
4.4). 
3.2.5.5 The Dissection of Other Organs 
After the dissection of the skeletal muscles of interest had concluded, other organs (the diaphragm, 
cardiac muscle, lungs, and brain) were dissected, coded and weighed. The fresh weight of the lungs 
and the heart were used for a normalised developing-weight comparison. All the samples were 
then fast frozen in liquid N2 and stored at −80 °C until the point of biochemical analysis (not part 
of this dissertation).  
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3.2.5.6 The Weight Statistics 
The weight fractions of the lungs and specific parts of the heart, the right ventricle and the 
combined left ventricle and septum, were calculated as: 
wx
wRat
 
Equation 3-1 
where, wx, symbols the weight of organ or organ part in question, and wRat, symbols the rat body 
weight. Furthermore, weight ratio between the ventricles of the heart, to obtain the Fulton-index, 
FI, was calculated as per the following formula: 
FI=
wr
w(l+s)
 
Equation 3-2 
where, wr symbols the weight of the heart’s right ventricle and w(l+s) symbols the combined weight 
of the heart’s left ventricle and septum. One-way ANOVA with Turkey’s Test was used to analyse 
the weight ratios of all the subgroups in the study with the threshold of significance at p≤0.05.    
3.2.6 The Trial Tests and the Developmental Actions 
Certain testing was needed to establish the custom experimental protocols that involved the rats, 
actions of which led to marked changes in the experimental strategy and procedures. The first 10 
rats, beginning with 5 female and then 5 male, were used to develop the rat experimental protocols 
and establish adequate sampling techniques. (From this point onwards, only male rats were used 
for the subsequent actions). The following 20 rats and the samples acquired from those, were used 
to establish the final versions of the rat experimental protocols, including carrying out the muscle 
damage protocol (see Chapter 3.2.4.3) only once. Furthermore, the sampling and the analytical 
processing techniques were established with those rats. 
3.2.7 The Data Processing & the Management System 
As part of an internal quality control setup for the project, all actions relating to the experimental 
and analytical procedures were carefully logged to ensure traceability and reliability of the results, 
using MS Excel. The acquisition of the sample data was obtained (real time) using tailored VBA-
tailored programming, where the entire sampling process was carefully registered using unique 9-
digit ID barcodes for each and every sample or sample fraction. All logging included hour, date and 
which agent carried out the action. The acquired log was imported into a VBA-tailored post-
sampling database which managed all analytical data and traceability and status; managing the 
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logs on sample banks, keeping information on localisation and utilisation for the count of freeze-
thaw cycles with reference to an hour, date and agent involved.  
3.2.8 Non-Conformity Issues 
A deviation report system was used throughout the experimental and analytical trials to register all 
non-conformity issues that occurred. The issues were divided and categorised into small deviations 
and big deviations. Small deviations included incidences that did not comply with given protocols, 
in a way that they did not require the action of stopping a procedure (experimental or analytical). 
Big deviations, on the other hand, included incidences that did require partially or fully stopping a 
procedure (experimental or analytical) until it was temporarily or permanently resolved by a 
supervising agent. 
The agent that experienced the incidence filled out a deviation report and forwarded it to the 
relevant supervising agent responsible for the procedure in question. Once a solution was 
provided, the supervising agent added the resolution to the report for completion. The reports 
were made accessible for the research group to see, and therefore all agents were updated in detail 
on the actions that took place. 
3.2.9 The General Statistical Approach 
The given values for each subgroup are generally expressed as the average accompanied with its 
standard deviation; unless otherwise noted. Linear T-statistics were used to evaluate regression and 
linear F-statistics for comparison with the threshold of significance at p≤0.050. The general route 
of F-statistics was with 1-way ANOVA due to the general experimental setup, whilst the post hoc 
tests were dependent on the analytical/sampling procedure involved. The main analytical 
descriptions in the following subchapters, outline the specific statistical involvement.  
3.2.10 Software Packages 
The data management was carried out using Microsoft Excel 2007, 2010 and 365 (version 12, 14 
and 15, respectively, Microsoft Corporation, USA) with an update throughout the years. All basic 
statistical calculations were carried out in Excel spreadsheets. The additional statistical analysis of 
ANOVA and post-hoc tests were carried out using SigmaPlot (version 11 and 12, Systat Software 
Inc., USA).  
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3.3 The AEY Performance Score 
3.3.1 The Innovative Premise 
The AEY Performance Score came about as a secondary (backup) measure for the experimental 
project, addressing the need to qualitatively quantify a rat’s performance, based on its running style 
and actions, whilst running on the treadmill. In its development, the style was based on three 
registry criteria, each with a resulting score value. The criteria were each designated its letter, A, E, 
Y; as the IATA airport code, AEY, for the town of Akureyri, from where the two agents come, who 
designed and defined the qualitative style codes and the related code of quantification. 
3.3.2 The Subject Count and the Developmental Stages 
Being a secondary measurement, developed at the onset of the experimental project, the registry 
notes cover NRat=130 overall. In retrospect, the development occurred in 4 stages, in the following 
order: (i) The commencement stage, NRat=20; (ii) the formation stage, NRat=36; (iii) the qualitative 
assessment and quantification stage, NRat=65; and (iv) the re-testing stage, NRat=10. 
3.3.3 The Equipment 
For the score, the following items were used: The rat treadmill and accompanying controller used 
during the training of the rats as per Chapter 3.2.3.1. Extensive registry protocols to log all actions. 
VBA tailored MS Excel spreadsheet to receive imported data, and to apply calculations according 
to the quantification protocol. 
3.3.4 The Registry Protocols 
3.3.4.1 Commencement- and Formation Stages (the ‘Historical’ Pretext)  
The Commencement Stage 
During the commencement stage, the agents were still getting to know the practical limitations of 
using the treadmill. These limitations were based on reoccurring artefacts that obscured the 
performance parameters, exclusively the two that were related to the electric shock count displayed 
on the treadmill controller. These artefact-incidences were generally based on either faeces or urine, 
disposed of by the running rats, touching the metal grid momentarily or for a longer time. If the 
displayed values (electric shock-related) from the monitor were the only values for future 
references, one could believe that the rat in question was touching the metal grid instead of 
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running continuously. The registry of these incidences gradually changed from informal 
observations to a categorised registry as part of a monitoring protocol during the treadmill 
sessions, where the artefacts and the error in the electric shock related parameters line out the 
criteria for the Y-part of the score. 
The Formation Stage 
During the formation stage, the A- and E-part of the score became gradually defined as the training 
treadmill protocols had been defined. The first observations involved a slacking tail of a rat that was 
running continuously. The tip of the tail seemed to be touching the metal grid and potentially 
affecting the reading from the treadmill controller (with increasing the electric shock count), 
although the rat could be considered a good runner. Moreover, throughout the stage, a trend was 
noticed by the experimenters. The rats seemed, in general, to be lifting their tails so the tip would 
not touch the metal grid, quite evidently, in the early part of a session. However, drawing closer to 
the end of a session, the tails were slack and perhaps touching the treadmill belt. Therefore, it 
seemed that the position of the tail could be somewhat telling of how tired the rat was during a 
session. These observations eventually formed the E-part of the score. 
Simultaneously, still more complex in defining, the informal registry of how a rat was running 
became developed. Between a ‘good’ performer and a ‘bad’ one, a running on the treadmill belt 
without touching the metal grid, as opposed to a rat continuously touching the metal grid, the 
electric shock count was adequately representative to distinguish the two. Relatively clever rats, 
however, still managed to partially avoid running with some logical or clever ways without touching 
the metal grid. Many of these ways required physical involvement by the experimenter (sometimes 
continuously throughout a session or series of sessions) as increasing the intensity of the electric 
shock had no influence on these situations. On the same note, the registry from the treadmill 
controller alone would indicate a rat like this as a good runner, whilst in reality, the rat might not 
have been training, and therefore, although going through all training sessions it could potentially 
be an outlier subject. This turned out to be more common than expected, thus, the physical 
positioning and actions of the rats when on the treadmill, eventually formed the A-part of the score. 
3.3.4.2 The Qualitative Assessment and the Quantification Stage 
At the beginning of this stage, all classifications for a qualitative assessment of all three criteria of 
the score were ready, and formal systematic registry was initiated (see protocol description in 
Chapter 3.3.4.3). The quantification stage took place after all the rats in the experiment had gone 
through the training, applying calculations on all the systematic qualitative assessment registry 
afterwards. In hindsight, this meant that the development of the quantification protocol was 
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independent of the assessment acquisition, thus more objective (see protocol description in 
Chapter 3.3.5). Still, some sub-classifications were gradually defined and incorporated during the 
qualitative assessment stage. However, the quantification method strategically does not 
differentiate between them, making sure the entire assessment would be equally valid, and 
furthermore, keeping the score criteria open for unforeseen classifications. 
3.3.4.3 The AEY Registry 
The treadmill protocols’ phase III (Chapter 3.2.4.5), representing steady velocity, was utilised to carry 
out the qualitative assessment. Throughout the entire phase III of each session, for each rat, in every 
session, the three criteria (A, E, Y) were assessed at the end of every 5 minutes, except in long 
duration of the muscle damage protocol, at the end of every 10 minutes. Fig. 4-7 and Fig. 4-8 (pp. 
80-81) in the Results (Chapter 4.2.1), show the resulting classification marks with a diagram and 
description, along with the assigned score value for each of the three score criteria. Note that the 
score value was not available at the actual time of the assessments. A typical registry and 
subsequent calculations can be found in Appendix C.5 (p. 192).  
During each registry period (RP) of 5 min (or 10 min), the rat could show many different styles, 
especially corresponding to the A-criteria. In the case of many styles (within the same criterion), the 
most representative were registered only once with the most dominant style underlined, which 
later, was taken into account in the quantification protocol.  
3.3.4.4 The Stage of Re-testing 
As all the rats for the research project had been sacrificed once the quantification was in place, rats 
for a small deviating project were used to quickly retest the data processing efficiency. These rats 
(see Chapter 3.3.2), with an extended exercise protocol for preconditioning up to 5 weeks, provided 
the opportunity to quickly retest the methodology and applying the automatised calculations for 
the score. No data on measuring the efficiency of the procedure is provided. Furthermore, these 
rats are not incorporated into any other analytical aspect presented in this dissertation.  
3.3.5 The Quantification Protocol 
3.3.5.1 Turning the Classifications into Scores 
Each score criterion would be represented with its resulting score value, but all of them had a style 
or classification that was considered the most favourable and representative of a theoretically ideal 
rat running on a treadmill. In a case of an ideal rat, the score value would be reflected in a score 
roof of 1.00 within each score criterion. Other styles of situations that were less favourable, with 
 Material and Methods 
61 
  
reference to the ideal rat, would reduce the score value until it would be representing a theoretically 
most unfavourable situation, reflected with a scoring floor of 0.00 within each score criterion. 
In the A-criterion, the rat commenced each session with the roof value 1.00, by default. Only one 
style was considered to represent the ideal runner and reduced this ‘1’ by the value of 0.00 (i.e. no 
effect). Meanwhile, the other styles were given negative values, i.e. styles with unfavourable traits of 
various degree, which reduced the default value according to the following formula: 
[A]RP=1+
∑αmark
nα
 
(Equation 3-3) 
where, the sum of the score value for each registered mark, Σ(αmark), divided by the number of A-
criterion marks, nα, added to ‘1’ would give the A-score, [A]RP, for any given registry period (RP), of 
(normally) 5 minutes. As each mark is only registered once within each registry period, an 
underlined dominant mark was treated as occurring twice, both in the score value sum and the 
mark count. Many of the unfavourable styles were visually different but assigned with a similar 
negative value. This meant that the score would not be designed to end up with a value that could 
be back traced to a specific average style, rather, the resulting value would be indicating how good 
a runner the rat was on the scale from 0 and 1. 
In the E-criterion, based on the tail position, the score value was obtained differently, with only 4 
(+1) possible style assignations. One tail position was considered the most favourable, with the roof 
value of 1.00. With two intermediate positions, given the score values of 0.75 and 0.50, and the 
most unfavourable position of the tail with the score value of 0.25, the score floor value of 0.00 was 
to reflect on an unfavourable A-criterion situation where marking the tail position would be 
impossible or redundant. The score for a registry period was calculated as: 
[E]RP=
∑ εmark
nε
 
Equation 3-4 
where, Σ(εmark), is the sum of the score value for each registered mark and, nε, the number of E-
criterion marks, giving, [E]RP, the E-score for any given registry period of (normally) 5 minutes. 
The Y-criterion, representing artefacts in the electric-shock parameters, commenced with the score 
roof value of 1.00, by default. This meant that if no incidence took place that would reduce the 
validity of the electric shock parameters, the Y-score would remain as 1.00. Any registered incidence 
would then have the effect that the score value would be lower. However, classifying different 
incidences with regards to influence on the score did not have any reasonable backing. Throughout 
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the historical observational registry, four main types of incidences covered the majority, and each 
was given the same reducing value of −0.15. Moreover, only the count of type of incidence (with 
reference to these four main types) would affect the value, giving the lowest score of 0.40, if all of 
them would occur during registry, according to the following formula: 
[Y]RP=1+∑υmark,          nυ-specific 
Equation 3-5 
where, the sum of the score value for each type of registered mark, Σ(υmark), is added to ‘1’, resulting 
in the Y-score for any given registry period, [Y]RP, of (normally) 5 minutes. As each type of 
observation was generally followed by a detailed description in the registry, they could vary in terms 
of content. It was not considered reasonable to code the situation further. Therefore, the Y-score 
only served to tell how much attention should be given to this part of the monitoring registry. 
However, if during monitoring registry, incidences were continuously reoccurring, and considered 
to have a major effect on the readings of the treadmill monitor, a specific registry mark would 
always change the sum of score values, Σ(υmark), to −1.00. This specific registry was independent of 
other registered marks in the registry period, reducing the [Y]RP to the score floor value of 0.00 to 
differentiate numerically from the lowest calculated score of 0.40.  
3.3.5.2 Averaging Out the Scores 
To represent an entire session regarding each score criterion, the score from each registry period 
within a given session was averaged out according to the following formula: 
[X̅]Sess=
∑ [X]RP,i
N
i=1
NRP
 
Equation 3-6 
where, for each score-criterion X (either A, E or Y), the average session score (or the session score, 
[X]Sess) was calculated by summing up the scores from the registry periods, [X]RP, divided by the 
number of registry period, NRP. With similar logic, a group of session scores could be added up and 
divided by the session count included, to represent the average score for a given period. 
3.3.5.3 The Representation of the AEY Score 
The AEY score was designed to be represented as [A;E;Y] to pool the three criteria together, where 
a theoretical best rat would have the score of [1;1;1] and the theoretically worst rat would have the 
score of [0;0;0]. Furthermore, as each score (averaged out or not) can represent different protocols, 
the score should always be accompanied by a represented analysed timeframe and information 
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about the training setup (θ, v, t, etc.) to evaluate the possibilities of any comparison if the score 
would be used for other protocols. 
3.3.5.4 The Data Overlook and Comparison 
The AEY scores were primarily pooled to weekly averages with quartile calculations for a descriptive 
overview of the scores involved, where the lower and upper fences marking ≈2SD could 
potentially differentiate the outliers. The use of the standard deviation (SD) and the standard error 
of mean (SEM) was applied to describe the variability and to estimate the homogeneity of the entire 
subject pool. 
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3.4 The Plasma Markers of Muscle Damage 
3.4.1 The Subject Count 
The total of NRat=20 was used to establish the eccentric exercise protocol for muscle damage 
induction; and after that, NRat=98 with the established experimental procedure. These 98 male rats 
were distributed with the objective of n=7 for each experimental subgroup as per Chapter 3.2.4.5. 
3.4.2 The Equipment and the Reagents 
Centrifuge (CM-6MT, ELMI Ltd, Latvia); ELISA kits: Rat CK-MM [2112-2], Rat Myoglobin [2110-2-N], 
Rat Skeletal Muscle Tn-I [2020-2-SK] (Life Diagnostics Inc., USA), each kit contained antibody-
coated 96-well plates and all necessary reagents; Microplate spectrophotometer (Infinite 200, 
Tecan Group Ltd, Switzerland), exported readings to an MS Excel spreadsheet; Vortex mixer (VX-
200, Labnet International Inc., USA); Plate agitator (Reciprocal 30, Labnet International Inc., USA); 
Tips and Precision pipettes [10, 20, 100, 200, 300(multi)-µL] (Research Plus, Eppendorf AG, 
Germany); 0.5-mL microtubes; 5-mL polypropylene test tubes; 0.5-L squirt bottle; distilled H2O. 
3.4.3 The Sampling 
Whole blood was received via the principal sampling procedure (see Chapter 3.2.5.3), and 
centrifuged at 2300 rcf (3531 rpm) for 15 min. The plasma was evaluated according to haemolytic 
appearance (Chapter 3.4.3.1) and then aliquoted into microtubes. Each tube contained about 120 
µL of plasma, enough to carry out one run of assays on both ELISA kits, to not influence the quality 
of the total plasma volume (from each rat) with freeze-thaw cycles if a second run was needed. 
Plasma aliquot in a microtube (from the same rat) was registered with a unique 9-digit sampling 
ID each. Strictly within 60 minutes after sampling, all microtubes were stored at −80 °C until the 
ELISAs were carried out. A diagram of the procedure is shown in Appendix C.6 (p. 193). 
3.4.3.1 The Plasma Haemolytic Appearance Evaluation 
A custom made key was constructed to evaluate the plasma with reference to its colour to indicate 
the level of haemolysis. This was carried out as a precautionary step in the case of haemolysis 
affecting any type of downstream plasma analysis. The haemolytic evaluation key and matching 
CMYK colour code are shown in Appendix D.1 (p. 194). 
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The distribution of non-outliers and outliers from the plasma assay results were checked against 
their evaluation with the key code, after, identifying any potential outliers with the A15 estimation 
and, thereafter, with quartile calculations.  
3.4.4 The ELISA procedure 
Each kit came with its protocol from the manufacturer (Appendix B.7, p. 180), which was followed 
exactly except using 3 wells (3 replicas) for reading each sample and concentration points within 
the kit’s calibration curve, as opposed to relying on 2 replicas. The fundamental reliability of 
measurement was determined by looking at relative standard deviation between the readings from 
the three replicas, according to the general formula: 
RSD=
SD
x̅
 
Equation 3-7 
where the relative standard deviation, RSD, is equal to the standard deviation, SD, divided by the 
average reading between the replicas. The average was considered to be good if RSD≤0.05 and 
acceptable if RSD≤0.10. Any average reading with an RSD>0.10 was either: (i) ‘cleaned’ if one 
reading point could be considered an anomaly and omitted (noting the subsequent quantification 
with an observation for the interpretation); or (ii) the sample was repeated (in the case of procedural 
error) or omitted entirely. Find further explanation in Chapter 3.4.6. 
3.4.5 Verifying the Use of the Muscle Damage Protocol 
The Rat Myoglobin and Rat Troponin-I kits were used for the first 20 rats to specifically evaluate the 
effectiveness of inducing muscle damage with the muscle damage protocol (which, at first, only 
included one session (1 Sess/d) on Day 0, but not two sessions (2 Sess/d) as per Chapter 3.2.4.5). 
The Rat Troponin-I kit, however, also demonstrated calibration curves with too high RSD values in 
general, and therefore to avoid any further uncertainty, the Rat Myoglobin and the Rat Creatine 
Kinase kits were used instead, thereafter, for the NRat=98. This was the same point at which all 
protocols were established including using the muscle damage protocol as 2 Sess/d. 
3.4.6 The Data Analysis 
All calibration curves were run in triplicate on each well plate to reduce any potential ambiguity and 
to provide the minimum basis for statistical analysis. The validity of each calibration curve was 
referenced to the coefficient of determination, R2, and was accepted if R2>0.999, preferably 
R2>0.9999. However, due to marked matrix effect in the lowest concentrations, the curve was 
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fractioned and experimental samples referenced to the linear fit that corresponded to the fraction 
part of the curve in question. 
Once all experimental samples had been quantified, after the RSD-‘cleaning’ or a re-run if 
necessary, the concentration values allocated to each experimental subgroup were revised in two 
separate ways: (i) based on the quartile calculations, using the 1.5IQR (Interquartile range) to 
detect the outliers, and then with the Grubb’s method (Ellison, Barwick and Farrant, 2009); and, in 
the case of detected outliers, (ii) the values of the outliers were reduced with the A15 estimation 
(Ellison, Barwick and Farrant, 2009). The comparison between the subgroups was based on two 
facts: (a) that the subgroups of negative control (absolute and relative) did not strictly follow the 
time line with respect to the critical point of muscle damage, whilst the other subgroups did (where 
2-way ANOVA would be appropriate); and (b) given the fact that the time factor (after the critical 
point) was separated by using different rats at each time point, and not the same rats throughout. 
— Therefore, the resulting statistical tests to determine the significance between the groups utilised 
was 1-way ANOVA accompanied with Turkey’s test post-hoc analysis for multiple comparison, with 
significant difference referenced to p<0.05. 
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3.5 The Gene Expression in Muscle Damage 
3.5.1 The Subject Count 
The total of NRat=42 male rats was used for the differential gene expression analysis to represent 
the 14 subgroups, each with n=3. The selection of the n=3 from n=7 per subgroups was primarily 
based on the size/quantity restraints of the analysed tissue, the m. soleus, in the sample processing 
as per Chapter 3.5.3. 
3.5.2 The Equipment and the Reagents 
Homogeniser (Polytron PT 3100, Kinematica AG, Switzerland); Dispersing aggregate (PT-DA 
07/2EC, Kinematica AG, Switzerland); Analytical balance (GF-200, A&D Instruments Ltd, United 
Kingdom); Thermobath (Certomat 886 362/8 WR, B. Braun AG, Germany); Centrifuge (CR3i, Thermo 
Electron Corporation, USA); RNA extraction kit (RNeasy Fibrous Midi Kit, QIAGEN GmbH, Germany), 
the kit contained specific filters, plastic ware and reagents; Solutions not included in the kit: Absolute 
Ethanol, 2 M DTT(dithiothreitol)-solution. For cleaning and sterilisation: 1 M NaOH solution, 70% 
(v/v) Ethanol solution, DEPC-treated water. Sterile consumables: filtered tips and precision pipettes 
[20, 200, 1000 µL] (Research Plus, Eppendorf AG, Germany); Surgical knife; 15-mL sample tubes]; 
25-G needles; 1-mL 3-piece syringe; 15-mL falcon tube; 0.5-mL cryogenic microtubes (to store 
analytical samples). 
3.5.3 The Sampling 
Frozen m. soleus tissue samples, prepared in the main sampling procedure (See chapter 3.2.5.4) 
were used as the most likely candidate of skeletal muscle to have induced muscle damage after 
the experimental application. Due to economic restraints, the downstream analysis only allowed 
for n=3 per each of the 14 experimental subgroups. The combined sample requirements for the 
RNA extraction kit and the subsequent downstream analysis, restricted the selection even further 
with using tissues of 200-250 mg, and not much less, for the RNA extraction, still, the highest RNA 
yield possible for the subsequent microarray analysis. The selected rats within each group were 
therefore based on getting the highest quantity of an m. soleus tissue sample (wmax = 250 mg) 
followed by rat having the next numerically lighter tissue, etc. The laboratory was then sterilised for 
the subsequent sample process. 
 Material and Methods 
68 
 
3.5.4 The Sample Processing 
3.5.4.1 The Homogenisation 
The samples were homogenised in a 15-mL sample tube on ice in the DTT-RLT buffer from the 
RNA extraction kit. The homogenisation was carried out in 3 cycles of 10-15 s at full speed (with 
pauses to check any stuck material that potentially wouldn’t get properly homogenised). After the 
final cycle, the buffer was applied on the dispersing aggregate to remove all tissue residues back 
into the sample tube, aiming to end up with the final ratio of 1 mL of buffer per every 100 mg of 
tissue. The tubes were store at −80 °C until the RNA extraction was be carried out. 
3.5.4.2 The RNA Extraction 
The RNA extraction was carried out as per the instructions from the manufacturer of the kit, with 
some necessary on-site adaptations (See protocol, Appendix B.8, p. 186). The extraction kit was 
chosen for being optimised for fibrous tissues and included genomic DNA removal step that could 
potentially contaminate the downstream analysis. In theory, the kit would yield 5-10 µg of RNA per 
10 mg of muscle tissue; with maximum 250 mg tissue capacity per sample (as mentioned above). 
The downstream analysis required a minimum of 200 µg of RNA per sample. Hence the primary 
criterion for selecting the n=3 samples was not to jeopardise the quality of the analytical results. 
The extracted RNA solution samples were stored at −80 °C until the microarray analysis was carried 
out.  
3.5.4.3 The Gene Expression Analysis 
The microarray gene expression analysis was carried out by Bioarray S.L. (Alicante, Spain) using a 
SurePrint G3 Rat Gene Expression Microarray (ID 028279, Agilent Technologies, USA). The quality 
and quantification controls, coverage, hybridization and scanning and the quality analysis of the 
processed arrays, was carried out according to the official protocol for Two-Colour Microarray 
Based Gene Expression Analysis, version 6.5 (Agilent Technologies, 2010).  
3.5.5 The Data Analysis 
The Bioarray research service provided all statistical data; carrying out the normalisation, relative 
quantification of the genes with differential expression. The analysis was carried out using the open 
source software Bioconductor which is based on the R programming language. All possible 
comparisons between the experimental subgroups for differential gene expression was calculated, 
and the significance expressed with a direct p-value and adjusted p-value for false discovery rate 
(FDR), p≤0.05 for a significant difference. For the adjusted p-value from the multiple testing to be 
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more representative, the number of included genes was decreased from the 30003 genes (almost 
the entire rat genome) to 742 genes. The 742 genes, collectively represented 12 expression 
pathways thought to be, at least, relevant to the experiment in question. These pathways were 
chosen according to the literature summary from SABiosciences/QIAGEN (Qiagen, 2012) and 
consisted of: Hypoxia signalling, Skeletal muscle myogenesis & myopathy, Angiogenesis, 
Angiogenetic growth factors, EGF/PDGF signalling, Inflammatory Cytokines & Receptors, mTOR 
signalling, Mitochondrial energy metabolism, Oxidative stress, Stem cell transcription factors, VEGF 
signalling, and Wound healing. 
The resulting analysis only represented the significant differential expression, fold change values, 
amongst all the subgroup comparisons, with reference to four expression pathways: Skeletal 
muscle myogenesis & myopathy, Hypoxia signalling, VEGF signalling and Wound healing; and 
adjusted to the 740 genes, mentioned above. The entire gene symbol and code list that mark the 
data analysis can be found in Appendix D.2 (p. 195).  
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4.1 The Weight Measurements 
To accompany the following results in this chapter, as a reminder, the rats were divided into groups 
with reference to the experimental Day 0, where the use of eccentric exercise (via downhill running) 
was intended to induce skeletal muscle damage. Thereafter, the rats were allocated to three groups 
defined by the recovery applications: the [C]-group, the positive controls with passive recovery; the 
[H]-group, recovery with intermittent hypobaric hypoxia sessions; and the [E]-group, which had the 
same recovery type as the [H]-group, followed by light rehabilitation exercise sessions.  
Within each group, the subgroups are defined by the corresponding [C], [H] or [E] and the day of 
sampling {Day No.}. The negative control groups were sampled one day prior to Day 0, 
representing sedentary and trained rats, A{−1} and R{−1} respectively.  
4.1.1 The Body weight of the Rats 
The routinised rat handling protocols (Chapter 3.2.2.3) ensured a 3-times/week weight registry for 
each rat. However, throughout the working period of the project, more rats than the study’s 
NRat=98 make up these registries. These rats are part of the initial phases, participating and the 
establishments of protocols, etc., and explains why the NRat is fairly fluid in this dissertation, 
depending on which data set is being presented. However, unless it is specified, the following 
results only involve the study’s main NRat=98. 
 
Fig. 4-1. The rats’ body weight log (Ninital=98), in kg, throughout the experimental procedure, in days, with a weight registry of 3 
times/week. The days reflect: the preconditioning period (Day −28 to −1); the day of skeletal muscle injury induction w/ 4 weight 
registries (Day 0); the recovery period (Day 1 to 14), where the N is dropping due to sampling. 
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In Fig. 4-1, the overall weight log presents the rat’s body weight, in kg, as a function of time, in days. 
The day count starts with a negative number, from Day −28 to Day −1, marking the 
preconditioning on the treadmill, until the experimental critical point on Day 0. During this period 
the rats are young and growing; coincidently commencing at the age of ≈28 days on Day −28. The 
dense section on Day 0 represents four weight registries, before and after both downhill running-
sessions on the day, mirroring a slight weight drop due to the strenuous exercise. The 2-week 
recovery period (from Day 1 to Day 14) continues to reflect a general increase in the body weight. 
All subgroups are embedded in the graph without showing any statistical distinction from the 
tendency of the average body weight profile, irrespective of being either entirely sedentary like the 
A{−1}-group or exercising throughout like the E{14}-group. (Still, closer analysis is presented below).  
Table 4-1. The development of rats' body weight throughout the different periods of the experimental process. 
Periods/Stages Time, week Days Sampling days NRat winitial, kg (±SD) dw/dt, kg/d 
Preparation (P) 1 −28 to −23   98 0.156 (±0.009) 9.6×10−3 
  2 −22 to −16   98 0.21 (±0.01) 8.7×10−3 
Training (T) 3 −15 to −8   98 0.27 (±0.01) 7.3×10−3 
  4 −7 to −1 Day −1 98 0.33 (±0.02) 7.3×10−3 
Day of injury protocol Day 0 0   84 0.39 (±0.02) −2.6×10−2  a 
Recovery (R)  5 1 to 7 Day 1, Day 3, Day 7 84 0.37 (±0.03) 6.6×10−3 
  6 8 to 14 Day 14 21 0.42 (±0.04) 6.7×10−3 
a Extrapolated rate from measurements throughout Day 0.       
 
Table 4-1 lists an overview of the weight statistics in relation to the different periods of the 
experimental procedure (Chapter 3.2.4.1), representing the weight (with standard deviation) at the 
start of the defined periods and the corresponding regression, i.e. the average weight rate (dw/dt). 
The subject count, NRat, changes in relation to how many rats have been sacrificed on each day of 
sampling, prior to the subsequently registered weight in the table. The overall tendency of the 
weight rate is indicative of a reduced increase; excluding the temporary weight loss on Day 0, that 
mirrors a small displacement, as shown in Fig. 4-1.  
Upon closer examination of the recovery period (Day 1 to Day 14), despite the overall weight 
tendency having slightly slowed down, each group, [C], [H] and [E], show a significant increase. Still, 
the only significant inter-group difference happens on Day 14, as shown in Fig. 4-2. Day 14, 
represents the point of which the differences between the groups are the greatest, in practice, and 
the average weight of E{14}, 0.43(±0.03) kg, is significantly lower (p=0.006) than average weight of 
C{14}, 0.47(±0.04) kg. This relatively lower weight of E{14} is confirmed by the fact that it is not 
significantly higher than that of E{07}. However, E{07} has significantly higher weight than both E{01} 
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(p=0.008) and E{03} (p=0.030). At the same time, C{14} and H{14} each have significantly higher 
average weight than all its corresponding subgroups, where the comparisons between C{14} and 
C{01}/C{03}/C{07} all have p<0.001 and the comparisons between H{14} and H{01}/{H{03}/H{07} all 
have p≤0.005. The negative control groups, absolute A{−1} and relative R{−1}, are not significantly 
different from each other having the average weight of 0.39(±0.03) kg and 0.37(±0.02) kg 
respectively. 
 
Fig. 4-2. The rats body weight-changes, in kg (±SD), after downhill-exercise induction of skeletal muscle injury on Day 0, between: 
[C] Control groups with passive recovery, [H] Hypoxia groups with hypoxia sessions, and [E] Hypoxia+Exercise groups; throughout 
Day 1 to Day 14. The negative controls, sedentary and trained rats, A{−1} and R{−1} respectively, are referenced from Day −1. 
Considering the time factor, only [E]-group and [C]-group have statistically different(*p=0.006) average weight, on Day 14, using 1-
way ANOVA with Turkey’s test. 
4.1.2 The Weight Fractions of the Lungs and the Heart Compartments 
The following weight fractions are always obtained with reference to the rat body weight for 
comparative purposes, except for the Fulton index (Chapter 4.1.2.1) which represents a different 
weight ratio. When comparing the three groups, [C], [H] and [E], during the recovery period, the 
average lung’s weight fraction is only significantly higher in E{03} at 0.5(±0.1) 10−2 in comparison 
with E{14} (p=0.020) and C{14} (p=0.017), both of which ratios are 0.36(±0.05) 10−2 (Fig. 4-3). 
Moreover, the [E]-group is showing the overall greatest deviations, especially in E{03}, in 
comparison with the other groups, whilst the tendencies of [H] and [C] groups are relatively more 
stable regarding the statistical variation. 
The weight fraction of the heart’s left ventricle and septum combined (Fig. 4-4) is overall without 
any significant changes within each group, [C], [H] and [E], throughout the recovery period. 
However, on Day 14, H{14} and E{14} with the ratios of 0.22(±0.05) 10−2 and 0.18(±0.01) 10−2 
respectively, are significantly different from each other (p=0.008) which does support the tendency 
of decrease between H{03} and H{14}. The pattern of, perhaps, gradually increasing weight fractions 
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Fig. 4-3. The average lung weight fraction (10−2, ±SD) to the rat body weight, wRat, during the recovery period (Day 1 to Day 14) for 
the [C] Control groups, the [H] Hypoxia groups, and the [E] Hypoxia+Exercise groups, after an induction of muscle damage on Day 
0, with absolute A{−1} and relative R{−1} negative controls on Day −1. Only the [E]-group on Day 3 appears statistically different from 
the [C] (p=0.017) and the [E]-groups (p=0.020) on Day 14, using 1-way ANOVA with Turkey’s test. 
 
Fig. 4-4. The average weight fraction (10−2, ±SD) of the heart’s left ventricle and septum together to the rat body weight, wRat, during 
the recovery period (Day 1 to Day 14) for the [C] Control group, the [H] Hypoxia group, and the [E] Hypoxia+Exercise group, after 
an induction of muscle damage on Day 0, with absolute A{−1} and relative R{−1} negative controls on Day −1. The only significant 
difference can be observed between the [H] and [E]-groups on Day 14 (p=0.008) using 1-way ANOVA with Turkey’s test. 
 
Fig. 4-5. The average weight fraction (10−3, ±SD) of the heart’s right ventricle to the rat body weight, wRat, during the recovery period 
(Day 1 to Day 14) for the [C] Control group, the [H] Hypoxia group, and the [E] Hypoxia+Exercise group, after an induction of muscle 
damage on Day 0, with absolute A{−1} and relative R{−1} negative controls on Day −1. Any possible tendencies are without any 
significant backing (using 1-way ANOVA with Turkey’s test).  
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within the [E]-group in general, that is shared by the [C]-group until after Day 7, is made less valid 
by the generally large variations within E{14} and C{14}. 
The heart’s right ventricle weight fraction (Fig. 4-5), appears to be mirrored by some tendency 
changes within each group [C], [H] and [E], throughout the recovery period. However, no group 
turns out to be significantly different from one another, and the ratios are, furthermore, oscillating 
more closely to and within the variability of A{−1} and R{−1} combined, or around the ratio of 
0.69 10−3. 
4.1.2.1 The Fulton Index 
The Fulton index (Fig. 4-6) describes the weight ratio between the heart’s right ventricle and the 
combined weight of the heart’s left ventricle and septum. The change in the index, theoretically, 
can be due to altered heart’s right ventricle alone, due to the heart’s left ventricle and septum alone, 
or due to parallel or opposite changes in both. In significant terms, the H{14}, index of 0.40(±0.01), 
is generally higher than that of the other [H]-groups (p<0.05), and is most likely to be due to the 
only significant difference, decrease, in the H{14}-weight ratio of the heart’ left ventricle and septum 
(Fig. 4-4). However, the variability in the heart’s right ventricle weight ratio seems to be reflected 
more markedly in the Fulton index, in general, when looking through the non-significant patterns 
within each group, [C], [H] and [E]. 
 
Fig. 4-6. The average changes in the rats Fulton Index, FI (±SD), during the recovery period (Day 1 to Day 14) for the [C] Control 
group, the [H] Hypoxia group, and the [E] Hypoxia+Exercise group, after an induction of muscle damage on Day 0, with absolute 
A{−1} and relative R{−1} negative controls on Day −1. The [H]-group on Day 14 is significantly different from the other [H]-groups on 
Day 1 (p=0.045), Day 3 (p<0.001) and Day 7 (p=0.005); and from the R{−1} (p=0.042), the [E]-group on Day 3 (p<0.014) and the [C]-
group on Day 7 (p=0.041); using 1-way ANOVA with Turkey’s test.  
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4.2 The AEY Performance Score 
4.2.1 The Resulting Score Tables 
The marks within the three criteria of the performance score, [A:E:Y], were quantified to fit a score 
scale from 0 to 1. The value of 1 in each criterion would be representing the theoretically good and 
well-trained runner-rat in a treadmill exercise session with no instrumental artefact affecting any 
accompanying numeric evaluation. The value of 0 in each criterion would be representing a rat that 
is impossible to get to run, making the E-criteria redundant, and the instrumentation would be 
mirroring the situation with continuous artefacts in the accompanying numeric evaluation. After an 
experienced-based approach to quantify the negative impact of each marked situation during the 
training sessions, the resulting tables with the marks and their accompanying score values, α, ε and 
υ for A, E and Y-criteria respectively, are presented in Fig. 4-7 and Fig. 4-8. The logical orders of 
marks are not necessarily represented with gradually changing score value, rather, representing the 
historical development. 
4.2.1.1 The A-Score Criteria with the α Score Values 
The A-criteria is demonstrated in Fig. 4-7 and covers the position of a rat running on a treadmill. 
The main positions of a rat that is running continuously involve continuously not touching the metal 
grid, and therefore resulting in low or no electric shock count by the treadmill apparatus, mark-A, 
or continuously touching the metal grid, represented by a high electric shock count, mark-C. In 
both cases, the rat could be a fairly good runner. Hence, the αA (the score value for mark-A) is 0.00, 
reflecting no deduction with reference to the hypothetical good rat, and αC=−0.30, reflecting some 
deduction. If a rat is continuously moving from the back of the treadmill belt to the front, away 
from the metal grids, stopping until its get closer to the metal grids again, etc. the rat is not showing 
continuous running. In this case, the αD ranges from −0.15 to −0.30, depending on the way it moves 
back and forth, i.e. how much running the rat is actually doing. 
In essence, marks-B, E, F, G and L, describe a rat that is avoiding running, still, positioning itself in a 
way that it does not receive electric shocks. Getting into these positions is likely to be somewhat 
indicative of a level of intelligence, but, affected by the speed of the moving belt. However, the 
value of α reflects how easily a rat could sustain or get away with the position, and the easier it 
seems to be, a lower α value was assigned. Mark-B has a very low score value, αB=−0.70, where a 
rat that cheats running by supporting itself on the front wall of the treadmill encasing only moving 
the with the hind limbs. Still, even if a rat described by marks-E, F and G, is sliding on the treadmill 
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belt, as demonstrated in the diagrams, and is not running at all in the position, it is not likely the rat 
can hold it like that for too long; and the marks all have the same score value, α=−0.50. Mark-L, 
αL=−0.50, reflects a particular situation where a rat discovers the treadmill belt is not covering the 
entire floor surface (the peripheral parts of the treadmill, if applicable). The rat discovers it can 
position one side of its body on the moving part, forced to move along with the limbs of the other 
side of body.  
Marks-H, I and J, describe a rat that is ‘preoccupied’ (in the loosest sense), where both rats of mark-
H are trying to walk backwards away from the metal grid to avoid shock (αH=−0.80) and a rat of 
mark-I, standing on the electric shock metal grid without repositioning itself (αI=−0.90). However, 
mark-J, αJ=−0.05 is simply reflecting a rat that is for the most part running but seems very distracted 
by the surroundings (perhaps due to stress). In fact, mark-J rats normally run quite well, hence the 
α is only hinting some difference. 
Mark-K, M and N rats, (α=[−0.40, −0.65, −0.65] respectively) rest the whole or part of their bodies 
onto the treadmill whilst running — Maybe not with the potential tactic of avoiding running, rather, 
these styles of running were more evident in the developing registry when the rats came across as 
really tired. Furthermore, this is more likely to happen in exhaustive sessions or when the treadmill 
belt is positioned with an inclination or declination. The negative impact of the marks also reflects 
how much ‘running’ the rat is doing in these positions. 
Lastly, any rat, that for any given reason is not capable of running, however, for some reason is still 
evaluated, could be given the α-score of −1.00. (There is no specific mark defined for that registry). 
4.2.1.2 The E-Score Criteria with the ε Score Values 
The E-criteria is demonstrated in the left side column in Fig. 4-8, where the marks value the tail’s 
position of a running rat. Holding the tail lifted (most likely, away from the metal grids) has a (+) 
mark and is considered as full score criteria, ε(+)=1.00. When the rat does the opposite, and the tail 
hangs onto the treadmill belt, (−) mark, the score value is ε(−)=0.25. The intermediate positions, 
(+/−) and (−/+) marks, are reflected with ε(+/−)=0.75 and ε(−/+)=0.50 respectively, although, exact 
position is somewhat subjective. The position of the tail in these conditions might be indicative of 
how tired the rats are, as it might change throughout a session. However, that logic is only 
applicable from resulting score value between 1.00 and 0.25, as the (0)-mark serves to indicate if 
evaluating the position of the tail is irrelevant or impossible, in relation to the A-criteria, for example 
with marks-G, H and I, and possible with marks-C and E. Moreover, in a confined area, the tail might 
be forced to simply bend due to the limits of the encasing.  
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Fig. 4-7. The AEY performance score, A-score criteria, describing a rat’s position whilst running on a treadmill, each represented with 
a mark, a diagram, a description and a representative score value, α. 
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Fig. 4-8. The AEY performance score, E-score and Y-score criteria, describing a position of a rat’s tail whilst running on a treadmill 
(E-criteria) and type of general incidences effecting electric shock parameters with the treadmill (Y-criteria). Each criterion is 
represented with a mark, a diagram or a description, and a representative score value, ε and υ for E and Y score respectively. 
 
4.2.1.3 The Y-Score Criteria with the υ Score Values 
The Y-criteria is demonstrated in the right side column in Fig. 4-8, where each mark describes a 
general type of incidence that could affect either the electric shock count or the accumulative time 
the shocks take. The score values for these most regular type incidences, ⓐ, ⓑ, ⓒ and ⓓ-mark, 
υ=−0.15 for each mark. Therefore, the υ does not numerically distinguish between the types of 
incidences, for the reason that the impact of one and the same type can vary extensively. Instead, 
as the υ values are summed up, the resulting score value does only describe how many types of 
incidences occurred, with the maximum count of four different types, giving an overall intermediate 
score between 1 and 0.40. However, in the case of too many artefacts rendering the descriptive 
electric shock parameters invalid, the registry could be marked with ⓧ, υⓧ=−1.00, overriding the 
existing υ values (as the resulting Y-score is not defined for negative values), resulting in the score 
of 0.00. As such, the Y-score is simply a reverse indication of how much attention, or how much 
truth, is in the accompanying electric shock count from the treadmill apparatus.  
4.2.2 Hypothetical References 
Any resulting AEY-score is calculated as explained in Chapter 3.3.5, using the defined score value 
for any given mark. However, the objective was not to make a score value traceable to a mark, as 
the steps of averaging out the score values make that redundant even if the score values were 
different for each mark within each score criterion. Still, to form some idea of how the values 
represent different rats, a hypothetical data, based on the registries are presented in Table 4-2.  
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Table 4-2. Hypothetical data for four different rats in a session where the speed is kept constant. 
 
The hypothetical data (Table 4-2) is based on five 5-min registry periods within a session where the 
speed is kept constant. Four conditions are described, i.e. four different rats — The rats are not 
necessarily running together: (i) Condition 1 with [A;E;Y]=[1.000;0.999;0.970], describes a rat that 
shows a good running style, does not to appear to be very tired and only one type of incident that 
reduced the validity of the electric shock count. (ii) Condition 2 with [A;E;Y]=[0.578;1.000;1.000], 
describes a rat that shows ways of avoiding running and therefore does not appear to be 
particularly tired. Therefore, without any case of incident affecting the electric shock parameters, by 
reading from them alone, they indicate a good runner. (iii) Condition 3 with [A;E;Y]= 
[0.767;0.575;0.880], describes a rat that seems generally tired and is somewhat struggling, with 
several incidences that have affected the validity of the electric shock parameters. Lastly, (iv) 
Condition 4 with [A;E;Y]=[0.499;0.225;0.480], describes a rat that, for whatever reason, seems to 
find the session difficult, confusing, etc. The A-marks suggest that the rat is constantly touching the 
metal grids. However, the registry has many incidences that affect the electric shock parameters 
that, again, would indicate a good runner if they were considered alone (although, the incidences 
per se are not related to how the rat is running). 
These references are by no means a gold standard for the conditions described, and only serve to 
bring the score into some perspective. They also emphasise the fact that it is important to 
understand the setup of a session, and interpret the resulting score considering all the parameters. 
Registry Period
Condition A E Y A E Y A E Y A E Y A E Y A E Y
1 A (+) A (+) A (+) A (+/−) A (+/−) ⓐ 1.000 0.900 0.970
Electric shock:
2 A, B (+) A, B, 
E
(+) B, C (+) C, G (+) A, B (+) 0.578 1.000 1.000
Electric shock:
3 A, C (+) ⓐ A, C, 
I
(+/−) −D, 
A
(−/+) C, 
+D
(−/+), 
(−)
ⓐ K, C (−) ⓐ, 
ⓑ
0.767 0.575 0.880
Electric shock:
4 C, 
−H, I
(0) ⓓ C, I (+/−) ⓓ, 
ⓒ
C, 
−H, I
(−/+), 
(0)
ⓓ, 
ⓧ
C, J, 
D
(−/+) ⓐ, 
ⓧ
+D, 
C, 
+H, I
(0) ⓐ 0.499 0.225 0.480
Electric shock:
Shock time: 23 s
Shock count: 130
Shock time: 295 s
1st-[5 min] 2nd-[5 min] 3rd-[5 min] 4th-[5 min] 6th-[5 min] [X]ave ,RP
0 0 3 Shock count: 16
Shock time: 6 s
11
15
32
27
2
26 37
The electric shock count is divided to represent the count occuring in each registry period. In practice, the number is likely 
to represent an accumulating count throughout.
5 7 10 3
5340067
22 13
Shock count: 187
Shock time: 345 s
Shock count: 40
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4.2.3 The Scope of Comparison 
The rats, N=65, that make up the quantitative AEY data, only represent a portion of the 
experimental subject count, NRat=98, randomly distributed between the subgroups that ever 
trained on the treadmill, from the point of incorporating the AEY systematic registry.  
4.2.4 The Preconditioning Period 
The preconditioning period, composed of 4 weeks, where during the former two weeks (the 
preparation stage) the rats trained with a gradually changing protocol, and during the latter two 
weeks (the training stage) the rats trained with a non-changing protocol. All days of training had 
2 Sess/d, except in Week 1, where the only day with two sessions was the last day. Furthermore, 
these experimental weeks were all separated by a weekend of rest between them. It became 
noticeable, especially in the latter two weeks, that there was an overall performance cycle in the 
running of the rats, both between Mondays and Fridays and between morning and afternoon 
sessions. 
In Fig. 4-9, the quartile analysis of average session-scores, separated into morning and afternoon 
sessions are displayed on a week basis throughout the preconditioning period. Bearing in mind 
that Week 1 has only one afternoon session, tendency indications in the quartile distributions are 
somewhat visible. The A-score seems to improve throughout the entire period with gradually less 
distribution of the score range, indicating that the running styles are generally more refined with 
scores changing from 0.7(±0.1) to 0.94(±0.09). This tendency is though flatter and closer to a score 
value of 1.00 in the afternoon sessions, changing from 0.9(±0.1) to 0.96(±0.05). The E-scores hint 
to an opposite trend throughout the period, compared with the A-scores, where the score seems 
to be dropping with time, from 0.97(±0.08) to 0.8(±0.2). in the morning sessions, and from 
0.96(±0.09) to 0.8(±0.1) in the afternoon sessions. Furthermore, between the morning and 
afternoon session, the E-scores are markedly lower, in general, indicating that the rats hold their tail 
in a lower position. The Y-scores, displayed on a narrower scale, show a relatively flat curve 
throughout the period both in the morning session and in the afternoon (both around score value 
of 0.99(±0.01)). However, with the exception of the one afternoon session on Week 1, the 
distribution of the score is slightly less dispersed in the afternoon.  
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Fig. 4-9. The average session AEY score throughout the preconditioning period (NRat=65) separated into morning (09:00h) and 
afternoon (17:00h) sessions. The average score within corresponding quartiles is marked with an “x”. Each week has 2 sessions per 
day, except Week 1 with only one afternoon session. 
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4.2.5 Throughout the Experimental Procedure 
After the preconditioning period, the exercise sessions to induce muscle damage on Day 0 were 
very different from what the rats had previously experienced. Apart from running downhill and at 
a slightly higher velocity, the duration of each session that day was to each rat’s exhaustion, with a 
minimum 4-h of rest in between them. In Table 4-3, the representative duration of both sessions 
on Day 0 is presented, both with reference to the entire experimental procedure (NRat=84) and the 
AEY-score evaluation (NRat=61). Irrespective of the subject count, here in question, the average time 
of the former session was two times longer than of the latter session, 120(±20) min and 
60(±20) min respectively. The remaining rats that carried out exercise during the recovery period, 
from Day 1 to Day 14, which were exclusively in the [E]-group hypoxia+exercise. Again, although 
the setup did not change throughout the period, the sessions were entirely different from before; 
slower, shorter, uphill, and only 1 Sess/d. The rats in the [E]-group that were evaluated for the AEY-
score, started at NRat=23 on Day 1, NRat=16 on Day 3, and NRat=12 on Day 7, and NRat=5 on Day 14. 
Table 4-3. The average duration of the eccentric-exercise sessions in minutes, on Day 0.  
 
In Fig. 4-10, the quartile analysis of the weekly training day scores (or working day scores) is 
presented throughout the experimental period. Whilst the weeks of the preconditioning period 
(Week 1 to Week 4) are separated by weekend-resting, the weeks of the recovery period (Week 5 
and Week 6) start on a Wednesday; locating the weekend resting ‘in the middle’. The recovery 
period is, therefore, split into three bits, to normalise the overall view: (i) Throughout the 
preconditioning period, the A-score showed a tendency of a score increase from 0.8(±0.1) in Week 
1 to 0.95(±0.07) in Week 4, and with the tendency of decreasing variability. On Day 0, with a very 
distinct protocol, the A-score dropped to 0.75(±0.09). However, through Week 5 and Week 6, the 
score increased from 0.8(±0.1) to 0.92(±0.08). In general, the A-score seems to get more refined 
with the reuse of the same type of protocol. (ii) The E-score demonstrates a different overall pattern 
through the entire experimental period. From Week 1 to Week 4, the score dropped from 
0.97(±0.05) to 0.86(±0.09) with some increasing variability. On Day 0, the score dropped to 
0.3(±0.1), and thereafter, through Week 5 and Week 6 it increased from 0.85(±0.09) to 1.00.  
Session tave SD tmax tmin
Included in the experimental procedure, NRat=84:
Former 123 22 168.0 58.0
Latter 62 23 132.2 25.1
Included in the AEY-score evaluation, NRat=61:
Former 123 24 168.0 58.0
Latter 64 25 132.2 25.1
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Fig. 4-10. The average training day AEY score throughout the preconditioning period (Week 1 to Week 4, NRat=65), Day 0 (NRat=61) 
and the recovery period (Week 5 to Week 6, NRat=23→5). The average score within corresponding quartiles is marked with an “x”. 
Before Day 0, each week is separated by weekend-resting. After Day 0, the experimental weeks are not determined by weekend-
resting.   
In general, the E-score tendencies seem to be related to the supposed level of exercise difficulty in 
each protocol or throughout time periods. The preconditioning period starts off very easy in terms 
of session parameters but gets heavier with time, and perhaps more difficult to sustain. The sessions 
on Day 0 are really difficult and leave the rats very tired, and perhaps remain tired for the next days. 
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However, during the recovery period, with a very easy but different protocol, the first-day 
experience (at the start of Day 1) might be quite clumsy, but thereafter the score is really high. 
Furthermore, the NRat is decreasing throughout the period which might have its statistical effect. (iii) 
The Y-score is quite flat throughout the preconditioning period, around 0.98-0.99, and shows a 
slight drop on Day 0 to 0.95(±0.05) which is likely to have to do with the augmented possibility of 
incidences with a longer session. During Week 5 and Week 6, however, the decreasing number of 
subjects makes the average incidences disproportional in comparison with the rest. 
4.2.6 Comparing the Preconditioning 
Although the rats evaluated and given the quantified AEY score do not have an even distribution 
in terms of the subject count for each experimental group, their average value might serve as a hint 
as to how homogenous the rats were regarding the training. 
Table 4-4. The average AEY score for the evaluated rats over Week 4 and Day 0. 
 
Table 4-4 lists which experimental group the rats, receiving a quantified AEY evaluation, eventually 
belonged. Furthermore, it reflects on the average AEY score for the sessions in Week 4, and the 
average AEY score for the two sessions on Day 0. Within each score criterion, the average values 
are all on a similar level, with fairly uniform variability between each group — both in the Week 4 
calculations and on Day 0. On a similar note, the SEM shows similarity throughout which 
numerically strengthens the idea of homogeneity. Given this similarity, the uniformly low SEM 
strengthens the idea of homogeneity even further. For the purpose of predicting uniformity, the Y-
score has less input for evaluating the subjects, still, is more relevant for the evaluating the treadmill 
apparatus. 
Group A E Y A E Y
R{−1} ave. 0.9 0.8 0.99
n=4 SD 0.1 0.1 0.01
SEM 0.05 0.07 0.005
[C]-group ave. 0.95 0.8 0.99 0.75 0.3 0.96
n=19 SD 0.07 0.1 0.01 0.08 0.2 0.05
SEM 0.02 0.03 0.003 0.02 0.04 0.01
[H]-group ave. 0.95 0.9 0.98 0.73 0.3 0.94
n=19 SD 0.06 0.1 0.01 0.08 0.2 0.07
SEM 0.01 0.03 0.003 0.02 0.04 0.01
[E]-group ave. 0.95 0.9 0.99 0.77 0.4 0.97
n=23 SD 0.08 0.1 0.01 0.09 0.2 0.03
SEM 0.02 0.03 0.002 0.02 0.04 0.006
Week 4 Day 0
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4.3 The Plasma Markers 
The key elements of the developmental phase of the eccentric exercise protocol for muscle 
damage are presented in the following chapter where N=20 rats provided data plasma marker 
data. Thereafter, in Chapter 4.3.2, the plasma marker data with reference to the actual experimental 
phase are introduced with NRat=98 (n=7/subgroup).   
4.3.1 The Developmental Phase 
4.3.1.1 The Procedural Results 
The Results Determining the Muscle Damage Protocol 
The initial eccentric exercise protocol to induce skeletal muscle damage was designed as a one 
session per day (1 Sess/d)-exercise protocol. However, lacking in literature results to demonstrate 
its potential impact on a healthy skeletal muscle, specifically estimated via plasma markers, required 
some trials to ensure how to best develop the protocol efficiently. After all, the rats would train on 
the treadmill through the fairly extensive preconditioning period, a necessary lead up to Day 0, and 
a faulty muscle damage protocol would clearly render the post physiological applications 
redundant.   
Fig. 4-11 shows the quantified levels of TnI in plasma over the recovery period (from Day 1 to 
Day 14) in rats with a passive recovery after the 1 Sess/d-muscle damage protocol. (The recovery 
process is equivalent to the definitive [C]-group). The overall profile indicates a descending pattern 
from a concentration level about 15(±2) ng/mL on Day 1. However, no TnI was measured in some 
of the rats’ plasma. Furthermore, the general range of deviation on Day 3, 7 and 14, greatly reduced 
the credibility of the concentration on Day 1 being particularly high and potentially reflecting 
muscle damage. 
 
Fig. 4-11. The plasma concentration of skeletal muscle troponin-I during a passive recovery period (Day 1 to Day 14) after a one 
session of eccentric-exercise to exhaustion on a treadmill. Each average(±SD) data point has n=4 rats included from Day 1 to Day 7, 
except for the markings at 0 ng/mL with n=1, and n=5 on Day 14.  
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Under the same conditions, the quantified profile of myoglobin in plasma is shown in Fig. 4-12. The 
profile, although with the overall tendency of decreasing concentration from 30(±20) ng/mL to 
15(±8) ng/mL, does not reflect a refined regression. Furthermore, the overall standard deviation is 
even greater than for the TnI values, comparing their RSD ranging between 2%-35% for the TnI 
measurements and 35%-100% for the Mb values. 
 
Fig. 4-12. The plasma concentration of skeletal muscle myoglobin during a passive recovery period (Day 1 to Day 14) after a one 
session of eccentric-exercise to exhaustion on a treadmill. Each average(±SD) data point has n=5 rats included. 
The Calibration Curves 
The calibration curves, with reference material provided by the ELISA kit manufacturer, were 
thoroughly analysed for each assay — And, although the resulting quantification of the samples in  
Fig. 4-11 and Fig. 4-12 did not per se raise any assay quality issues, despite not displaying particularly 
favourable results, the curves alone looked ‘suspicious’; the TnI curve in particular.  
In Fig. 4-13, a representative TnI calibration curve is demonstrated; not coming across as a 
promising quantification reference. The calibration curve was run twice (always in triplicate) with 
the first kit used and once with the second kit (the run displayed in here), all of them giving similar 
results. The overall linear fit calculates at R2=0.9781, way below the acceptance threshold. 
Furthermore, excluding the highest concentration level, 50 ng/mL, which seems to put the curve 
off-trend, the curve seems to have the general potential of being non-linear with R2=0.9204. 
In Fig. 4-14, a representative Mb calibration curve is demonstrated; coming across a lot more 
promising in comparison with the TnI calibration curve. Although, here, the highest concentration 
level, 100 ng/mL is designed to be included in the RoQ (range of quantification), it calculates with 
R2=0.9937, which is a poor linear fit for a calibration curve. However, in contrast to the TnI calibration 
curve, there is considerably less uncertainty when it comes to analysing the Mb calibration curve. 
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Fig. 4-13. The TnI calibration curve divided into the profiles of its three well-replicas. The overall linear regression giving the slope 
m=0.02815 and the intercept b=0.13289 and the fit R2=0.98094. The range of the relative standard deviation between the replicas 
RSD=[0.038-0.313]. Excluding the highest concentration point yields y=0.023423x+0.15818 with R2=0.920359.  
 
 
Fig. 4-14. The Mb calibration curve divided into the profiles of its three well-replicas. The overall linear regression giving the slope 
m=0.013562 and the intercept b=0.088306 and the fit R2=0.993739. The range of the relative standard deviation between the 
replicas RSD=[0.001-0.066]. Excluding the highest concentration point yields y=0.015486x+0.06748 with R2=0.999233. 
 
Table 4-5. The parametric overview for quickly evaluating the TnI and the Mb calibration curves. 
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TnI-calibration curve Mb-calibration curve
Theoretic Measured Calculated Theoretic Measured Calculated
Conc. Dilution Absorb. Replicas Conc. Recovery Dilution Conc. Dilution Absorb. Replicas Conc. Recovery Dilution
ng mL
−1
factor A450nm RSD ng mL
−1
% factor ng mL
−1
factor A450nm RSD ng mL
−1
% factor
50.00 2 1.594 0.14 51.91 104% 2.65 100.00 2 1.401 0.01 96.78 97% 1.75
25.00 2 0.685 0.07 19.62 78% 1.39 50.00 2 0.840 0.00 55.43 111% 2.01
12.50 2 0.531 0.16 14.15 113% 1.71 25.00 2 0.462 0.02 27.57 110% 2.18
6.25 2 0.366 0.04 8.27 132% 1.69 12.50 2 0.260 0.06 12.66 101% 2.68
3.13 2 0.271 0.31 4.90 157% 2.18 6.25 2 0.152 0.07 4.73 76% 2.94
1.56 2 0.196 0.26 2.25 144% - 3.13 2 0.110 0.02 1.61 52% 4.35
0.78 N/A 0.132 0.14 -0.05 N/A N/A 1.56 N/A 0.093 0.00 0.37 N/A N/A
0.00 N/A 0.081 0.08 -1.83 N/A N/A 0.00 N/A 0.079 0.01 -0.72 N/A N/A
TnI-calibration curve is expressed with the linear regression of y=0.028158x +0.13289.
Mb-calibration curve is expressed with the linear regression of y=0.013562x +0.088306.
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Table 4-5 summarises the differences between the two calibration curves, for TnI and Mb 
quantification. The ‘measured’ section of the table shows the variability between the absorbance 
values of the three replicas, where the TnI curve has the majority of data points with RSD>0.10, 
whilst the Mb-curve has only two data points with RSD>0.05 yet RSD<0.10. The ‘calculated’ section 
of the table show each curve re-quantified with reference to the average linear regression they 
reflect, and the difference ratio (the recovery) between the two. The updated dilution factor then 
gives an idea how linear the regression between the data points is truly.   
In essence, the Mb calibration curve in Fig. 4-14 can be considered valid for quantification as long 
as the overall curve is roughly fractioned around the points it is bending, re-estimating the linear 
regression within each new fraction. The changes in the recovery and the dilution factor of the 
recalculated curve help to find the points of bending. Unknown samples are then quantified with 
reference to within which fraction they fall. The need for estimating the curves in this way is not 
uncommon in samples with matrices that can influence the absorbance reading. The matrix effect 
is noticeable when the compound of interest is very diluted and requiring a closer point of view of 
the calibration curve. The first 3 to 4 data points on the Mb calibration curve do show a different 
tendency (if extrapolated) in comparison with the rest. 
 
Fig. 4-15. The reference-sample matrix effect visible in the lowest concentration levels of the Mb calibration curve giving them 
collectively a slightly different regression rate. 
4.3.1.2 The Decisions Before the Next Step 
Despite using the TnI and Mb plasma markers with only a few rats, the results were still indicative 
enough to take the next step of changing. In that process, three decisions were taken: (i) The rats 
could run a little bit faster in the muscle damage protocol, judging from the monitoring registry. 
Thus, introducing a speed range during the steady-velocity phase (phase III), mainly to affect the 
rats the ran the longest in a training lot, when the other rats had already been removed from the 
treadmill. (ii) To carry out the muscle damage exercise session two times on the same day, with the 
0.00
0.10
0.20
0.30
0.40
0 10 20
A
4
5
0
n
m
[M
b
]
c, ng/mL
 Results 
92 
 
minimum of a 4-h break in between sessions. Still, options were limited to make each session per 
se harder for the rats. (iii) To discontinue the use of the manufacture’s troponin-I ELISA for the 
muscle damage, due to two bad experiences, and take a ‘risk’ with a different one, as the subject 
count needed to be reset when starting using creatine kinase plasma marker ELISA instead 
accompanying the myoglobin ELISA. 
4.3.2 The Experimental Phase 
The following overall data reflects what has been referred to as the experimental procedure in the 
previous chapters, with all the established treadmill protocols and group setup unchanged. In the 
context of the plasma markers, this period refers to using only Mb and CK as muscle damage 
plasma markers, with the aforementioned two sessions of eccentric exercise to induce muscle 
damage on Day 0. With the NRat=98 (n=7 per each of the 14 subgroups), the quartile calculations 
did not identify any outliers — however, the Grubb’s method identified two according to the 
quantified plasma marker data, one in subgroup E{03} in the Mb analysis, and one in subgroup 
R{−1} in the CK analysis. The comparative statistical analysis was run both before and after 
smoothing out the outlier with statistical A15-estimation.  
4.3.2.1 Myoglobin Concentration in the Plasma 
The Intra-Experimental Group Comparison 
Two negative controls are thought to set the scene regarding relevant thresholds for the 
experimental groups, from Day −1. The average plasma concentration in the absolute group 
measured A{−1}=50(±40) ng Mb/mL, and the average concentration in the relative group 
measured R{−1}=40(±40) ng Mb/mL. The RSD for each were about 83% and 100% respectively, 
and no statistical analysis would differentiate between the two, given their averages are too close 
to each other. Moreover, since the variability was that great, an outlier could not be determined 
with our methods could not determine one. 
Fig. 4-16 shows the plasma concentration of Mb for the [C]-group during the recovery period. On 
Day 1, the subgroup C{01}=200(±100) ng Mb/mL has the highest average concentration, and the 
only one that is significantly different from all the other positive controls, overall with p≤0.034; and 
also significantly different from the negative controls (p≤0.018). The other subgroups do not 
demonstrate any significant difference between them. The overall pattern commences with the 
variable basal concentrations on Day −1 and reaches its significant peak on Day 1, after the 
induction of muscle damage. The concentration level starts dropping back to the basal level on 
Day 3 (C{03}). There seems to be a slight tendency after the drop reaches its minimum on Day 7 
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(C{07}=40(±20) ng/mL) for an increase, mirrored on Day 14 (C{14}=50(±20) ng/mL). However, this 
intra-basal range tendency does not have statistical backing.  
 
Fig. 4-16. The plasma concentration of myoglobin [Mb] in rats, with quartile distribution (average as ‘X’), of the [C] positive control 
groups (C{01}, C{03}, C{07} and C{14}) during a 14-d passive recovery after eccentric-exercise induced skeletal muscle damage. The 
C{01} with 200 (SD:100) ng Mb/mL is significantly from the rest of the (p≤0.034), including the absolute and relative controls, A{−1} 
and R{−1} respectively (p≤0.018), sampled prior to the muscle damage.  Analysis with: 1-way ANOVA with Turkey’s test (p<0.05). 
 
Fig. 4-17. The plasma concentration of myoglobin [Mb] in rats, with quartile distribution (average as ‘X’), of the [H] hypoxia groups 
(H{01}, H{03}, H{07} and H{14}) during a 14-d recovery, with intermittent hypoxia, after two eccentric-exercise sessions on a treadmill. 
The H{01} with 200 (SD:200) ng Mb/mL is significantly different from the rest of the subgroups (p≤0.004), including the absolute and 
relative controls, A{−1} and R{−1} respectively (p≤0.017), sampled prior to the muscle damage.  Analysis with: 1-way ANOVA with 
Turkey’s test (p<0.05).  
The hypoxia group, [H], Fig. 4-17, shows a very similar pattern as the [C]-group; perhaps, slightly 
more exaggerated profile. From the basal range on Day −1, the concentration reaches its peak on 
Day 1 (H{01}=200(±200) ng Mb/mL) and is the only significantly different subgroup from the rest 
in the [H]-group, with overall p≤0.004, and the negative controls (p≤0.017). After Day 1 the 
concentration falls to the basal range, and even to the range’s lower concentration levels, reaching 
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its minimum on Day 7 (H{07}=20(±20) ng/mL). Just like the non-significant tendency between the 
[C]-groups, the concentration seems to have slightly risen again on Day 14 (H{14}=30(±30) ng/mL).  
 
Fig. 4-18. The plasma concentration of myoglobin [Mb] in rats, with quartile distribution (average as ‘X’), of the [E] hypoxia+exercise 
groups (E{01}, E{03}, E{07} and E{14}) during a 14-d recovery, with intermittent hypoxia and light exercise, after two eccentric-exercise 
sessions on a treadmill. The E{03}=100(SD:200) ng Mb/mL, was detected with an outlier (Grubbs method) and adjusted according 
to A15 estimation resulting in E{03}’=90(SD:70) ng Mb/mL (new average as black circle). No groups are significantly different from 
each other, neither before and after outlier-treatment: Analysis with: 1-way ANOVA with Turkey’s test (p<0.05).  
The Mb plasma concentration pattern within the [E]-group (Fig. 4-18) is markedly different from 
the rest, and it does not have any significant difference between any of the subgroups (including 
the negative controls). Therefore, strictly statistically, the tendency is fairly planar. Furthermore, on 
Day 3, E{03}=100(±200) ng Mb/mL, has the former outlier of two in the entire experiment. Upon 
reducing the outlier’s effect on the average and the variability, with the statistical A15 method, the 
new concentration calculates as E{03}’=90(±70) ng/mL. The average is on a similar scale, but the 
deviation has reduced greatly. However, it still does not affect the significance in the comparison, 
but, adds on a more reliable criterion to the tendency, especially when compared to 
E{01}=100(±60) ng/mL. The adjusted non-significant Mb-pattern, starting at the basal range, rises 
on Day 1 and gradually decreases until Day 14. 
The Inter-Experimental Group Comparison 
Fig. 4-19 mirrors a panoramic image of all the experimental groups and the representative plasma 
[Mb] concentration. With a focus on the inter-inter-experimental group comparison, C{01} and 
H{01} are the only subgroups significantly different from all the other subgroups not belonging to 
Day 1. Still, between themselves, C{01}, H{01} and E{01} are not significantly different from another. 
If a statistical A15-‘fine tuning’ is applied, the position of C{01} and H{01} becomes clearer, as C{01} 
becomes significantly different from all the hypoxia+exercise (E) subgroups, and H{01} becomes 
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significantly different from them as well except E{01}. This is a good indication of the inter-pattern 
on Day –1: as C{01} and H{01} have the highest concentration values, still not significantly different 
from each other, and C{01} is significantly different then E{01} which has a lower concentration 
value, and H{01} and E{01} are not significantly different. The pattern seems to be 
C{01}>H{01}>E{01} (in terms of myoglobin concentration), and the rest of the subgroups have a 
somewhat planar tendency and at the same concentration level as the control negative subgroups.  
 
Fig. 4-19. The plasma concentration of myoglobin [Mb] in rats, with quartile distribution (average as ‘X’), with the attention on inter-
experimental group comparison of the [C] control, [H] hypoxia and [E] hypoxia+exercise, on the four sampled recovery days {01, 03, 
07 and 14} after two-eccentric exercise sessions. C{01} and H{01} are significantly different from each other’s corresponding subgroups 
(p≤0.005 and p≤0.031, respectively). C{01} is significantly different from all [E]-groups (p≤0.007) and H{01} in comparison with [E]-
groups (p≤0.036), except with E{01}. Analysis with: 1-way ANOVA with Turkey’s test (p<0.05), includes A15-outlier adjustment on 
group E{03}. 
 
4.3.2.2 Creatine Kinase Concentration in the Plasma 
The Intra-Experimental Group Comparison 
Starting with the reference groups, or the negative controls from Day −1. The average plasma 
concentration in the absolute group was measured at A{−1}=400(±300) ng CK/mL, and the 
average concentration in the relative group at R{−1}=170(±80) ng CK/mL. The groups are no 
significantly different from each other, and their corresponding RSD is about 80% and 50% 
respectively. One outlier could be detected in R{−1}, with the Grubb’s method, which was 
smoothed out using the A15 estimation resulting in R{−1}’=140(±30) ng CK/mL, which did not 
affect the non-significance. However, the absolute negative group, with such high variability, and 
no determined outliers, was never significantly different from any of the other subgroups in the 
following results.  
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Fig. 4-20 shows the plasma concentration of CK for the [C]-group during the recovery period. On 
Day 1, the subgroup C{01}=800(±400) ng CK/mL has the highest average concentration, and the 
only one that is significantly different from the other positive controls, overall with p≤0.027; and 
also significantly different from R{−1} (p=0.011). The other subgroups do not demonstrate any 
significant difference between themselves. Excluding the aspect of A{−1}, the overall pattern 
commences with the reference basal level on Day −1 and reaches its significant peak on Day 1, 
after the induction of muscle damage. Thereafter, the concentration drops back to the upper part 
of the basal level and stays around 200-210 ng CK/mL from Day 3 to Day 14. 
 
Fig. 4-20. The plasma concentration of creatine kinase [CK] in rats, with quartile distribution (average as ‘X’), of the [C] positive control 
groups (C{01}, C{03}, C{07} and C{14}) during a 14-d passive recovery after eccentric-exercise induced skeletal muscle damage. The 
C{01} with 800 (SD:400) ng CK/mL is significantly from the rest of the (p≤0.027), and the relative-negative control, R{−1} (p≤0.011), 
sampled prior to the muscle damage. The R{−1}=170(±80) ng CK/mL, has been treated with outlier analysis showing its altered 
average as ‘black circle’ at R{−1}’=140(±30) ng/mL.  Analysis with: 1-way ANOVA with Turkey’s test (p<0.05). 
 
Fig. 4-21. The plasma concentration of creatine kinase [CK] in rats, with quartile distribution (average as ‘X’), of the [H] hypoxia groups 
(H{01}, H{03}, H{07} and H{14}) during a 14-d recovery, with intermittent hypoxia, after eccentric-exercise induced skeletal muscle 
damage. The H{01} with 800 (SD:700) ng CK/mL is significantly from the rest of the (p≤0.003), and the relative-negative control, R{−1} 
(p≤0.007), sampled prior to the muscle damage. The R{−1}=170(±80) ng CK/mL, has been treated with outlier analysis showing its 
altered average as ‘black circle’ at R{−1}’=140(±30) ng/mL.  Analysis with: 1-way ANOVA with Turkey’s test (p<0.05). 
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The hypoxia group, [H]-groups Fig. 4-21, shows similarity to the [C]-groups; perhaps, slightly more 
exaggerated profile. From the basal range on Day −1, the concentration reaches its peak on Day 1 
(H{01}=800(±700) ng Mb/mL) and is the only significantly different subgroup from the rest in the 
[H]-group, with overall p≤0.003, and the R{−1} (p=0.007). After Day 1 the concentration drops 
down to the basal range, and perhaps a bit lower, and stays there at about 100 ng CK/mL.  
The CK plasma concentration pattern within the [E]-groups (Fig. 4-22) is markedly different from 
the rest. Still, it does not have any significant differences between any of the subgroup. From the 
basal level on Day −1, the concentration suddenly rises on Day 1 (E{01}=500(±400 ng/mL) and has 
continued to rise on Day 3 (at E{03}=700(±500) ng/mL). From Day 7 to Day 14 it seems to be 
gradually decreasing ending at 300(±200) ng/mL.  
 
Fig. 4-22. The plasma concentration of creatine kinase [CK] in rats, with quartile distribution (average as ‘X’), of the [E] 
hypoxia+exercise groups (E{01}, E{03}, E{07} and E{14}) during a 14-d recovery, with intermittent hypoxia and exercise, after eccentric-
exercise induced skeletal muscle damage. The concentration is the highest at E{01}=500(±400) ng/mL and E{03}=700(±500) ng/mL. 
However, no groups are significantly different from one another. The R{−1}=170(±80) ng CK/mL, sampled prior to the muscle 
damage induction, has been treated with outlier analysis showing its altered average as ‘black circle’ at R{−1}’=140(±30) ng/mL.  
Analysis with: 1-way ANOVA with Turkey’s test (p<0.05). 
The Inter-Experimental Group Comparison 
The overall comparison of the CK concentration in plasma (Fig. 4-23) demonstrates, first of all, very 
similar patterns between the [C] and the [H] groups. Both C{01} and H{01} are significantly different 
higher than all the other subgroups within the [C] and the [H] groups. However, these peaks, along 
with E{01} and E{03} are not significantly different from each other. E{03}, which represents the peak 
of the [E]-group, seems to be significantly different from the H{07} and H{14}, but not from its own 
corresponding E[07} and E{14}, nor the C{07} and C{14}.  This suggests that the pattern of the [E]-
group, generally, has a higher concentration than [C] and [H] groups (on the Day 7 and 14). Whilst 
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C{07} and C{14} are somewhere in the middle around the basal range of R{−1}, the [H]-group drops 
the lowest concentration of them all, after its peak on Day 1.  
 
Fig. 4-23. The plasma concentration of creatine kinase [CK] in rats, with quartile distribution (average as ‘X’), with the attention on 
inter-experimental group comparison of the [C] control, [H] hypoxia and [E] hypoxia+exercise, on the four sampled recovery days 
{01, 03, 07 and 14} after two-eccentric exercise sessions. C{01} and H{01} are significantly different from each other’s corresponding 
subgroups (p≤0.004 and p≤0.017, respectively). E{03} is significantly different from H{07} and H{14} (p≤0.034), and H{01} in 
comparison with E{14} (p=0.034). Analysis with: 1-way ANOVA with Turkey’s test (p<0.05), includes A15-outlier adjustment on group 
R{−1}. 
4.3.3 Outliers and the Plasma Evaluation  
Table 4-6 shows the intra-distribution, in percentage, of the plasma samples with the non-outliers 
and pushed outliers, with reference to the haemolytic evaluation of each plasma. The data lot from 
the NRat=98 essentially did not have any problems concerning outlier, and only two were detected 
with the Grubb’s method. Both plasma samples had been evaluated as ‘+++’ (Order no. 8 in the 
table) and, therefore, no particular reason to link the level of haemolysis to the outliers.  However, 
the RSD for each subgroup in the plasma analysis was generally rather high. The A15 estimation 
was run z10-cycles for all subgroups (not just the ones with the Grubb’s-outliers), to determine the 
most likely outliers, and of them, to see which would be determined as an outlier with quartile 
calculations of all the new A15-adjusted groups.  
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Table 4-6. The intra-distribution of Mb and CK plasma markers non-outliers, IQR-outliers and A15-outliers throughout the 
haemolytic order of FEH·lab’s plasma evaluation core. 
 
The overview, given in the Table 4-6, demonstrates that in the three criteria, the majority of the 
plasma had the appearance order from No. 4 to No. 7. Only the samples rated with the highest 
haemolytic appearance (red/dark red, Order no. 10) only appears in the plasma of the ‘pushed’ 
outliers. Comparing the concentration values of the plasma of Order No. 10, it appeared they 
collectively were with [Mg]<85 ng/mL and [CK]<360 ng/mL. Thus, the haemolytic appearance does 
not predict an outlier via the ELISA assays in question. 
  
Order Code non outliers A15-outliers IQR-outliers *
1 - 2%
2 (-) 8% 7%
3 (+) 8% 3%
4 + 21% 13%
5 (++) 14% 20% 33%
6 ++ 19% 23% 17%
7 (+++) 17% 10% 17%
8 +++ 8% 13% 17%
9 (++++) 3% 3%
10 H 7% 17%
Total: 100% 100% 100%
* IQR-outliers are simultaneously A15-outliers.
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4.4 The Differential Gene Expression 
As previously explained (Chapter 3.5.1), the subject count for the differential expression analysis 
reflects n=3 per subgroup (NRat=42), i.e. chosen from the existing n=7 per subgroups. The choice 
was based on fulfilling the assay criteria regarding the required minimum sample quantity, which 
coincidently ruled many of the rats out by default, as the dissected m. soleus was generally quite 
small. 
4.4.1 The RNA Extracted Samples and Global Overview of the Expression 
The resulting RNA extract from each sample was sent to the commercial analyser who checked 
each sample for quantity and quality (i.e. contamination). All samples passed with the quality grade 
Class 1 for integrity values, volume and concentration for the DNA microanalysis; with the exception 
of two samples that were replaced with other Class 1-graded sample to complete the subject count 
in each corresponding subgroup. The sample assessment can be found in Appendix D.3, p. 199. 
Table 4-7 demonstrates the overall count of the significantly upregulated and downregulated 
genes between any two subgroups. The gene count is limited to the statistical correction of false 
rate discovery with reference to the selected 742 relevant genes (Appendix D.2). Of any two 
compared groups, one is the objective and the other is the reference group (the latter one in table 
Table 4-7: vs ‘Group’), meaning that any value reflects a difference, present in the objective group 
in comparison with the reference group. Overall, the most numerous differential expression take 
place on Day 1, after the muscle damage induction, with only minor significant differences 
throughout the recovery period, until day 14.  
Based on the selected gene pathways to reflect the profiles of each experimental subgroup, the 
following results are presented in four parts according to: (1) the Skeletal Muscle (Myogenesis and 
Myopathy) pathway, (2) the Hypoxia Signalling pathway, (3) the VEGF pathway, and (4) the Wound 
Healing pathway. Although there are some pattern parallels between the genes within the same 
pathway, they can show different expression profiles when comparing all the subgroups. In theory, 
if a gene would be differentially expressed in all possible comparisons of the groups, there would 
be 91 of them to interpret. Multiplying that by the number of genes in a pathway, and then repeat 
for the other pathways, make the overall picture extremely intricate. Although these 91 
comparisons would not realistically all demonstrate differential gene expression, there still are 
between 1 and 45 for the significantly expressed genes. For this reason, when looking at the 
upregulation and downregulation profiles of each gene, only the numerical results of the pathway 
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line with the highest count of significantly expressed genes in most subgroup comparison will be 
presented here, along with some standout genes which show a significant expression throughout 
the recovery period. The expression profiles of significant genes within all the pathway lines (both 
before and after the false rate discovery correction) can be found in Appendix D.4 (p. 201). 
Table 4-7. The number genes in m. soleus with significant up- and downregulation between the all the subgroups (n=3 each) in the 
experiment. 
 
4.4.2 The Skeletal Muscle (Myogenesis and Myopathy) Pathway 
Table 4-8 shows the pathway lines within the Skeletal Muscle pathway, listed with all the genes that 
compose them along with an absolute gene count (Ngene) and a relative count (Ngene%) with 
reference to the 84 different genes in the pathway. Note that some genes may be repeated 
between the different lines, which does not affect the overall count. The genes (or the gene 
symbols) in boldface letters are significantly expressed (p≤0.05), with an ordinary t-test, in at least 
Reference Reference
vs  A{−1}: R{−1} [C]: C{03} vs C{01} C{07} vs C{03} C{14} vs C{07}
Up 0 Up 22 0 0
Down 0 Down 6 0 0
Total 0 Total 28 0 0
C{01} C{03} C{07} C{14} H{01} vs C{01} H{03} vs C{03} H{07} vs C{07} H{14} vs C{14}
Up 30 0 0 0 Up 0 0 0 0
Down 35 2 0 0 Down 0 0 0 0
Total 65 2 0 0 Total 0 0 0 0
H{01} H{03} H{07} H{14} E{01} vs C{01} E{03} vs C{03} E{07} vs C{07} E{14} vs C{14}
Up 70 2 0 0 Up 19 0 1 0
Down 63 2 0 0 Down 5 0 0 0
Total 133 4 0 0 Total 24 0 1 0
E{01} E{03} E{07} E{14}
Up 55 10 1 0 [H]: H{03} vs H{01} H{07} vs H{03} H{14} vs H{07}
Down 37 3 2 0 Up 21 0 0
Total 92 13 3 0 Down 13 0 0
Total 34 0 0
vs  R{−1}: C{01} C{03} C{07} C{14} E{01} vs H{01} E{03} vs H{03} E{07} vs H{07} E{14} vs H{14}
Up 11 0 0 3 Up 0 0 1 0
Down 30 0 1 0 Down 0 0 0 0
Total 41 0 1 3 Total 0 0 1 0
H{01} H{03} H{07} H{14}
Up 32 1 1 1 [E]: E{03} vs E{01} E{07} vs E{03} E{14} vs E{07}
Down 23 2 2 0 Up 11 0 0
Total 55 3 3 1 Down 13 0 0
E{01} E{03} E{07} E{14} Total 24 0 0
Up 38 0 4 1
Down 43 0 3 0
Total 81 0 7 1
Information provided by Bioarray S.L. (Alicante, Spain).
Subgroups Subgroups
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one of the subgroup comparisons, and are accompanied with their relative gene count (Np%) 
referenced to the 84 different genes of the pathway. Genes in boldface letters marked with an 
asterisk are, furthermore, significantly expressed after the false discovery rate corrections 
(p(adj)≤0.05), and are accompanied with the relative gene count (Np(adj)%) referenced to the 84 
genes in the pathway.  The genes in lightface letters do not demonstrate any significant differential 
expressions.  
Table 4-8. The Genes of the Skeletal Muscle (Myogenesis and Myopathy) Pathway. 
 
Table 4-9 shows the distribution of the maximum significant relative count, both with and without 
the false discovery rate correction, for the genes in the subgroups within all the pathway lines. The 
relative count demonstrates the greatest subgroup-coverage in three pathway lines: Contractility 
Dystrophin-Glycoprotein Complex, Contractility Titin Complex, and Myogenesis. However, the 
focus is not on the highest percentage in the table per se, but how close these percentages are to 
their corresponding pathway line percentage given in Table 4-8; and if the percentage is 
Line Genes (Symbols) Ngene Ngene% Np% Np(adj)%
Capn3*, Emd*, Lmna*, Cav3*, Dmd*, Dysf*, Dag1, Camk2g, Mapk1, Sgca. 10 12% 10% 7%
Actn3*, Capn3*, Lmna*, Myot*, Cryab*, Tnnt3*, Tnni2*, Trim63*, Acta1, Des, 
Ttn, Myh1, Myh2, Mapk1, Mstn, Neb, Sgca, Tnnt1.
18 21% 15% 10%
Hk2*, Slc2a4*, Cs*, Pdk4. 4 5% 5% 4%
Atp2a1*, Tnnt3*, Tnni2*, Myh1, Myh2. 5 6% 6% 4%
Mb, Myh1, Tnnc1, Tnnt1. 4 5% 4% 0%
Rps6kb1*, Dmpk, Ikbkb. 3 4% 1% 1%
Myod1*, Mef2c*, Hdac5*, Myog*, Adrb2*, Dmd*, Rps6kb1*, Agrn*, Igfbp5*, 
Cast*, Utrn*, Cav1*, Bmp4, Capn2, Acta1, Myf5, Igfbp3, Igf1, Mbnl1, Myf6, 
Ppp3ca, Bcl2, Ctnnb1, Mstn, Musk, Myog, Pax3, Rhoa. 
28 33% 25% 14%
Myod1*, Adrb2*, Acvr2b*, Rps6kb1*, Igfbp5*, Acta1, Igf1, Myf6,  Mstn. 9 11% 10% 6%
Il6*, Tgfb1*, Igf2*, Adipoq, Fgf2, Igf1, Lep, Mstn. 8 10% 7% 4%
Ppargc1a*, Prkaa1*, Slc2a4*, Prkab2, Ppargc1b, Adipoq, Pparg , Lep, 
Prkag1, Prkag3.
10 12% 8% 4%
Fbxo32*, Casp3*, Nos2*, Rps6kb1*, Ppargc1a*, Trim63*, Foxo3, Capn2, 
Ppargc1b, Mstn.
10 12% 11% 7%
Fbxo32*, Akt2*, Il1b*, Trim63*, Mapk8*, Utrn*, Mapk14, Tnf, Akt1, Mapk3, 
Nfkb1, Mapk1, Mmp9.
13 15% 13% 7%
Diabetes/Metabolic Syndrome:
Skeletal Muscle Hypertrophy:
Skeletal Muscle Contractility, Other:
Skeletal Muscle Contractility, Fast-Twitch Fibres:
Skeletal Muscle Wasting/Atrophy, Dystrophy:
Skeletal Muscle Contractility, Dystrophin-Glycoprotein Complex:
Skeletal Muscle Contractility, Energy Metabolism:
Skeletal Muscle Contractility, Slow-Twitch Fibres:
Skeletal Myogenesis:
Skeletal Muscle Autocrine Signalling:
Skeletal Muscle Contractility, Titin Complex:
The suggested 84 different genes for the pathway by Sabiosciences (2015). Significantly expressed genes (p≤0.05) are in boldface
letters. Genes marked with an asterisk are significant (p(adj)≤0.05) with a false discovery rate-corrected p-value. 
Skeletal Muscle Wasting/Atrophy, Autophagy:
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maintained high throughout the subgroup-coverage in the pathway line. With reference to Np(adj)%, 
the Contractility Dystrophin-Glycoprotein Complex pathway line should be as close to 7% (as per 
Table 4-8) and is here seen with a maximum of 6.0% (i.e. 80% of the 7.0%) in three of the subgroups. 
The other subgroups show somewhat similar percentage. The Contractility Titin Complex pathway 
line should be close to Np(adj)%=10%, and is here with a maximum of 4.8% (i.e. 50% of the 10%) in 
only one subgroup; still, the percentage of others are following close behind. The Myogenesis 
pathway line should be as close to Np(adj)%=14%, and is here seen with a maximum of 6.0% (i.e. 
40% of the 14%) in three of the subgroups, and the other subgroups follow somewhat closely. 
Therefore, of these three pathway lines, the Contractility Dystrophin-Glycoprotein Complex 
pathway line has the greatest coverage.  
Table 4-9. The Overall Profile Coverage of the Skeletal Muscle (Myogenesis and Myopathy) Pathway Based on the Maximum 
Relative Count of Significantly Expressed Genes.  
 
Day −1
R{−1} C{01} H{01} E{01} C{03} H{03} E{03} C{07} H{07} E{07} C{14} H{14} E{14}
Np% 6.0% 7.1% 7.1% 2.4% 6.0% 2.4% 1.2% 6.0% 7.1% 2.4% 7.1% 7.1%
Np(adj)% 3.6% 6.0% 4.8% 1.2% 6.0% 2.4% 6.0% 3.6%
Np% 2.4% 8.3% 7.1% 6.0% 8.3% 7.1% 3.6% 2.4% 7.1% 4.8% 3.6% 4.8% 4.8%
Np(adj)% 4.8% 3.6% 3.6% 3.6% 1.2% 2.4% 2.4% 3.6% 2.4%
Np% 2.4% 1.2% 2.4% 2.4% 1.2% 1.2% 1.2% 2.4% 1.2% 2.4% 2.4%
Np(adj)% 1.2% 1.2% 1.2% 1.2% 2.4%
Np% 3.6% 2.4% 4.8% 4.8% 2.4% 1.2% 1.2% 1.2% 4.8% 2.4%
Np(adj)% 1.2% 1.2% 3.6% 1.2%
Np% 1.2% 4.8% 3.6% 6.0% 3.6% 3.6% 3.6%
Np(adj)%
Np% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2%
Np(adj)% 1.2%
Np% 2.4% 7.1% 13.1% 9.5% 3.6% 8.3% 10.7% 4.8% 11.9% 8.3% 3.6% 11.9% 10.7%
Np(adj)% 1.2% 6.0% 3.6% 1.2% 3.6% 1.2% 4.8% 6.0% 4.8% 6.0%
Np% 1.2% 3.6% 4.8% 4.8% 2.4% 3.6% 6.0% 4.8% 7.1% 6.0%
Np(adj)% 2.4% 1.2% 1.2% 2.4% 3.6% 3.6%
Np% 1.2% 1.2% 2.4% 3.6% 1.2% 2.4% 2.4% 1.2% 2.4% 2.4% 1.2% 2.4% 2.4%
Np(adj)% 1.2% 1.2% 1.2% 2.4% 2.4% 1.2% 1.2%
Np% 2.4% 2.4% 2.4% 3.6% 2.4% 3.6% 3.6% 1.2% 1.2% 1.2% 2.4% 2.4%
Np(adj)% 1.2% 1.2% 1.2% 1.2% 1.2%
Np% 2.4% 6.0% 4.8% 4.8% 2.4% 2.4% 3.6% 2.4% 6.0% 4.8% 2.4% 3.6% 6.0%
Np(adj)% 1.2% 2.4% 1.2% 1.2% 1.2% 1.2% 3.6% 1.2% 1.2% 1.2%
Np% 2.4% 8.3% 4.8% 6.0% 3.6% 3.6% 4.8% 2.4% 4.8% 4.8% 1.2% 1.2% 2.4%
Np(adj)% 1.2% 2.4% 1.2% 1.2% 1.2% 2.4% 2.4% 1.2% 1.2% 2.4%
Skeletal Muscle Hypertorphy.
Day 1 Day 3 Day 7 Day 14
Skeletal Muscle Contractility: Dystrophin−Glycoprotein Complex.
Skeletal Muscle Contractility: Titin Complex.
Skeletal Muscle Contractility: Energy Metabolism.
Skeletal Muscle Contractility: Fast−Twitch Fibres.
Skeletal Muscle Contractility: Slow−Twitch Fibres.
Skeletal Muscle Contractility: Other.
Skeletal Myogenesis.
Skeletal Muscle Autocrine Signalling.
Diabetes/Metabolic Syndrome.
Skeletal Muscle Wasting/Atrophy: Autophagy.
Skeletal Muscle Wasting/Atrophy: Dystrophy.
Np%, relative count of significantly expressed genes (p≤0.05) with ordinary t-test.
Np(adj)%, relative count of significantly expressed genes (p(adj)≤0.05) with an adjusted p-value for false rate discovery.
Line
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The Skeletal Muscle Contractile - Dystrophin-Glycoprotein Complex Profile. 
Table 4-10  demonstrates the profile of significant differential expression that corresponds to the 
Skeletal Muscle Contractile Dystrophin-Glycoprotein Complex pathway line. For a given gene the 
average expression, for each objective vs reference group, is displayed in a logarithmic ratio, i.e. fold 
changes on a log2-scale (log2(FC). The positive fold changes represent upregulated differential 
expressions and are written in a white font on a dark background, to distinguish them from the 
negative fold changes that represent downregulated differential expressions. The fold changes 
marked with an asterisk and written with boldface letters are significant after the false discovery 
rate correction, whilst the others are only significant with the t-test. 
Table 4-10. The Skeletal Muscle Contractility – Dystrophin-Glycoprotein Complex Gene Profile of the Significant Differential Fold 
Changes (log2(FC)). 
 
Capn3 Emd Lmna Cav3 Dmd Dysf Dag1 Camk2g
Day −1 A{−1} R{−1}
A{−1} −0.59* 0.28 0.57* −0.23  0.49*   
R{−1} −0.52* 0.24 0.48*   0.30   
A{−1} −0.56* 0.36* 0.72* −0.41* −0.39 0.50*   
R{−1} −0.49* 0.31* 0.64* −0.29 −0.44 0.31   
A{−1} −0.64* 0.32* 0.59* −0.39*  0.41 −0.26  
R{−1} −0.57* 0.27 0.50* −0.26   −0.24  
C{01}        −0.61
A{−1}   0.48   0.48   
R{−1}   0.39      
C{01} 0.52*        
A{−1}   0.36   0.33   
H{01} 0.44 −0.29 −0.36 0.30 0.53    
A{−1}   0.49   0.33   
R{−1}   0.41      
E{01} 0.39   0.28     
C{03} C{07}   −0.28      
A{−1}     0.44    
R{−1}     0.39    
H{01} 0.70* −0.42* −0.57* 0.36* 0.84*    
C{07}     0.38    
E{01} 0.61* −0.27 −0.40* 0.27  −0.38  0.46
E{03}   −0.30   −0.29   
H{07}     −0.37    
R{−1} C{14} 0.33       0.48
A{−1}       −0.24  
R{−1} 0.34      −0.23  
H{01} 0.84* −0.30* −0.52* 0.36* 0.71* −0.30   
H{03} 0.39        
E{01} 0.62* −0.35* −0.44* 0.21 0.37 −0.39   
E{03}   −0.34   −0.30   
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E{07}
E{01}
H{07}
H{01}
E{03}
H{03}
Day 1
C{01}
Gene (Symbol)
H{14}
E{14}
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value 
(false discovery rate corrected). Positive fold change values are in white letters on dark background. Genes within
this pathway line with no significant differential expression are: Mapk1, Sgca.
Day 7
Day 3
Day 14
C{03}
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None of the genes in the pathway line demonstrate significant differential expressions between the 
R{−1} and the A{−1} subgroups on Day −1, and, therefore, jointly situate the reference level. 
However, the general physiological reference for the three groups, the [C], [H] and [E], is the R{−1} 
subgroup. Capn3 is downregulated on Day 1 in all the three groups, still, without any significant 
difference between them. The downregulation is then returned to the reference level on Day 3, 
especially for the [C]-group, and then more pronouncedly from Day 7 for the [H] and the [E]-
groups. There is even slight evidence of upregulation in the [H]-group on Day 14. Contrary to 
Capn3, Emd shows an upregulation in all three groups on Day 1, although slightly more 
pronounced in the [H]-group. The [C]-group shows an indication of being immediately 
returned to reference level on Day 3. In the [H] and [E]-groups the upregulation is 
returned to the reference level on Day 14, sooner for the [H]-group, from Day 3/7, from 
Day 7/14 for the [E]-group. The exact measurable day depends on whether which level 
of significance is taken into account. Lmna shows an upregulation in all the groups on 
Day 1, that is gradually returned to the reference levels on Day 7 for the [C] and [H]-
groups, whilst the gradual change within the [E]-group is much slower, especially until 
Day 3. Cav3 is downregulated on Day 1, with the more significant change in the [H] and 
[E]-groups, that is returned on Day 3. Moreover, on Day 1, the downregulation with 
reference to A{−1} and R{−1}, suggests that Cav3 might be slightly downregulated in the 
R{−1} compared to A{−1}, still, not significantly. Dmd shows the most marked response 
on Day 1 in the [H]-group with a small downregulated expression, which seems to be 
returned on Day 3 but reversed to an upregulation on Day 7 and thereafter. The [E]-
group seems to be shadowing this pattern of the [H] group, as its only significant 
expression, throughout, is present on Day 14 with a small upregulation. Dysf shows an 
upregulation on Day 1 in all the groups; that seems prolonged until Day 3, and 
furthermore, more emphasises in reference to the A{−1}-group. The [E]-group indicates 
to show a slightly more notable return of this upregulation from Day 7 to Day 14. The 
semi one-time significant differential expressions of Dag1 and Camk2g are too isolated to be 
indicative of any trend and do, furthermore, only show significant expression according to the t-
test. Mapk1 and Sgca do not show any significant differential expressions. 
The Skeletal Muscle Contractility — The Titin Complex Profile; the Energy Metabolism Profile; the Fast-
Twitch Fibres Profile; the Slow-Twitch Fibres Profile; and Other Related Genes 
The tables of differential expression of the following five profiles can be found in Appendix D.4.1: 
The Titin Complex Profile (Table ApxD - 3); the Energy Metabolism Profile (Table ApxD - 4); the 
Fast-Twitch Fibres Profile (Table ApxD - 5); the Slow-Twitch Fibres Profile (Table ApxD - 6); and 
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Other Related Genes (Table ApxD - 7). Between these profiles, the most significantly expressed 
genes, apart from Capn3 and Lmna, already described above, are Myot, Hk2 and Atp2a1. None is 
expressed differentially between the R{−1} and A{−1}. Myot is downregulated in all groups on Day 
1, which is returned to reference level on Day 3. The [H]-group might be slightly less 
downregulated, although, not significantly. Hk2 is only responsive in the [E]-group on Day 1, 
reflected in an upregulation which is returned from Day 7. Group [C] and [H] are also responsive 
(the [C]-group less than the [H]-group) with a significant downregulation on Day 7. The difference 
in the downregulation between all the groups on Day 7 suggest a slight more reaction in the [H]-
group. Atp2a1 is downregulated in the [C] and [H]-groups on Day 1, which is then returned on 
Day 3. On the contrary, the [E]-group is upregulated on Day 1 which is gradually returned 
thereafter. 
The Skeletal Muscle — The Myogenesis Profile; and the Hypertrophy Profile 
The tables of differential expression of the following two profiles can be found in Appendix D.4.1: 
The Myogenesis Profile (Table ApxD - 8); and the Hypertrophy Profile (Table ApxD - 9). Between 
these profiles, the most significantly expressed genes are Myod1, Mef2c and Myog. None is 
expressed differentially between the R{−1} and A{−1}. Myod1 is upregulated in all groups on Day 
1, which is gradually returned to reference level on Day 7. The [C]-group is responsive to a lesser 
extent, and there is an indication of the [E]-group being more responsive. Mef2c is downregulated 
in all groups on Day 1 and immediately returned to reference level on Day 3, still, without any 
significant differences between the groups. Myog is upregulated in the [H] and [E]-groups on Day 
1 and gradually returned to reference level on Day 7, with no distinction between the two groups. 
However, the [C]-group does not show any significant expression. 
The Skeletal Muscle — The Autocrine Signalling Profile; and the Diabetes/Metabolic Syndrome Profile 
The tables of differential expression of the following two profiles can be found in Appendix D.4.1: 
The Autocrine Signalling Profile (Table ApxD - 10); and the Diabetes/Metabolic Syndrome Profile 
(Table ApxD - 11). Between these profiles, the most significantly expressed genes are Il6, Tgfb1 and 
Ppargc1a. None is expressed differently between the R{−1} and A{−1}. Il6 is upregulated in the [E]-
group on Day 1 and immediately returned to reference level on Day 3. However, the [C] and  [H]-
groups do not show any significant differential expression. Tgfb1 is the most responsive gene in 
the [H]-group, with an upregulation on Day 1 which gradually returns to reference level on Day 7. 
Both the [C] and [E]-groups are upregulated to a slightly lesser extent on Day 1 (to even lesser 
extent in the [E]-group), and maintained upregulated until Day 3. Thereafter the expression returns 
to the reference level.  
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The Skeletal Muscle Wasting/Atrophy — The Autophagy Profile; and the Dystrophy Profile 
The tables of differential expression of the following two profiles can be found in Appendix D.4.1: 
The Autophagy Profile (Table ApxD - 12); and the Dystrophy Profile (Table ApxD - 13). Between 
these profiles, the most significantly expressed genes are Fbxo32, Casp3, Akt2 and Trim63. Fbxo32 
is downregulated on Day −1 in the R{−1} in comparison with A{−1}. On Day 1 it then shows an 
upregulation in the [C] and [H]-groups, but to slightly more extent in the [C]-group. The 
upregulation is maintained in both groups until Day 14, although it slightly lags in the [C]-group in 
between Day 3 and Day 7, but rises up again on Day 14. The [E]-group does not show any 
significant differential expression of Fbxo32. Casp3 is not expressed differentially between R{−1} 
and A{−1}. On Day 1 the gene is upregulated in all three groups and maintained upregulated on 
Day 3 in the [H]-group. After upregulation in the [H] and [E], the expression immediately returns to 
the reference level on Day 7. The [C]-group shows less gradual return. Akt2 is not expressed 
differentially between R{−1} and A{−1}. On Day 1 the gene is downregulated in all three groups 
and maintained downregulated until Day 7 in the [E]-group. The [C]-group immediately returns to 
reference level on Day 3, whilst the [H]-group does so gradually until Day 14. Trim63 is 
downregulated on Day −1 in the R{−1} and are also downregulated in the [C] and [H]-groups on 
Day 1. The [H]-group then immediately returns to reference level on Day 3, whilst the [C]-group 
has a slightly more planar return. The [E]-group, on the other hand, immediately returns to 
reference level on Day 1 and maintains it until Day 14. 
4.4.3 The Hypoxia Signalling Pathway 
Table 4-11 shows the pathway lines within the Hypoxia Signalling pathway, listed with all the genes 
that compose them along with an absolute gene count (Ngene) and a relative count (Ngene%) 
referenced to the 84 different genes of the pathway. As for the other pathways, some genes may 
be repeated between the different lines, without affecting the overall count. The genes in boldface 
letters have significantly expressed (p≤0.05), with an ordinary t-test, in at least one of the subgroup 
comparisons, and are accompanied with their relative gene (Np%) referenced to the 84 different 
genes of the pathway. Genes in boldface letters marked with an asterisk are, furthermore, 
significantly expressed after the false discovery rate corrections (p(adj)≤0.05), and are accompanied 
with the relative gene count (Np(adj)%) referenced to the 84 genes in the pathway. The genes in 
lightface letters do not demonstrate any significant differential expressions. 
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Table 4-11. The Genes of the Hypoxia Signalling Pathway. 
 
Table 4-11 shows the distribution of the maximum significant relative count, both with and without 
the false discovery rate correction, for the genes in the subgroups within all the pathway lines. The 
relative count demonstrates the greatest subgroup-coverage in three pathway lines; Angiogenesis, 
Metabolism, and Regulation of Apoptosis.  However, the focus is not on the highest percentage in 
the table per se, but how close these percentages are to their corresponding pathway line 
percentage given in Table 4-12, and if the percentage is maintained high throughout the 
subgroup-coverage in the pathway line.  
With reference to Np(adj)%, the Angiogenesis pathway line should be as close to 11% (as per Table 
4-12) and is here seen with a maximum of 8.3% (i.e. 78% of the 11%) in three of the subgroups. 
The other subgroups show somewhat similar percentage. The Metabolism pathway line should be 
close to Np(adj)%=13%, and is here with a maximum of 4.8% (i.e. 36% of the 13%) in only one 
subgroup; still, the percentage of others are following close behind. The Regulation of Apoptosis 
pathway line should be as close to Np(adj)%=11%, and is here seen with a maximum of 4.8% (i.e. 
44% of the 11%) in three of the subgroups, and the other subgroups follow somewhat closely. 
Therefore, of these three pathway lines, the Angiogenesis pathway line has the greatest. 
Line Genes (Symbols) Ngene Ngene% Np% Np(adj)%
Arnt*, Per1, Hif1a, Cops5, Hif3a, Hnf4a. 6 7% 6% 1%
Egln3*, P4hb*, Tp53*, Apex1*, P4ha1, Nfkb1,  Cdkn2a, Egln1. 8 10% 7% 5%
Hmox1*, Btg1*, Adora2b*, Anxa2*, Plau*, Serpine1*, Lox*, Pgf*, Vegfa*, 
Jmjd6, Angptl4, F3, Gpi, Egr1, Edn1, Epo, Mmp9.
17 20% 15% 11%
Anxa2*, Plau*, Serpine1*, Aldoa*, F10, F3 , Slc16a. 7 8% 7% 5%
Mif*, Ndrg1, Ruvbl2, LOC367198. 4 5% 4% 1%
Pdk1*, Pfkl*, Ero1l*, Hk2*, Pgam1*, Slc2a1*, Aldoa*, Ldha*, Pkm*, Ddit4*, 
Pgm2*, Pfkp, Gpi, Gys1, Tpi1, Eno1, Pfkfb3, Pfkfb4, Pgk1, Slc2a3.
20 24% 18% 13%
Bnip3*, Btg1*, Pim1*, Mif*, Ddit4*, Ier3, Bnip3l, Adm, Nos3. 9 11% 6% 11%
Btg1*, Pim1*, Mxi1*, Ccng2*, Mif*, Pgf*, Odc1, Igfbp3, Met, Adm, Nampt, 
Nos3, Blm, Egr1, Txnip.
15 18% 14% 7%
Usf2*, Bhlhe40, Fos, Rbpjl. 4 5% 4% 1%
Tfrc*, Slc16a3*, Slc2a1*, Vdac1, Slc2a3. 5 6% 5% 4%
Lgals3*, Ctsa*, Ankrd37*, Car9, Dnajc5, Eif4ebp1, Map3k1. 7 8% 8% 4%
Transporters, Channels & Receptors:
Regulation of Cell Proliferation:
Metabolism:
The suggested 84 different genes for the pathway by Sabiosciences (2015). Significantly expressed genes (p≤0.05) are in boldface
letters. Genes marked with an asterisk are significant (p(adj)≤0.05) with a false discovery rate-corrected p-value. 
DNA Damage Signalling & Repair:
Regulation of Apoptosis:
Transcription Factors:
Other Responsive Genes:
HIF1 & Co-Transcription Factors:
Angiogenesis:
Coagulation:
Other HIF1 Interactors:
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Table 4-12. The Overall Profile Coverage of the Hypoxia Signalling Pathway Based on the Maximum Relative Count of Significantly 
Expressed Genes. 
 
The Hypoxia Signalling Angiogenesis Profile 
Table 4-13 demonstrates the profile of significant differential expression that corresponds to the 
Hypoxia Signalling Angiogenesis pathway line. For a given gene the average expression, for each 
objective vs reference group, is displayed in fold changes on a log2-scale (log2(FC). The positive fold 
changes represent upregulated differential expressions and are written in a white font on a dark 
background, to distinguish them from the negative fold changes that represent downregulated 
differential expressions. The fold changes marked with an asterisk and written with boldface letters 
are significant after the false discovery rate correction, whilst the others are only significant with the 
t-test. 
Day −1
R{−1} C{01} H{01} E{01} C{03} H{03} E{03} C{07} H{07} E{07} C{14} H{14} E{14}
Np% 1.2% 4.8% 1.2% 2.4% 2.4% 1.2% 1.2% 2.4% 2.4% 1.2% 2.4% 2.4% 1.2%
Np(adj)% 1.2%
Np% 3.6% 4.8% 2.4% 2.4% 3.6% 2.4% 1.2% 3.6% 2.4% 2.4% 3.6% 3.6%
Np(adj)% 1.2% 3.6% 1.2% 1.2% 2.4% 2.4% 2.4% 1.2%
Np% 3.6% 9.5% 9.5% 3.6% 4.8% 7.1% 2.4% 8.3% 10.7% 1.2% 9.5% 9.5%
Np(adj)% 7.1% 8.3% 1.2% 3.6% 4.8% 4.8% 8.3% 8.3%
Np% 3.6% 4.8% 3.6% 2.4% 3.6% 3.6% 1.2% 3.6% 3.6% 1.2% 3.6% 3.6%
Np(adj)% 3.6% 3.6% 2.4% 1.2% 2.4% 1.2% 3.6% 2.4%
Np% 1.2% 1.2% 1.2% 1.2% 2.4% 1.2% 1.2%
Np(adj)% 1.2%
Np% 8.3% 4.8% 6.0% 9.5% 6.0% 6.0% 2.4% 7.1% 4.8% 2.4% 6.0% 7.1%
Np(adj)% 2.4% 3.6% 3.6% 2.4% 2.4% 2.4% 4.8% 2.4% 2.4% 4.8%
Np% 6.0% 4.8% 6.0% 3.6% 4.8% 6.0% 3.6% 6.0% 1.2% 3.6% 3.6%
Np(adj)% 2.4% 3.6% 4.8% 1.2% 2.4% 2.4% 3.6% 3.6% 3.6% 3.6%
Np% 6.0% 4.8% 7.1% 1.2% 3.6% 6.0% 3.6% 7.1% 1.2% 4.8% 7.1%
Np(adj)% 1.2% 3.6% 3.6% 1.2% 1.2% 2.4% 2.4% 2.4% 6.0%
Np% 1.2% 1.2% 1.2% 2.4% 1.2% 1.2%
Np(adj)% 1.2%
Np% 2.4% 2.4% 3.6% 3.6% 2.4% 1.2% 2.4% 3.6% 2.4% 2.4% 3.6% 3.6%
Np(adj)% 1.2% 1.2% 2.4% 2.4% 2.4% 2.4%
Np% 4.8% 4.8% 2.4% 2.4% 4.8% 2.4% 1.2% 3.6% 2.4% 3.6% 3.6%
Np(adj)% 3.6% 2.4% 1.2% 1.2% 2.4% 1.2% 2.4% 1.2%
Np%, relative count of significantly expressed genes (p≤0.05) with ordinary t-test.
Np(adj)%, relative count of significantly expressed genes (p(adj)≤0.05) with an adjusted p-value for false rate discovery.
Metabolism.
Day 1 Day 3 Day 7 Day 14
HIF1 & Co−Transcription Factors.
Other HIF1 Interactors.
Angiogenesis.
Coagulation.
DNA Damage Signalling & Repair.
Regulation of Apoptosis.
Regulation of Cell Proliferation.
Transcription Factors.
Transporters, Channels & Receptors.
Other Responsive Genes.
Line
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Table 4-13. The Hypoxia Signalling Angiogenesis Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
None of the genes in the pathway line demonstrate significant differential expressions between the 
R{−1} and the A{−1} subgroups on Day −1, and, therefore, jointly situate the reference level. Hmox1, 
Btg1 and Adora2b all show similar profiles of upregulation on Day 1, which has returned to 
reference level on Day 7, in the [H] and [E]-groups. The return is perhaps indicated to be slightly 
faster in the [E]-group. However, the [C]-group does not show any significant reaction on any of 
the days. Anxa2 is similar to Hmox1, Btg1 and Adora2b regarding being only significantly reactive 
in the [H] and [E] groups and not in the [C]-group, demonstrating an upregulation on Day 1 that 
has returned bac to the reference levels on Day 7. However, the upregulation is still detectable on 
Day 3. Furthermore, the overall expression levels do indicate that the gene is slightly upregulated 
in R{−1} in comparison with A{−1}, still, not significantly. Plau shows a similar pattern to Anx2, 
commencing with an upregulation on Day 1 for the [H] and [E]-groups, still, also seems to be 
Hmox1 Btg1 Adora2b Anxa2 Plau Serpine1 Lox Pgf Vegfa Jmjd6 Angptl4 F3 Gpi
Day −1 A{−1} R{−1}
A{−1}     0.69 1.21 1.29       
R{−1}      1.16    −0.38    
A{−1} 1.26 0.57* 0.52 1.33* 1.05* 1.99* 2.03*  −1.11*     
R{−1} 1.23 0.46*  0.99 0.73 1.94* 1.46*  −0.62     
C{01}  0.35            
A{−1} 1.96* 0.89* 0.72* 1.09* 1.29* 2.24* 1.90*  −0.62     
R{−1} 1.93* 0.79* 0.50 0.76 0.97* 2.20* 1.34 0.74      
C{01} 1.59* 0.68*   0.60 1.03  0.59   2.92   
H{01}  0.32      0.56      
A{−1}    0.87  0.97 1.94       
R{−1}      0.92 1.38       
A{−1}    0.83 0.56  1.77  −1.02     
R{−1}       1.20   −0.33    
H{01} −0.98 −0.30 −0.45   −1.51*        
A{−1}    0.82 0.56 1.85* 1.59  −0.98     
R{−1}      1.80 1.02       
E{01} −1.51* −0.80* −0.72*  −0.72   −0.73   −2.49   
H{03}      1.37        
C{03} C{07}      −0.97 −1.04       
A{−1}        −0.63  −0.36    
R{−1}          −0.43    
H{01} −1.38* −0.69* −0.53 −1.32* −0.66 −1.59* −1.17       
H{03}  −0.39  −0.81          
A{−1}     0.57 1.14        
R{−1}      1.09        
E{01} −1.82* −1.07* −0.66* −1.12* −0.71 −1.10 −1.21 −0.73   −2.84   
E{03}    −0.84     0.91     
C{07}      1.14        
R{−1} C{14}            −0.74  
H{01} −1.39* −0.69* −0.62* −1.22* −0.81* −1.44* −1.46*  0.68     
H{03}  −0.39  −0.72   −1.20  0.59     
H{07}        0.55      
A{−1}      1.02       −0.29
R{−1}      0.97        
E{01} −1.84* −1.01* −0.79* −1.27* −0.94* −1.22 −1.84* −0.77*      
E{03}    −1.00   −1.52  0.62     
Timing R
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E{03}
H{03}
H{01}
Day 1
C{01}
E{01}
Day 3
C{03}
E{07}
Day 7
H{07}
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false discovery rate
corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line with no significant differential
expression are: Egr1, Edn1, Epo, Mmp9.
Day 14
H{14}
E{14}
 Results 
111 
  
slightly upregulated in C{01} which is then immediately returned. The upregulation is gradually 
returned to reference levels on Day 14, from being with somewhat more emphasised upregulation 
at the start. Serpine1 is upregulated in all three groups on Day 1 and is prolonged until Day 3 for 
the [C]-group and until Day 14 for the [E]-group, although both seem to decrease gradually. The 
[H]-group, which is upregulated to a similar level of [E]-group, shows a little bit steeper decrease in 
the upregulation on Day 3 (in comparison with the [C]-group) but is maintained at that level 
throughout, until Day 14. Lox is also upregulated in all the groups on Day 1, which is slightly 
prolonged until Day 3, and thereafter returned to reference level on Day 14 in the [E]-group, whilst 
the [H]-group is slightly lagging. The [C]-group, however, shows an indication of gradually 
increasing the upregulation until Day 3 but has dropped on Day 7. Pgf is mostly reactive in the [E]-
group, demonstrating an upregulation on Day 1 that is returned on Day 3. Vegfa is mostly reactive 
in the [H] and [E] groups, showing an upregulation on Day 1, perhaps more pronounced in the [H]-
group, but gradually returns until Day 14. Whilst Angptl4 seems to be upregulated only in the [E]-
group, which is returned on Day 3; Jmjd6, F3 and Gpi show too sporadic significant expressions to 
make them logical. Egr1, Edn1, Epo and Mmp9 do not show significant differential expression. 
The Hypoxia Signalling — The HIF1 & Co-Transcription Factors Profile; and the Profile of Other HIF1 
Interactors 
The tables of differential expression of the following two profiles can be found in Appendix D.4.2: 
The HIF1 & Co-Transcription Factors Profile (Table ApxD - 15); and the Profile of Other HIF1 
Interactors (Table ApxD - 16). Between these profiles, the most significantly expressed genes are 
Egln3 and Tp53. Neither is expressed differentially between the R{−1} and A{−1}. Egln3 is 
downregulated on Day 1 in all three groups, but to a lesser extent in the [E]-group. On Day 3 all 
three groups have immediately returned expression back to the reference level. Tp53 is 
upregulated in group [H] on Day 1, but immediately returns to reference level on Day 3. However, 
the [C] and [E]-groups do not show any significant differential expression for this gene. 
The Hypoxia Signalling — The Coagulation Profile; the DNA Damage Signalling & Repair Profile; and the 
Metabolism Profile 
The tables of differential expression of the following three profiles can be found in Appendix D.4.2: 
The Coagulation Profile (Table ApxD - 17); the DNA Damage Signalling & Repair Profile (Table 
ApxD - 18); and the Metabolism Profile (Table ApxD - 19). Between these profiles, the most 
significantly expressed gene is Pdk1, which is, furthermore, not expressed differentially between the 
R{−1} and A{−1}. Pdk1 is downregulated in all three groups on Day 1, with a hint of gradual 
difference from less downregulated [C]-group to the more downregulated [E]-group (with the [H]-
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group in between). The expression is gradually returned in the [H] and [E]-groups on Day 14 and 
Day 7 respectively, whilst the [C]-groups does so on Day 7.  
The Hypoxia Signalling — The Regulation of Apoptosis Profile; and the Regulation of Cell Proliferation 
Profile 
The tables of differential expression of the following two profiles can be found in Appendix D.4.2: 
The Regulation of Apoptosis Profile (Table ApxD - 20); and the Regulation of Cell Proliferation 
Profile (Table ApxD - 21). Between these profiles, the most significantly expressed genes are Bnip3 
and Pim1. Neither is expressed differentially between the R{−1} and A{−1}. Bnip3 is downregulated 
in all three groups on Day 1, with the [E] group to a somewhat lesser extent. Whilst the expression 
in the [C] and [H]-groups returns in relatively planar manner, the expression in the [E]-group do so 
until Day 14, but with a more pronounced gradient. Pim1 is upregulated in all three groups on Day 
1, with the [C]-group to a lesser extent, whilst no difference can be seen between the [H] and [E]-
groups. The [H] and [E]-groups, thereafter, show a gradual return to the reference level until Day 
14. 
The Hypoxia Signalling — The Transcription Factors Profile; the Transporters, Channels & Receptors 
Profile; and the Profile of Other Responsive Genes 
The tables of differential expression of the following three profiles can be found in Appendix D.4.2: 
The Transcription Factors Profile (Table ApxD - 22); the Transporters, Channels & Receptors Profile 
(Table ApxD - 23); and the Profile of Other Responsive Genes (Table ApxD - 24). Between these 
profiles, the most significantly expressed genes are Tfrc and Lgals3. Neither is expressed 
differentially between the R{−1} and A{−1}. Tfrc seems to react slowly, without any significant 
differential expression on Day 1, but then downregulated on Day 3, mostly emphasises in the [H]-
group. This downregulation is then maintained from Day 3 until Day 14. Lgals3 is upregulated in all 
three groups on Day 1, ranking with the higher upregulation in the [H]-group, followed by the [C]-
group, then the [E]-group (although the difference between them is not significant). The overall 
expression is then gradually returning to reference level on Day 14. 
4.4.4 The VEGF Pathway 
Table 4-14 shows the pathway lines within the VEGF pathway, listed with all the genes that 
compose them along with an absolute gene count (Ngene) and a relative count (Ngene%) with 
reference to the 84 different genes in the pathway. genes may be repeated between the different 
lines, which does not affect the overall count. The genes (or the gene symbols) in boldface letters 
are significantly expressed (p≤0.05), with an ordinary t-test, in at least one of the subgroup 
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comparisons, and are accompanied with their relative gene count (Np%) referenced to the 84 
different genes of the pathway. Genes in boldface letters marked with an asterisk are, furthermore, 
significantly expressed after the false discovery rate corrections (p(adj)≤0.05), and are accompanied 
with the relative gene count (Np(adj)%) referenced to the 84 genes in the pathway.  The genes in 
lightface letters do not demonstrate any significant differential expressions. 
Table 4-14. The Genes of the VEGF Pathway. 
 
Table 4-15 shows the distribution of the maximum significant relative count, both with and without 
the false discovery rate correction, for the genes in the subgroups within all the pathway lines. The 
relative count demonstrates the greatest subgroup-coverage in two pathway lines: Small G-Protein 
Signalling and Akt & PI-3-Kinase Signalling. However, the focus is not on the highest percentage 
in the table per se, but how close these percentages are to their corresponding pathway line 
percentage given in Table 4-14 and if the percentage is maintained high throughout the subgroup-
coverage in the pathway line. Concerning Np(adj)%, the Small G-Protein Signalling pathway line 
Line Genes (Symbols) Ngene Ngene% Np% Np(adj)%
Vegfc*, Kdr*, Flt1*, Pgf*, Vegfa*, Vegfb, Pdgfc, Figf, Nrp1,  Flt4, Nrp2. 11 13% 11% 6%
Pik3r1*, Pik3ca*, Akt2*, Pik3r3*, Pik3r2*, Akt3, Pik3r5, Akt1, Pik3cb, 
Pik3cd, Pik3cg.
11 13% 12% 6%
Nras*, Raf1*, Rac1*, Rac2*, Shc2, Src, Hras, Kras. 8 10% 8% 5%
Hsp90aa1*, Hspb1*. 2 2% 2% 2%
Map2k1*, Mapk11*, Mapk14, Mapkapk3, Mapk3, Map2k2, Mapk1, Mapk12, 
Mapk13, Mapkapk2.
10 12% 6% 2%
Nfatc2, Nfatc3, Nfatc4, Nfat5, RGD1560225. 5 6% 4% 0%
Pla2g2d*, Pla2g2e*, Pla2g1b*, Pla2g6*, Pla2g12a*, Pla2g2a, Pla2g4a, 
Pla2g3, Pla2g5, Pla2g2f, Pla2g10, Pla2g12b, Pla2g4b, Plcg1, Plcg2.
15 18% 13% 6%
Prkca*, Prkcb, Prkcg. 3 4% 2% 1%
Ppp3cc, Ppp3r1, Ppp3cb, Ppp3ca, Ppp3r2. 5 6% 6% 0%
Arnt*, Nfatc2, Nfatc4, Hif1a, Nfatc3 , Nfat5, RGD1560225. 7 8% 6% 1%
Bad*, Casp9, Cdc42. 3 4% 2% 1%
Ptk2*, Pxn. 2 2% 2% 1%
Grb2*, Sh2d2a*, Cav1*, Sphk2, Nos3, Ptgs2 , Sphk1. 7 8% 7% 4%
Growth Factors & Receptors:
Heat Shock Proteins:
The suggested 84 different genes for the pathway by Sabiosciences (2015). Significantly expressed genes (p≤0.05) are in boldface
letters. Genes marked with an asterisk are significant (p(adj)≤0.05) with a false discovery rate-corrected p-value. 
Akt & PI-3-Kinase Signalling:
Cell Motility, Migration & Morphology:
Phospholipase A2 & C:
Others:
Protein Phosphatases:
Apoptosis & Cell Cycle:
Transcription Factors:
Protein Kinase C:
Small G-Protein Signalling:
MAP Kinase Signalling:
Nfat Signalling:
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should be close to 4.8% (5% as per Table 4-14) and is here seen with a maximum of 4.8% (i.e. 100% 
of the 5%-reference) in one of the subgroups. The other subgroups show similar percentage. The 
Akt & PI-3-Kinase Signalling pathway line should be close to Np(adj)%=6%, and is here seen with a 
maximum of 3.6% (i.e. 60% of the 6%) in two subgroups, and the other subgroups follow somewhat 
closely. Therefore, of these two pathway lines, the Small G-Protein Signalling pathway line has the 
greatest coverage.  
Table 4-15. The Overall Profile Coverage of the VEGF Pathway Based on the Maximum Relative Count of Significantly Expressed 
Genes. 
 
Day −1
R{−1} C{01} H{01} E{01} C{03} H{03} E{03} C{07} H{07} E{07} C{14} H{14} E{14}
Np% 1.2% 3.6% 3.6% 2.4% 4.8% 4.8% 4.8% 3.6% 1.2% 4.8% 2.4%
Np(adj)% 2.4% 1.2% 1.2% 2.4% 2.4%
Np% 4.8% 2.4% 6.0% 3.6% 2.4% 2.4% 6.0% 2.4% 1.2% 6.0% 1.2%
Np(adj)% 2.4% 2.4% 2.4% 3.6% 1.2% 3.6% 1.2% 1.2% 1.2%
Np% 2.4% 6.0% 4.8% 4.8% 2.4% 2.4% 1.2% 4.8% 3.6% 4.8% 4.8%
Np(adj)% 1.2% 3.6% 3.6% 1.2% 4.8% 3.6% 3.6% 3.6%
Np% 1.2% 2.4% 1.2% 2.4% 1.2% 2.4% 2.4% 2.4% 2.4%
Np(adj)% 1.2% 1.2% 2.4% 1.2% 2.4% 1.2%
Np% 2.4% 2.4% 1.2% 2.4% 2.4% 2.4% 1.2% 2.4% 2.4% 2.4% 1.2%
Np(adj)% 1.2% 2.4% 1.2% 1.2% 1.2% 1.2% 1.2%
Np% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 2.4%
Np(adj)%
Np% 1.2% 3.6% 6.0% 7.1% 6.0% 4.8% 3.6% 1.2% 6.0% 4.8% 2.4% 7.1% 4.8%
Np(adj)% 2.4% 2.4% 2.4% 1.2% 1.2% 1.2% 2.4%
Np% 2.4% 2.4% 2.4% 1.2% 1.2% 1.2% 1.2% 2.4% 1.2% 1.2% 1.2% 2.4%
Np(adj)% 1.2% 1.2% 1.2% 1.2%
Np% 1.2% 2.4% 1.2% 1.2% 1.2% 1.2% 1.2%
Np(adj)%
Np% 3.6% 1.2% 3.6% 1.2% 1.2% 1.2% 1.2% 2.4% 1.2% 1.2% 1.2% 2.4%
Np(adj)% 1.2%
Np% 2.4% 2.4% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2%
Np(adj)% 1.2%
Np% 1.2% 1.2% 1.2% 1.2% 1.2%
Np(adj)% 1.2% 1.2% 1.2%
Np% 2.4% 3.6% 2.4% 1.2% 2.4% 2.4% 1.2% 2.4% 2.4% 1.2% 2.4% 2.4%
Np(adj)% 1.2% 2.4% 1.2% 1.2% 1.2% 1.2%
Np%, relative count of significantly expressed genes (p≤0.05) with ordinary t-test.
Np(adj)%, relative count of significantly expressed genes (p(adj)≤0.05) with an adjusted p-value for false rate discovery.
Nfat Signalling.
Day 1 Day 3 Day 7 Day 14
Growth Factors & Receptors.
Akt & PI−3−Kinase Signaling.
Small G−Protein Signalling.
Heat Shock Proteins.
MAP Kinase Signalling.
Phosholipase A2 & C.
Protein Kinase C.
Protein Phosphatases.
Transcription Factors.
Apoptosis & Cell Cycle.
Cell Motility, Migration, & Morphology.
Line
Others.
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The VEGF Small G-Protein Signalling Profile 
Table 4-16 demonstrates the profile of significant differential expression that corresponds to the 
VEGF Small G-Protein Signalling pathway line. For a given gene the average expression, for each 
objective vs reference group, is displayed in fold changes on a log2-scale (log2(FC). The positive fold 
changes represent upregulated differential expressions and are written in a white font on a dark 
background, to distinguish them from the negative fold changes that represent downregulated 
differential expressions. The fold changes marked with an asterisk and written with boldface letters 
are significant after the false discovery rate correction, whilst the others are only significant with the 
t-test.  
Table 4-16. The VEGF Small G-Protein Signalling Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
None of the genes in the pathway line demonstrates significant differential expressions between 
the R{−1} and the A{−1} subgroups on Day −1, and, therefore, jointly situate the reference level. 
Nras shows an upregulation in all of the three groups on Day 1, with expression values that 
simultaneously suggest that the gene is non-significantly upregulated in R{−1} in comparison with 
Nras Raf1 Rac1 Rac2 Shc2 Src Hras
Day −1 A{−1} R{−1}
A{−1} 0.40 −0.52*      
R{−1}  −0.6*      
A{−1} 0.53* −0.39 0.43* 1.14* 0.33   
R{−1} 0.36 −0.47* 0.37 0.92 0.29   
A{−1} 0.53* −0.51* 0.28 1.16*    
R{−1} 0.37 −0.6*  0.94    
A{−1} 0.44  0.29  0.41 0.37  
R{−1}     0.38 0.27  
C{01}  0.45*   0.33   
A{−1}     0.38  −0.51
R{−1}     0.35  −0.38
H{01}  0.32      
E{01} E{03}  0.34  −0.82    
A{−1} C{07}      0.24  
H{01} −0.64* 0.42* −0.40* −1.08*    
H{03} −0.38       
E{01} −0.67* 0.44*  −1.27*    
E{03} −0.46       
A{−1}     0.30   
R{−1}     0.26   
C{14}     0.29   
H{01} −0.53* 0.46* −0.31 −1.22*    
R{−1} −0.36       
E{01} −0.74* 0.39* −0.31 −1.28*    
E{03} −0.52       
Timing
Gene (Symbol)
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E{14}
E{07}
Day 7
Day 14
H{14}
H{03}
H{07}
E{01}
Day 1
C{01}
H{01}
Day 3
C{03}
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected). Positive fold change values are in white letters on dark
background. Genes within this pathway line with no significant differential expression are: Kras.
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A{−1}. With, apparently, more emphasised upregulation in the [H] and [E]-groups, the expression 
is gradually returned to reference level on Day 7. Raf1 seems to be expressed fairly evenly between 
all the three groups on Day 1 with a downregulation. The expression is then returned to reference 
levels from Day 3 onwards, perhaps more quickly in the [C]-group. Rac1 is overall more expressed 
in the [H]-group, with an upregulation on Day 1 which has gradually returned on Day 7. Rac2, is 
overall expressed in the [H] and [E]-groups, with a similar profile as Rac1, upregulated on Day 1, 
which has returned on Day 7 back to the reference level. Shc2 demonstrated no differential 
expression for the [E]-group but is upregulated for the [H]-group from Day 1 to Day 14. The [C]-
group seems to shadow the pattern for the [H]-group, with only significant upregulation on Day 3. 
Although with fairly sparse significant data, Src, seem to be gradually upregulated until Day 3 which 
thereafter gradually return, only in the [C]-group. Hras is only expressed with a significant 
downregulation in H{03}, but without any significance in any of the rest of the comparisons. Kras 
does not show any significant differential expression. 
The VEGF — The Growth Factors & Receptors Profile; and the Akt & PI-3-Kinase Signalling Profile 
The tables of differential expression of the following two profiles can be found in Appendix D.4.3: 
The Growth Factors & Receptors Profile (Table ApxD - 26); and the Akt & PI-3-Kinase Signalling 
Profile (Table ApxD - 27). Between these profiles, the most significantly expressed genes are Vegfc 
and Kdr. Neither is expressed differentially between the R{−1} and A{−1}. Vegfc is only responsive 
in the [H] and [E]-groups, showing a downregulation on Day 1, to a slightly more extent in the [E]-
group (although not significantly). Both groups demonstrate less downregulation on Day 3, which 
then takes a dip on Day 7, but rises again on Day 14, with the expression at reference level in the 
[H]-group. Kdr is downregulated in all three groups on Day 1, with a more notable expression in 
the [H]-group. The groups are similarly downregulated still on Day 3, but thereafter gradually return 
to the reference level (again, more pronounced in the expression in the [H]-group). 
The VEGF — The Heat Shock Proteins Profile; the MAP Kinase Signalling Profile; and, the Nfat Signalling 
Profile  
The tables of differential expression of the following three profiles can be found in Appendix D.4.3: 
The Heat Shock Proteins Profile (Table ApxD - 28); the MAP Kinase Signalling Profile (Table ApxD - 
29); and, the Nfat Signalling Profile (Table ApxD - 30). Between these profiles, the most significantly 
expressed genes are Hspb1 and Mapk2k1. Neither is expressed differentially between the R{−1} 
and A{−1}. Hspb1 is only significantly responsive in the [H] and [E]-groups, showing upregulation 
on Day 1. The [H]-group gradually returns from Day 3 until Day 14. The [E]-group is maintained 
upregulated on Day 3, but takes a sudden dip to reference level on Day 7 and then becomes 
downregulated on Day 14. Map2k1 is mostly responsive in the [H]-group, with an upregulation on 
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Day 1 which gradually returned to its reference level on Day 7 and stays that way until Day 14. The 
[E]-group indicates that it is shadowing the profile of the [H]-group, but to a much lower extent. 
The VEGF — The Phospholipase A2 & C Profile; the Protein Kinase C Profile; and the Protein 
Phosphatases Profile 
The tables of differential expression of the following three profiles can be found in Appendix D.4.3: 
The Phospholipase A2 & C Profile (Table ApxD - 31); the Protein Kinase C Profile (Table ApxD - 32); 
and the Protein Phosphatases Profile (Table ApxD - 33). Between these profiles, the most 
significantly expressed gene is Pla2g2d, which is upregulated in R{−1} in comparison with A{−1}, on 
Day −1, and even more so in all the groups on Day 1. Whilst the [C] and [H]-groups maintain the 
upregulation until Day 14, with a non-significant decrease, after Day 3, the [E]-group takes a dip 
until Day 14, towards its reference level. 
The VEGF — The Transcription Factors Profile; the Apoptosis & Cell Cycle Profile; the Cell Motility, 
Migration & Morphology Profile; and the Profile of Other Related Genes 
The tables of differential expression of the following four profiles can be found in Appendix D.4.3: 
The Transcription Factors Profile (Table ApxD - 34); the Apoptosis & Cell Cycle Profile (Table ApxD 
- 35); the Cell Motility, Migration & Morphology Profile (Table ApxD - 36); and the Profile of Other 
Related Genes (Table ApxD - 37). Between these profiles, the most significantly expressed gene is 
Ptk2 and is not expressed differentially between the R{−1} and A{−1}. Ptk2 is mostly responsive in 
the [H]-group where it is downregulated on Day 1 and gradually returns to its reference level on 
Day 14. However, the [E]-group is also downregulated on Day 1 but indicates a more planar return 
to reference level thereafter.  
4.4.5 The Wound Healing Pathway 
Table 4-17 shows the pathway lines within the Wound Healing pathway, listed with all the genes 
that compose them along with an absolute gene count (Ngene) and a relative count (Ngene%) 
referencing the 84 different genes in the pathway. Note that some genes may be repeated between 
the different lines, which does not affect the overall count. The genes (or the gene symbols) in 
boldface letters are significantly expressed (p≤0.05), with an ordinary t-test, in at least one of the 
subgroup comparisons, and are accompanied with their relative gene count (Np%) referenced to 
the 84 different genes of the pathway. Genes in boldface letters marked with an asterisk are, 
furthermore, significantly expressed after the false discovery rate corrections (p(adj)≤0.05), and are 
accompanied with the relative gene count (Np(adj)%) referenced to the 84 genes in the pathway.  The 
genes in lightface letters do not demonstrate any significant differential expressions. 
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Table 4-17. The Genes of the Wound Healing Pathway. 
 
Table 4-17 shows the distribution of the maximum significant relative count, both with and without 
the false discovery rate correction, for the genes in the subgroups within all the pathway lines. The 
relative count demonstrates the greatest subgroup-coverage in two pathway lines: Remodelling 
Enzymes and Inflammatory Cytokines & Chemokines.  However, the focus is not on the highest 
percentage in the table per se, but how close these percentages are to their corresponding pathway 
line percentage given in Table 4-18, and if the percentage is maintained high throughout the 
subgroup-coverage in the pathway line. Concerning the Np(adj)%, the Remodelling Enzymes 
pathway line should be as close to 6% (as per Table 4-18) and is here seen with a maximum of 4.8% 
(i.e. 80% of the 6%) in three of the subgroups. The other subgroups show somewhat similar 
percentage. The Inflammatory Cytokines & Chemokines pathway line should also be close to 
Np(adj)%=6%, and is also seen with a maximum of 4.8% in three of the subgroups. However, the 
percentage of the subgroups are less close to the reference Np(adj)%. Therefore, of these two 
pathway lines, the Remodelling Enzymes pathway line has the greatest coverage.  
Line Genes (Symbols) Ngene Ngene% Np% Np(adj)%
Col14a1*, Col4a1*, Col1a2, Col5a2, Col5a1, Col3a1, Col1a1, Col5a3, Col4a3, 10 12% 12% 2%
Plaur*, Ctsl1*, F13a1*, Plau*, Mmp7*, Fga, Ctsk, Mmp2, Ctsg, F3, Plg, 
Mmp1, Mmp9, Plat, Serpine1, Timp1.
16 19% 13% 6%
Itga1*, Itgb1*, Itga6*, Cdh1, Itga5, Itgb5, Itga4, Itgb3 , Itga2, Itga3, Itgav, 12 14% 10% 4%
Rac1*, Actc1, Tagln, Acta2, Rhoa. 5 6% 4% 1%
Ccl7*, Ccl12*, Il6*, Il1b*, Cxcl3*, Il10, Cxcl1, Ifng, Il4 , Cd40lg, Cxcl11, Cxcl5, 13 15% 11% 6%
Pdgfa*, Csf3*, Hbegf*, Mif*, Fgf7, Hgf, Angpt1, Fgf2, Fgf10, Ctgf, Igf1,  Csf2, 
Egf, Tgfa, Tgfb1, Tnf, Vegfa.
17 20% 13% 5%
Tgfb1*, Stat3*, Tgfbr3. 3 4% 2% 2%
Wnt5a*, Wisp1, Ctnnb1. 3 4% 2% 1%
Pten, Mapk3, Mapk1. 3 4% 2% 0%
 Il6st, Egfr. 2 2% 1% 0%
Ptgs2. 1 1% 0% 0%
Growth Factors:
Extracellular Matrix & Cell Adhesion, Cytoskeleton:
Inflammatory Cytokines & Chemokines:
The suggested 84 different genes for the pathway by Sabiosciences (2015). Significantly expressed genes (p≤0.05) are in boldface
letters. Genes marked with an asterisk are significant (p(adj)≤0.05) with a false discovery rate-corrected p-value. 
Signal Transduction, Phosphorylation:
Extracellular Matrix & Cell Adhesion, Cellular Adhesion:
Extracellular Matrix & Cell Adhesion, Remodelling Enzymes:
Extracellular Matrix & Cell Adhesion, ECM Components:
Signal Transduction, Other:
Signal Transduction, Receptors:
Signal Transduction, WNT:
Signal Transduction, TGF:
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Table 4-18. The Overall Profile Coverage of the Wound Healing Pathway Based on the Maximum Relative Count of Significantly 
Expressed Genes. 
 
The Wound Healing ECM & Cell Adhesion – Remodelling Enzymes Profile 
Table 4-19 demonstrates the profile of significant differential expression that corresponds to the 
Wound Healing ECM & Cell Adhesion – Remodelling Enzymes pathway line. For a given gene the 
average expression, for each objective vs reference group, is displayed in fold changes on a log2-
scale (log2(FC). The positive fold changes represent upregulated differential expressions and are 
written in a white font on a dark background, to distinguish them from the negative fold changes 
that represent downregulated differential expressions. The fold changes marked with an asterisk 
and written with boldface letters are significant after the false discovery rate correction, whilst the 
others are only significant with the t-test.  
Day −1
R{−1} C{01} H{01} E{01} C{03} H{03} E{03} C{07} H{07} E{07} C{14} H{14} E{14}
Np% 1.2% 1.2% 1.2% 7.1% 7.1% 6.0% 3.6% 1.2% 4.8% 3.6% 4.8% 8.3%
Np(adj)% 1.2% 1.2% 1.2% 1.2%
Np% 2.4% 2.4% 4.8% 6.0% 1.2% 4.8% 3.6% 2.4% 4.8% 6.0% 2.4% 4.8% 6.0%
Np(adj)% 1.2% 4.8% 3.6% 1.2% 1.2% 3.6% 2.4% 4.8% 4.8%
Np% 1.2% 3.6% 6.0% 6.0% 3.6% 7.1% 6.0% 2.4% 2.4% 2.4% 1.2% 3.6% 2.4%
Np(adj)% 1.2% 3.6% 1.2% 1.2%
Np% 2.4% 1.2% 2.4% 1.2% 3.6% 2.4% 1.2% 1.2% 1.2% 1.2% 2.4% 1.2%
Np(adj)% 1.2% 1.2%
Np% 2.4% 7.1% 1.2% 6.0% 1.2% 4.8% 8.3% 2.4% 8.3%
Np(adj)% 1.2% 4.8% 1.2% 2.4% 2.4% 4.8% 2.4% 4.8%
Np% 6.0% 4.8% 3.6% 2.4% 1.2% 2.4% 2.4% 3.6% 3.6% 2.4% 2.4% 7.1%
Np(adj)% 1.2% 2.4% 1.2% 1.2% 1.2% 2.4%
Np% 1.2% 2.4% 2.4% 1.2% 1.2% 1.2% 2.4% 1.2% 2.4% 2.4%
Np(adj)% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2%
Np% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% 1.2%
Np(adj)% 1.2%
Np% 1.2% 1.2% 1.2% 1.2%
Np(adj)%
Np% 1.2%
Np(adj)%
Np%, relative count of significantly expressed genes (p≤0.05) with ordinary t-test.
Np(adj)%, relative count of significantly expressed genes (p(adj)≤0.05) with an adjusted p-value for false rate discovery.
Day 7 Day 14
Extracellular Matrix & Cell Adhesion: ECM Components.
Signal Transduction: WNT.
Signal Transduction: Phosphorylation.
Signal Transduction: Receptors.
Line
Extracellular Matrix & Cell Adhesion: Remodelling Enzymes.
Extracellular Matrix & Cell Adhesion: Cellular Adhesion.
Extracellular Matrix & Cell Adhesion: Cytoskeleton.
Inflammatory Cytokines & Chemokines.
Growth Factors.
Signal Transduction: TGF.
Day 1 Day 3
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Table 4-19. The Wound Healing ECM & Cell Adhesion – Remodelling Enzymes Gene Profile of Significant Differential Fold Changes 
(log2(FC)). 
 
In general, none of the genes in the pathway line (except for F13a1 and Mmp7) demonstrate 
significant differential expressions between the R{−1} and the A{−1} subgroups on Day −1, and, 
therefore, jointly situate the reference level. Plaur is only reactive in the [H] and [E]-groups, with a 
prolonged upregulation between Day 1 and Day 3 in the [E]-group which has returned on Day 7. 
The [H]-group, however, does only show the upregulation on Day 1 before being returned on 
Day 3. Ctsl1 shows a similar response as Plaur, with an upregulation on Day 1 in the [H] and [E]-
groups which gradually returns to the reference levels thereafter. Plau, is again, similar to Plaur, with 
Plaur Ctsl1 F13a1 Plau Mmp7 Fga Ctsk Mmp2 Ctsg F3 Plg
Day −1 A{−1} R{−1}   1.08  0.92       
A{−1}   1.49* 0.69        
R{−1}     −0.84*       
A{−1} 0.96* 0.90* 1.81* 1.05*        
R{−1} 0.90* 0.60  0.73 −0.76*       
C{01} 0.51 0.54          
A{−1} 1.38* 0.75 1.54* 1.29*  0.45      
R{−1} 1.33*   0.97* −0.79* 0.48      
C{01} 0.93*   0.60  0.54      
H{01}      0.55      
A{−1}   1.07         
R{−1}     −1.05       
A{−1}   1.50 0.56   0.76 0.87    
R{−1}     −1.06*       
H{01} −0.70 −0.50     0.67     
A{−1} 0.71  1.44 0.56        
R{−1} 0.66    −0.57       
C{03}     0.48       
H{03}     0.48       
E{01} −0.66   −0.72  −0.39      
A{−1}       0.80 0.83    
R{−1}     −1.07*       
C{03}            
R{−1}     −0.84       
H{01} −1.12* −0.98* −1.42* −0.66        
H{03}   −1.11         
A{−1}    0.57        
R{−1}     −0.78       
C{07}            
E{01} −1.14* −0.88* −1.12 −0.71  −0.41      
E{03}   −1.02         
A{−1}     0.58       
R{−1}          −0.74  
C{07}     0.73  −0.83     
R{−1}     −0.48       
C{14}         −0.25   
H{01} −0.88* −0.96* −1.20* −0.81*        
H{03}   −0.89  0.57       
A{−1}      0.51      
R{−1}  −0.58   −0.59 0.54      
C{14}      0.54      
H{14}      0.55     −0.63
E{01} −1.27* −1.04* −1.30* −0.94*        
E{03} −0.60 −0.58 −1.21   0.45 −0.64     
E{07}      0.47      
Timing
H{07}
E{03}
C{07}
E{07}
Day 14
C{14}
H{14}
E{14}
Day 1
H{03}
Day 3
C{03}
Day 7
H{01}
C{01}
E{01}
Gene (Symbol)
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Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false discovery rate
corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line with no significant differential
expression are: Mmp1, Mmp9, Plat, Serpine1, Timp1.
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an upregulation on Day 1 on all three groups, that is slowly returning to the reference level on Day 
14 in the [E]-group, and perhaps a little bit sooner for the [H]-group. Both F13a1 and Mmp7 are 
upregulated in R{−1} in comparison with A{−1}, which slightly alters the perspective as to whether 
the significant expression is up or downregulated. The F13a1 does show an upregulated expression 
peak on Day 1 in all the groups, with the most emphasis on the [H]-group. On Day 3 the expression 
has overall slightly reduced, and from Day 7 and onwards, back to the reference level of A{−1}; with 
a slightly steeper change in the [H]-group in comparison with the [E]-group, and possibly with the 
most planar change in the [C]-group. In Mmp7 the upregulation on Day −1 seems to have returned 
close to the reference level of A{−1} on Day 1 in all the groups. This return seems to be maintained 
throughout until Day 14, where there is a hint for a slight upregulation again, in both the [C] and 
[H]-groups. Meanwhile, the return in the [E]-group is more planar throughout and on Day 14 as 
well. Fga only demonstrates differential expression for the [E]-group, with an upregulation on Day 
1, which is partially reduced on Day 3 and Day 7 but continued to be maintained upregulated on 
Day 14. Ctsk, Mmp2, Ctsg, F3 and Plg show too sparse differential expression between the groups 
for any trend description, although Ctsk and Mmp2 seem to be more reactive in the [H] on Day 3. 
Mmp1, Mmp9, Plat, Serpine1 and Timp1 do not show any significant differential expression. 
The Wound Healing ECM & Cell Adhesion — The ECM Components Profile; the Cellular Adhesion 
Profile; and the Cytoskeleton Profile 
The tables of differential expression of the following three profiles can be found in Appendix D.4.4: 
The ECM Components Profile (Table ApxD - 39); the Cellular Adhesion Profile (Table ApxD - 40); 
and the Cytoskeleton Profile (Table ApxD - 41). Between these profiles, the most significantly 
expressed genes, apart from Rac1 described in the VEGF Pathway, are Col4a1 and Itga1. Neither is 
expressed differentially between the R{−1} and A{−1}. Col4a1 is most responsive on Day 7 and Day 
14, with downregulation in the [H] and [E]-groups, although, to a slightly less extent in the [H]-
group. Itga1, however, is mostly responsive in the [H]-group with a downregulation on Day 1 which 
is return fairly immediately, or on Day 3. 
The Wound Healing — The Inflammatory Cytokines & Chemokines Profile; and the Growth Factors 
Profile 
The tables of differential expression of the following two profiles can be found in Appendix D.4.4: 
The Inflammatory Cytokines & Chemokines Profile (Table ApxD - 42); and the Growth Factors 
Profile (Table ApxD - 43). Between these profiles, the most significantly expressed genes, apart from 
Il6 described in the Skeletal Muscle Pathway, are Ccl7, Ccl12, Il1b and Pdgfa. None is expressed 
differentially between the R{−1} and A{−1}. Ccl7 is quite strongly affected on Day 1 in both the [H] 
and [E] groups (slightly more so in the [E]-group), demonstrated with an upregulation, which is 
though returned on Day 3. Ccl12, shows a similar pattern, although, overall slightly expressed and 
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also to a lesser degree in the [H]-group. Il1b is only responsive in the [E]-group, with an 
upregulation on Day 1 which gradually returns to its reference level on Day 14. Pdgfa is very similar 
to Il1b regarding the effect within the [E]-group, with the addition of being slightly downregulated 
on Day 1 in the control group that is thereafter returned.  
The Wound Healing Signal Transduction — The TGF Profile; the WNT Profile; the Phosphorylation Profile; 
and the Receptor Profile 
The tables of differential expression of the following five profiles can be found in Appendix D.4.4: 
The TGF Profile (Table ApxD - 44); the WNT Profile (Table ApxD - 45); the Phosphorylation Profile 
(Table ApxD - 46); and the Receptor Profile (Table ApxD - 47). Between these profiles, the most 
significantly expressed gene, apart from Tgfb1 described in the Skeletal Muscle Pathway, is Stat3. 
Stat3 does not show any significant differential expression between R{−1} and A{−1}, but is 
significantly upregulated in the [E]-group on Day 1, but is gradually returned to its reference level 
until Day 14. The [H]-group shadows the same profile, but not to the same extent. 
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5.1 Overture 
With a quick glimpse of the results, two important things that are difficult to justify as being 
successfully concluded as set out in our experimental objectives. (i) Inducing muscle damage in the 
trained rats, as the experimental critical point, was not as impactful as we hoped. Therefore, any 
trend analysis throughout the recovery period is mostly based on non-significantly different results. 
(ii) Any measurement, reflecting the low level of muscle damage, is not reinforced by the fact that 
the evolution throughout the recovery period is not based on continuous measurements of the 
same subjects. Therefore, the variability within and between subgroups potentially does not follow 
a specific trend by its own.  
However, in favour of the results, the subgroups are not represented by extreme variability and 
therefore, both the experimental execution as a whole and its impact on the subjects, in general, is 
reflective of being uniform. The timespan of the complete experimental execution itself and any 
potential changes related to that, could have easily played a bigger role in the uncertainty of the 
results. 
5.2 AEY 
It goes without saying that it is easy to design a scoring system that is only based on good runners, 
with results reflecting just that, that they are indeed good runners! The main objective of the 
development of the AEY scoring system, however, was to provide a way to assess different levels 
of performances of the rats when running on the treadmill. The fact that in the majority of published 
work, problems with training the rats are not mentioned, is somewhat understandable as the 
majority of rats trained run relatively well, or at the very least, can be trained to do so over time. Still, 
the relativeness of being a ‘good runner’ can be categorised.  
From our experience, we could see that some rats seem to have no issues with running; as if they 
could do with increased speed for the running to become troublesome. Other rats, appeared to 
put such focus on not receiving an electric shock from the metal grid that the contrary occurred; 
they ended up touching the metal grid continuously and, overall, took them a relatively long time 
to become continuous runners. The question is, therefore, at the end of a training period where 
both of these types of rats would be running continuously, ‘are these rats equal in physiological 
terms?’ Hence, the next fundamental question is whether the score itself can quantitatively 
differentiate between these types of rats in a way that correlates to the qualitative difference 
observed when they are monitored during their training. 
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5.2.1 Are the Averages Useful? 
Whilst the elements within the A-criteria have been quantified by their impact on the theoretical 
best style of running (mark-A), the fairly simple underlying mathematical design is not constructed 
in a way that, e.g. an average score from a training session, could be directly back traced to the 
most dominant style/mark registered. For that sort of evaluation, one would need to look at the 
actual registry and use different statistical tools. Thus, all the accumulative average calculations 
render the back tracing-style estimation improbable. Furthermore, between certain A-styles, it is 
difficult to establish which of them a rat is putting more effort into running as opposed to putting 
effort into doing anything else. Therefore, the applied score value (α) was intentionally made to be 
the same in some cases. In this way, one needs to look at the marks in the registry sheet for the A-
score, the α score value, and the calculated scores, as three somewhat-independent parameters. 
The E-criteria focuses exclusively on the positioning of the tail as a sign of tiredness. Therefore, the 
marks of the E-criteria are more descriptive and correlate better with the actual score value (ε) they 
give, in contrast with the α. The assessment for the Y-criteria is different altogether. It serves more 
as a quality control index for the data output from the treadmill monitoring apparatus. Although 
the digital data output for the electric shocks is not shown here, in the work of Tekin, Dursun and 
Ficicilar (2008),the authors have mentioned how the shock count seems to ‘more or less’ represent 
a good or a bad runner. However, the unknown portion of this ‘more-or-less-notion’ is probably 
reflected in the Y-score. 
We repeatedly noted that the rats caught up differently with the running for the first few training 
sessions, as expected. We can see this progression reflected in the greatest deviation in the A-score 
on Week 1 and decreasing until Week 4. Simultaneously, the E-score demonstrates increasing 
deviation from Week 1 to Week 4. This might seem contradictory. Still, let us bear in mind that 
concerning the treadmill speed, the session count and duration, the hypothetical power output 
increases over the weeks, and moreover, could also be considered as accumulating. We like to think 
that although the rats respond very differently to the running at the beginning, the sessions, per se, 
are more difficult in Week 4.  
The exercise sessions at Day 0 are very different from the four weeks prior, being downhill running-
to-exhaustion protocol. During this protocol, more A-style variety takes place (registry data not 
shown) reflected in a lower average A-score and with greater underlying variation, just as in the E-
score. On the contrary, in the weeks that follow (Week 5 - Week 6), the exercise protocol is designed 
to be easier where both A- and E-score improving; the A-score with greater deviation. The overall 
lower Y-score does not necessarily have anything to do with the overall changed protocol structure, 
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apart from the fact that it is likely that as the duration of each session at Day 0 was considerably 
longer, the frequency of artefacts could have been greater. 
5.2.2 Are the Averages Useful? 
It is likely that motor control memory plays a role in the success of a good A-score. Thus, frequent 
similar session might improve it, whilst less frequent or different sessions do not. Perhaps the 
training time related to circadian and internal biorhythms also plays a considerable part (Boersma 
et al., 2012). Comparing the morning and afternoon sessions throughout the weeks, there is not a 
very noticeable difference in the A-score. Possibly, it has somewhat improved on an individual level 
in the afternoon, which was the general feeling through the training from the experimenters’ point 
of view. On the contrary, as the resting period before the afternoon session is short, the E-score 
(representing tiredness) decreases in the afternoon sessions. However, one should not numerically 
compare the scale of the separate changes that occur between these two scores (A and E scores).  
Furthermore, as the hair on the rat’s tail is considered ‘preventing’ it from receiving an electric shock, 
we cannot exclude that some rats realised that whilst others reacted with a squeak even before 
actually touching the grid. In the former case, the E-score is not reliable. However, the general 
observation, before the systematic qualitative assessment took place, was that the tail was held up 
in the beginning, and was lagging at the end of sessions or when a rat seemed to be very tired 
after that session. As a semi-disclaimer with the Y-score interpretation; It is true that, when stressed, 
rats deposit more faeces and urine which could lead to a lower Y-score (via apparatus artefacts). 
One could then logically assume that after a long period of training, the stress factor is markedly 
less prominent and represented in a potentially higher Y-score in comparison with the 
commencing score. However, in our experience, this is not a reliable correlation.  
As many physiological parameters, the variables represented in AEY score are likely not to be 
identical in a repeated measurement for the same individual. However, we do believe that the 
number of rats that have been observed plays in favour of the score’s reliability. One could argue 
that even so, the scores, presented in this dissertation, are generally fairly high, thus, what type of 
distinction between the rats can we truly make? We cannot dispute the fact that the mark values 
could have been distributed differently between the defined styles, resulting in a different 
representative average score. However, we do underpin the fact that here we are representing the 
average scores. Presumably, a lot can happen over six weeks and perhaps a weekly-average 
representation is not necessarily the best choice. Still, with these weekly averages, we are able to 
observe tendencies in the results. In the experimental setup followed for this evaluation, we 
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consider that deviation in the scores represented on a weekly basis are indicating enough to lead 
us to the potential outlier rats for a more profound analysis.  
The negative aspect of the proposed score is that the qualitative assessment is far from being 
automatic, although it gets easier with practice. There are many calculations involved, albeit simple, 
and setting them up in software like MS Excel or Matlab is one way to work automatically through 
them. The main benefits, besides the pinpointing of potential outliers, are that the method provides 
a systematic way to compare rats and different studies. Still, the assessment leading up to an 
individual AEY-score will always be subject to some bias. Similar to Borg’s scale for rating perceived 
exertion, the next step in developing the AEY score would be to correlate it with VO2 measurements 
(Borg, 2001; Borg and Kaijser, 2006) and perhaps that would either fortify our style-score correlation 
or shed some new light on the running performance score measurements. Perhaps it is difficult 
and unrealistic to get a %VO2(max) correlation with specific running styles, but maybe it could 
correlate to either or both of our 0-1 scale in the A- and the E-score. 
5.3 Plasma 
5.3.1 Muscle Damage Protocol 
At this stage it was difficult to use the concentration values specifically to determine how effective 
the 1 session per day (1 Sess/d) protocol was, especially as no reference samples from prior to the 
critical point were available. However, the relative-relationship between the other samples gave a 
sufficient clue to estimate the effectiveness of the protocol. Although, both TnI and Mb ELISAs gave 
some indication of descending concentration from Day 1 and onwards, the standard deviation is 
too great for each day. Therefore, despite the absence of a reference sample, the solution was 
simple — The objective of the muscle damage protocol needed to be much more pronounced, 
giving a potentially descending concentration profile a clearer image as different concentration 
profiles would also need to distinguish different experimental group later on. However, there is a 
roof to making these changes. It is difficult to go beyond the point of exhaustion (if rats 
demonstrated no visible signs of muscle damage) in the 1 Sess/d-protocol is difficult. The velocity 
during the protocol could not be increased too much, as it would not be favourable to potentially 
exhaust the rats before inducing the muscle damage. Furthermore, any alteration needed to result 
in a humane treatment. The resulting procedure to induce muscle damage was therefore running 
the same protocol twice during the day with a minimum of 4 h between the end of the former 
session and the beginning of the latter session. In this way the good runners that would not have 
any muscle damage in the former session and endure longer in it, would have 4-h rest and 
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hopefully have the muscle damage induced in the latter. Meanwhile the worse runners that would 
have induced muscle damage form the former session (and removed quickly from the treadmill) 
would have a little more rest between sessions and not likely to endure for long in the latter session 
and then quickly ending that one as well. This clearly meant that it was not likely that the level of 
the muscle damage would be equal for all the rats; still, the aim was to at least try to ensure muscle 
damage and hopefully with a generally pronounced effects. Still, with practically no more anymore 
ethical room to change the procedure anymore, the muscle damage protocol was now considered 
established. 
5.3.2 Plasma marker ELISAs 
As mentioned, each ELISA (Mb and TnI) had been run twice with similar results for the calibration 
curves. The TnI-calibration curve is simple not acceptable with that high RSD values. There could 
be potentially many factors that contribute to the outcome; imprecise pipetting between well-
replicas, imprecise pipetting during the dilution of the calibration standard; inconsistent reagents 
used in the assay; instrumental error in the absorbance reading; the well plate coating was 
inconsistent; the nature/size of the marker; etc. However, the factors that can be controlled in the 
laboratory have more to do with the pipetting or instrumental maintenance. Still, it would be logical 
for any of these inconsistencies to be reflected in the myoglobin ELISA as well, and not in the 
troponin-I ELISA, two times.  
Therefore, as this was also at the point of altering the muscle damage protocol to the point of not 
being able to force any more changes there, it was decided to not take any more chances with the 
troponin-I ELISA and replace it with creatine kinase (CK-MM) biomarker ELISA, accompanying the 
myoglobin ELISA; Crossing the fingers the calibration curves would be reliable from this point on. 
The TnI-calibration curve, clearly, reduces the validity given to the TnI quantification to estimate the 
muscle damage protocol. However, greater deviation in those samples only under backup the 
decision made about the protocol.  
Moreover, the analysis of the calibration curve, led to other procedural changes. To avoid any 
potential inaccuracy due to low quality pipetting practice, a pipetting precision test was set up to 
train every agent working with the ELISAS, and a secondary procedure to analyse every calibration 
curve and re-run samples that did not fit into the most reliable parts of the curve, if possible. 
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5.3.3 The Negative Controls 
The relative expectancy between the two controls, the absolute negative A{−1} and the relative 
negative R{−1}, would be somewhat as the following, both for myoglobin myoglobin and creatine 
kinase — Given that the sedentary rats A{−1} were not exposed to any type of controlled exercise, 
the concentration of the plasma markers should be really low. Meanwhile, the trained rats R{−1} 
did go through regular training for 4 weeks, still the objective of that training was not to cause 
induced muscle damage, therefore ideally the plasma marker concentration would be similar to 
the control group, or, given that the training could have caused some damage (although hopefully 
none) it would be logical that the plasma markers concentration would be somewhat higher than 
for A{−1}. Simultaneously, the notion that CK plasma markers have been detected after exercise in 
other studies (Kanda et al., 2013, 2014), it would not be surprising that R{−1} would have higher 
plasma marker concentration than A{−1}. Furthermore, as the rats are still growing at this stage, the 
cellular turnover might be the reason for any basal concentration in A{−1}. The CK in plasma has 
been suspected to be due to this turnover process if the concentration is not related to exercise or 
injury (Sayers and Clarkson, 2003). 
Although the results demonstrate no significant difference between A{−1} and R{−1}, we can say 
that the regular cellular turnover or other related basal processes are likely to contribute to the 
plasma marker concentration (given that the concentrations are not 0). Furthermore the training 
(prior to the planned induction of the muscle damage) is not causing any muscle damage (at least 
not detectable via the plasma markers). However, it is difficult to ignore the visible difference 
between the A{−1} and R{−1} in the box plots (reminding that the box plot the entire data range in 
the group with the whiskers). The CK-MM concentration, especially, does not suggest equal 
subgroups (another reminder: the N is equal in all subgroups). A part from the average 
concentration being much lower (A{−1}=400(±200) ng/mL, R{−1}=170(±80) ng/mL), the rats in 
A{−1} seem much more heterogeneous than the rats in R{−1} if taking note of the variability. This 
goes against our speculations, as we would, furthermore, logically assume that the R{−1} should 
have greater variability in the concentration in comparison with A{−1} as all rats might not 
potentially respond to the exercise in a similar way. So what can this be? Is it possible that the 
implication of 'unnatural and regular' exercise is somewhat restricting the natural variability? Let us 
remind ourselves that there is no significant difference between the two subgroups though; still, 
before pondering about this anymore, let us check the rest of the data. 
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5.3.4 Muscle damage and Recovery 
It is clear, by looking on Day 1 for all group, the latest version of the muscle damage protocol is 
better than the one used in the developmental phase, even if the data set is small there. However, 
without analysing the subsequent days to the finest detail, the majority of the subgroups have 
concentration values back at the level of the negative controls; which in theory would mean 
'everything back to normal'. Still, how effective is the induction of muscle damage, in the end? 
Should the protocol have been more harsh? 
We consider that we were at the ethical limits in terms of protocol design for inducing muscle 
damage. Perhaps, the velocity settings could have been a little higher or the declination even 
steeper. However, the duration which depended on each rat (until either exhaustion or visible signs 
of muscle damage), and the rats could not have been forced more than that without discarding 
their welfare. What about the training prior to the muscle damage? 
It is possible that untrained rats (although the first few minutes, or more, of the protocol would 
have gone into 'making' the rats run in the first place) that they would induce muscle damage even 
quicker and perhaps more severe, given that they would not have a proper hang on how to 
manoeuvre themselves on the treadmill. Still, that option would not have been representative for 
the project's premises of muscle damage in trained rats. Then what about the training itself? With 
the logic displayed by the plasma marker data, sedentary and trained rat groups (A{−1} vs R{−1}) 
are not significantly distinct. Therefore, reducing the training to make a higher jump to muscle 
damage plasma marker concentration, probably would not have demonstrated any more 
noticeable difference (Ahmadi, Sinclair and Davis, 2008).  
Increasing the training, in order to make a difference between A{−1} and R{−1} greater, relying on 
the fact that the plasma marker concentrations in R{−1} would be a little higher due to exercise or 
even small injury, would possibly only make the goal of inducing muscle damage even harder. 
Although, not being the aim of the project either, the muscle damage protocol could have been 
carried out 2 per day and on more than one day. This would probably not make the recovery 
pattern practically drop to the baseline on Day 3. Still, interpreting that data would be more 
complex as the injury period would have over night hours of (partial) recovery; and the data would 
essentially represent recovery of reinjured partially-recovered tissue. Thus, the at least carrying out 
the induction only during one day, provides more fundamental ideas. 
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5.4 Differential Gene Expression 
The coverage of significantly expressed gene expression only identifies the best pathway or profile 
line fit, and was used here to systematic choosing. However, looking at the coverage in this way 
does not reduce the validity of the genes that form the other pathway lines, but reflects the 
strongest profile. 
5.4.1 The Skeletal Muscle Pathway 
Capn3 is a Ca2+-dependent protease that plays a role in the regulation of sarcomeric turnover 
(Stuelsatz et al., 2010). Its downregulation on Day 1 in all three groups, [C], [H] and [E]-groups, might 
be an indication of the impact of damaged tissue. Whereas on Day 3 and until Day 14, the gene 
ends up being upregulated in both the [H] and [E]-groups as part of the regenerating tissue — and 
even slightly more so in the [H]-group. The return from the downregulation in the [C]-group 
demonstrates the slowest rate to the reference level. Emd expresses structural protein for the 
cytoskeleton (Tilgner et al., 2009), and irrespective of which group, all of them get upregulated on 
Day 1 to a fairly equal level. The upregulation is then gradually returned until Day 14 in the [H] and 
the [E]-groups, whilst the return in the [C]-group falls within non-significant changes, and therefore 
slower. The profile is therefore in favour of either the conditions of the [H] or the [E]-group, as no 
significant difference between them is detectable. Lmna expresses proteins that play a role in 
nuclear and chromatin stability (Boschmann et al., 2010), which seems to mirror an immediate 
reaction on Day 1 with an upregulation in all the groups, which is still quite strong on Day 3. The 
strongest upregulation takes place in the [H]-group. Thereafter, the [H] and [E]-groups show an 
immediate return of the expression on Day 7 and Day 14, whilst the return in the [C]-groups is quite 
milder. Dmd encodes dystrophin which anchors the skeletal muscles cytoskeleton to the 
extracellular matrix (Taylor et al., 2010). Although it shows the most downregulation on Day 1 in 
the [H]-group, it is also within that group where it is upregulated significantly on Day 7 and Day 14, 
indicating a long-term effect of hypoxia in relation to the muscle damage.  
Myot encodes myotitin, which stabilises the contractile filament when ‘working’ (Claeys et al., 2009). 
The downregulation on Day 1, might be representative of a tissue damage that needs to be 
addressed by degrading the corresponding injured cells, and therefore, the process of Myot is 
slowed down. Still, as only being evident on Day 1, it might be indicative of a mild muscle damage. 
Hk2 encodes hexokinase which converts glucose into glucose-6-phosphate (Ahn et al., 2009) 
destined for utilisation and it is, therefore, reasonable that the only significant upregulation on 
Day 1 appears in the [E]-group. However, as it does not continue to be differentially upregulated, 
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it is possible that the first rehabilitation session is having some ‘shock’ effect. Atp2a1 expresses the 
pumps that reduce the intracellular level of Ca2+ in muscle cells, by pumping the calcium into 
sarcoplasmic reticulum (Kimura et al., 2005). As the [C] and [H]-groups are sedentary after the heavy 
exercise induction of muscle damage, we could assume that as a response and perhaps a 
precaution or preparation for potentially similar situation to follow, the Atp2a1 is downregulated 
but then the downregulation is reduced over the following days. Similarly, the [E]-group might have 
shown the same profile if a light exercise was not a part of their new regime after the muscle 
damage, and as a response to the hypoxia+exercise, Atp2a1 is upregulated, with a more gradual 
return over the recovery period, perhaps mirroring the mild level of exercise. 
Myod1 is a transcription promoter that plays a role in the differentiation of myoblasts (Yang et al., 
2009). All of the groups do demonstrate upregulation on Day 1, which indicates muscle tissue 
repair. As the [H] and [E]-groups show a little higher degree of response, it is likely that the hypoxia 
favours the condition. Furthermore, the indication of the [E]-group, showing even stronger 
upregulation response (although not significantly), might mirror a more hypoxic environment, 
proposed by the addition exercise. Mef2c is a transcription promoter that plays a role in maintaining 
the state of differentiated muscle cells (McDermott et al., 1993). If the tissue has suffered damage, 
the regeneration process needs to ignore the effect of this promoter and is therefore 
downregulated as a response. However, since the upregulation is only visible on Day 1, the 
expression indicates a mild level of tissue damage. Moreover, with no significant difference 
between the three groups, it is somewhat telling for an equal level of muscle damage. Myog is a 
transcription promoter that plays roles in differentiating the myoblasts (Li et al., 2009), similar to 
Myod1. As the [H] and [E]-groups are only responsive with an upregulation, in comparison with the 
[C]-group, that does not show any significant differential expression, it seems that the role of 
hypoxia boosts the expression of this gene. The addition of exercise to hypoxia does not have any 
further effect on the expression.  
Il6 expresses a cytokine as part of an acute response to an inflammation (Novakova et al., 2010). As 
the [E]-group does only demonstrate significant differential expression, in comparison with the 
other groups, and from Day 1, it is likely that the addition of exercise to the regime is slightly 
counteractive and causes more inflammation in the wounded tissue. Tgf1 expresses cytokines that 
regulate proliferation, differentiation and migration of leukocytes as a response to a damaged area 
(Hussein et al., 2010). Given the [H]-group demonstrates the most responsive differential expression 
on Day 1, it is likely that the hypoxic environment acts as a promoter. However, since the [E]-group 
also undergoes hypoxia, perhaps, a slightly wounding effect of the exercise itself reduces the effect 
of hypoxia as a promoter. Ppargc1a partakes in regulating the mitochondrial gene expression 
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which in turn determines the muscle fibre type (Little et al., 2010). It is, therefore, reasonable that 
the [E]-group, being the only group carrying out exercise during the recovery period, demonstrates 
a responsive differential expression, whilst the sedentary groups, [C] and [H], do not.  
Fbxo32 is generally upregulated in muscle atrophy as a response to protein loss (Csibi et al., 2009). 
The gene is downregulated on Day −1 after the preconditioning period, indicating growing or 
strengthening muscle system. As a response to muscle damage, the gene is upregulated, in the [C] 
and [H] groups on Day 1, which is maintained. However, the [E]-group, not showing any significant 
differential expression, might show a favourable counteracting effect, due to the addition of light 
exercise to hypoxia. Casp3 plays an active role in apoptosis (González et al., 2010), and is 
upregulated in all three groups on Day 1. The continuing upregulation on Day 3 in the [H]-group 
might suggest a stronger response for a repair, in relation to hypoxia. Akt2 expression in myoblasts, 
forms part of their differentiation as part of regeneration, but has also been shown to cause cell 
death in its absence (Rotwein and Wilson, 2009). As the gene is downregulated on Day 1, it is 
possible that is mirrors the reaction of terminating damaged cells, and do so more efficiently with 
hypoxia which has a gradual return of the downregulation until Day 14, and with the addition of 
exercise to hypoxia, even further. Trim63, showing a downregulation in R{−1} in comparison with 
A{−1} seems to have its logic to those genes that are upregulated parallel to protein loss (Centner 
et al., 2001; Csibi et al., 2009) in relation to degradation related to damaged fibres. Although this 
indicates the exercise difference between the R{−1} and A{−1} groups is in favour of the exercise; it 
does not explain the downregulation per se. Assuming we accept that small direct injuries are part 
of a ‘healthy’ exercise training, the upregulation of the genes can be easily triggered, but are still 
designated for the degradation of a ‘seriously’ damaged fibre. The downregulation of these genes 
could then be part of a secondary protective mechanism to reduce the interactive effects of the 
proteins they encode. The consequence of this secondary protective mechanism could be 
reinforced by the slow increase in upregulation from Day 1 to Day 14. The downregulation on Day 
−1 is somewhat levelled out on Day 1, which could mean that the effect of the injury protocol is 
generally fairly subtle and not injurious enough (or at least relative to this exercise protection). 
However, as the gene gets more upregulated with throughout [E]-group, but not in [H]-group, it is 
likely that injury was induced and is now provoked by the application of exercise.  
5.4.2 The Hypoxia Signalling Pathway 
Hmox1 encodes an enzyme that catalyses the degradation of haem in erythrocytes and also signals 
cells for apoptosis (Biburger et al., 2010). It is only significantly responsive in the [H] and [E]-groups 
and more so in the [E]-group, showing an upregulation on Day 1; which is in line with the 
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occurrence of tissue damage. However, this upregulation as markedly reduced on Day 3, and back 
to reference level on Day 7, underpinning a mild and manageable tissue damage. Btg1 plays an 
important role in the process of angiogenesis, promoting it with being expressed (Iwai et al., 2004). 
It shows a parallel profile to Hmox1, emphasising a mild tissue damage, and the augmented [E]-
group seems to benefit from the occurrence of exercise in addition to hypoxia. Adora2b is 
expressed as part of tissue protection against hypoxia (Yang et al., 2009), and only significantly 
responsive in the [H] and [E]-group, with an upregulation on Day 1, but to fairly similar levels; and 
is thereafter returned. Curiously, it does not respond to the actual hypoxia sessions, indicating that 
the tissular hypoxia is not necessarily determined by the hypoxia on a systemic level (given that it 
effective enough there as well). Furthermore, it also suggests that any additional hypoxia pretended 
to be caused by the addition of exercise to hypoxia in the [E]-group, is not effective in that way, but 
is so in the muscle damage protocol, where the rats run to exhaustion. The only thing that reduces 
that credibility, at least with the measurements presented here, is the lack of differential expression 
in the [C]-group on Day 1; however, as the expression levels of this gene seem fairly low in general, 
it is likely that non-significant upregulation took place. Anxa2 plays a part in angiogenesis 
(Aitkenhead et al., 2002) and is only responsive in the [H] and [E]-groups (slightly more in the [H]-
group) and is upregulated on Day 1, with a slow return on Day 3. However, on Day 7 it has returned 
completely. It does slightly suggest some accumulative hypoxic effect on between Day 1 and Day 3, 
but no effect that is longer term than that. The expression of Plau reflects proteolysis as part of 
extracellular matrix degradation (Luikart et al., 2002) making the manifestation of angiogenesis 
more probable. It is upregulated on Day 1 in the [H]-group, but even slightly more in the [E]-group, 
indicating the influence of hypoxia in general to the remodelling of the tissue. Serpine is involved 
in the regulation of fibrinolysis (Heit et al., 2013), and its upregulation in all groups is indicative of 
the effect of tissue damage. Interestingly, the [H]-group returns its upregulation back on Day 3, 
whilst the [E]-group continues to upregulate (although slightly reduced) until Day 14. Meanwhile, 
the profile of the [C]-group is somewhere in the middle of the other two. This does indicate an 
effect of the hypoxia to inhibit fibrinolysis, but the effect of the additional exercise to forego the 
inhibition. 
In normoxia, Egln3 expresses a cellular oxygen sensor that catalyses the formation of 
hydroxyproline in the HIF alpha proteins as part of their degradation (Cioffi et al., 2003). Between 
all the groups on Day 1, the gene seems downregulated the most in the [C]-group, whilst it is less 
downregulated in the [H]-group, and then even less in the [E]-group. This could support the role 
hypoxic-dependant pathways in repairing tissues. If so, the downregulation in the [C]-group averts 
degrading the HIF-alpha protein, which also would have happened in hypoxia. Therefore, in the 
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[H]-group, downregulating Egln3 is less important. The addition exercise then seems to temporarily 
increase the level of hypoxia even further, and again, the downregulation of Egln3 is even less 
important. However, the results suggest a short-term and long-term effect. Short-term, where 
hypoxia and exercise are more effective in promoting hypoxic-dependant pathways (given the level 
of tissue damage) and long-term, where the hypoxia alone seems more effective regarding 
promoting the pathway in comparison with hypoxia+exercise. Tp53 is a transcription factor that 
takes part in regulating cell cycle arrest, apoptosis and DNA repair (Matlashewski et al., 1984). It is 
mostly responsive in the [H]-group, with an upregulation on Day 1, emphasising the immediate 
effect of hypoxia alone to a damaged tissue, in comparison with the hypoxia+exercise.  
Pdk1 regulates metabolite flux and downregulates aerobic respiration as a response to hypoxia 
and oxidative stress (Kim et al., 2007). As all the groups react with downregulating the gene on 
Day 1, which is returned thereafter, oxidative stress as a consequence of the exercise-induction of 
tissue damage, is possibly the greatest factor here. On that note, the [E]-group seems to push the 
downregulation a slightly further than the [H]-group, which does suggest hypoxia+exercise to be 
more effective on that specific front, whilst the [C]-group show the least responsive downregulation 
between the three. Bnip3 takes part in promoting the induction of cell death pathway (Ghavami et 
al., 2009), and is downregulated in all groups on Day 1 as a short-term effect. There is little difference 
between the [C] and [H]-groups (although the [H]-group has the gene slightly less downregulated). 
However, the [E]-group is demonstrating a markedly less downregulation in comparison with the 
other two. The different downregulation in the [E]-group hints either to the rats of that group 
having less tissue damage; or the addition of exercise to hypoxia promoting less need of the 
induction of the cell death pathway. Still, the data does not suggest exercise causing more tissue 
damage, unless the effect of hypoxia was that stronger (in comparison with the [H]-group) that it 
counteracted any damage in relation to exercise, and even more. Pim1 encodes for kinases the 
regulate control cell growth, differentiation and apoptosis by inhibition to protect the cell (Borillo 
et al., 2010). With the gene being upregulated in all groups on Day 1, especially the [C]-group 
although significantly lower than in the [H] and [E]-groups, suggest a protective element caused by 
the preconditioning training until Day −1 in the first place, and at least hypoxia promoting the 
upregulation even further. Whilst this immediate reaction gradually gets reduced throughout the 
recovery period, the duration of the expression is a little bit stronger, which in turn, favours the 
addition of exercise having a protective element to it. 
Tfrc encodes a receptor for cellular iron uptake that mediates endocytosis which leads to the 
positive regulation of the T-cells (Buchegger et al., 1996) and the B-cells. However, whilst not being 
expressed differentially on Day 1 in any of the group, and thereafter being downregulated (the 
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gene being mostly responsive in the [H]-group), does indicate a contradictory result, given that 
upregulation would be expected. The potential way for the function of the gene being true and 
reflecting the experimental groups in question, excluding the fact of the data being reversed or 
gene function being wrong, might consider a suppression of this route of activating T- and B-cells 
as it might negatively influence another favourable pathway for tissue repair. However, that 
possibility is not backed up by any scientific finding. Lgals3 plays a role in e.g. regulating apoptosis 
and T-cell regulation (Kariya et al., 2010) and is upregulated in all groups on Day 1, underpinning 
the existing of tissue damage repair. Interestingly, the [H]-group has the highest upregulation (of 
the three groups, markedly) and is kept on upregulated (although decreasing) until Day 14. Whilst 
the [E]-group demonstrates a significant upregulation (higher than in the [C]-group) it rate of 
returning to the reference levels are fairly slow, which in this case, does not favour the addition of 
exercise during the recovery. 
5.4.3 The VEGF Pathway 
Nras encodes Ras-protein that part takes in the role of migrating leukocytes (Davidsson et al., 2010) 
which fit with its upregulation on Day 1 in all the groups as a response to tissue damage. The 
application of hypoxia, in general, seems to upregulate this gene even further. Raf1 is activated by 
GTP-bound Ras protein but has hindering effect onto cell proliferation and differentiation (Zang, 
Hayne and Luo, 2002), which explains the downregulation on Day 1; however, without any hypoxia 
or hypoxia+exercise applications, the downregulation is reduced more quickly in comparison with 
the rest. Rac encodes proteins involved in cell growth, cytoskeletal reorganisation and the activation 
of protein kinases (Frasa et al., 2010); conditions that aid in the repair of damaged tissue. Between 
the groups, Rac is expressed overall more in the [H]-group with an upregulation, underpinning the 
hypoxic boost to the system. Rac2 regulates various processes, such as phagocytosis (Kwofie and 
Skowronski, 2008), which might also be a favourable function in the situation of damaged tissue, 
most likely provoked by hypoxia, according to the results. Shc2 encodes a signalling adapter 
necessary to organise the signalling pathway in neurons (Teodorczyk et al., 2015), but can aid in the 
regeneration of tissue damage, and demonstrates the strongest expression in the [H]-group, but 
also more pronouncedly until Day 3, but drops thereafter. 
Both Vegfc and Kdr (encoding a receptor protein) promote angiogenesis and endothelial growth 
(Terman et al., 1992; Joukov et al., 1996). After the induction of muscle damage, Vegfc and Kdr are 
generally downregulated, with the most hint of upregulation not until Day 14. It is slightly possible 
that Vegfc, for example, affects the permeability of the blood vessels, which might justify its 
downregulation. Hspb1 is involved in stress resistance and actin organisation (Evans, Britton and 
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Zachary, 2008), and Mapk2k1 encodes a protein that binds ligands and cytokines (Si and Liu, 2009). 
Both are most responsive on Day 1 in the [H] and [E]-groups, regarding Hspb1 and in the [H]-group 
mostly, regarding Mapk2k1. Both data underpin the level of hypoxia alone, with reference to Kdr; 
whilst Hspb1 is likely to be jointly affected by the conditions of the [H] and [E]-group. Pla2g2d 
encodes a secreted enzyme that is involved with an inflammation and an immune response 
(Lambeau and Gelb, 2008). The fact that the gene demonstrates upregulation in the R{−1} indicates 
that there might have been some small tares before the induction of skeletal muscle injury. It 
explains the upregulation thereafter in the [C] and [H]-groups if injury-induction was successful. 
However, the mild exercise seems to reduce this expression effect. Ptk2 partakes in regulating of 
cell migration (Lee et al., 2010), which is promoted via its downregulation. The [H]-group seems to 
be the most responsive, due to the hypoxia, and the gene is downregulated on Day 1, just after the 
muscle damage. The [E]-group however, does not show the same drop, i.e. downregulation as in 
the [H]-group, but is generally more downregulated overall the period, suggesting the 
compensating effect of exercise on top of the hypoxia; and potentially more long-term reactions. 
The overall effect within the VEGF pathway is the general favourable dominance of intermittent 
hypoxia alone. From this pathway aspect, the addition of exercise after hypoxia, is more 
deconstructive in general, at the start; but does seem to be more favourable as a long term 
application. 
5.4.4 The Wound Healing Pathway 
The expression of Plau and Plau-protein receptor, Plaur, reflect proteolysis as part of extracellular 
matrix degradation (Luikart et al., 2002). The process that seems to be enhanced with an 
upregulation on Day 1 in the [H]-group, but even slightly more in the [E]-group, indicating the 
influence of hypoxia to the remodelling of the tissue. This sign of degradation is, furthermore, 
supported by the upregulation of Ctsl1, encoding for a lysosomal proteinase (Lankelma et al., 2010), 
in the both the [H] and [E]-groups, on Day 1. Although, the upregulation is with more emphasises 
in the [H]-groups, suggesting the favourable effects of hypoxia as well. Mmp7 which is involved in 
tissue remodelling and promotes angiogenesis (Ito et al., 2009), however, does give the [E]-group 
a more negative image. The preconditioning exercise prior to the induction of muscle damage, 
does seem to upregulate the gene, whilst the damage reduces it in all three groups and maintains 
it that way, but to slightly less extent in the [E]-group, suggesting the beneficial effects of adding 
light exercise to the hypoxia session. Both F13a1 and Fga partake in the process of coagulation 
following vascular injury (Carty et al., 2010; Ivaskevicius et al., 2010). However, their upregulation on 
Day 1 (and Day 3 F13a1), with some emphasis on the [E]-group, does suggest a negative effect of 
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the application of exercise to hypoxia, and maybe some type of re-rupturing, especially given that 
Fga is upregulated on Day 14 as well. 
Col14a1 and Itga1 express collagen and collagen binding receptor, which enhance the extracellular 
matrix and inhibit angiogenesis (Nyberg et al., 2008). The immediate downregulation of Itga1 on 
Day 1 in the [H]-group suggest the favourable effects of hypoxia, whilst the addition of exercise, in 
this case, might be inflammation reducing. The late downregulation of Col4a1 at Day 7 and Day 14, 
indicate a long-term of the effect of both the hypoxia alone and with light exercise, at least to the 
extent of making ways for angiogenesis. Ccl7 and Ccl12 express chemokines which secreted to 
attract macrophages during inflammation (Lee et al., 2009), and their brief upregulation on Day 1, 
both in the [H] and [E]-group, suggest an initial response to induction of muscle damage. However, 
the response is short lived as on Day 3 the genes have their expression returned. As the difference 
between the two groups is very little and not significant, although stronger in the [E]-group, the 
addition of exercise is not evident to be any more favourable in comparison with hypoxia which 
these data suggest. However, as Il1b, which encodes for a cytokine (Bensi et al., 1987) is only 
responsive in the [E]-group, with an upregulation on Day 1 and thereafter returns to reference 
levels, there might be some hypoxia+exercise related effect. The question is if it is increasing the 
inflammation, and therefore upregulated, or since it would be likely to continue to do so 
throughout the recovery period, the expression of Il1b might be a slight sign of favourable effect 
from the addition of exercise with hypoxia. The Day 1-upregulation of Stat3 as being a signal 
transducer for interleukins (Ito et al., 2010), might suggest a mild push by the condition of hypoxia 
as a response to a mild muscle damage, which is then further augmented by the addition of light 
exercise. Given that the upregulation is thereafter gradually returned, furthermore, emphasises the 
mild level of tissue damage. The fact that the genes are not expressed differently between the R{−1} 
and the A{−1}-groups, underlines that the preconditioning training was not causing any damage 
either, prior to the planned induction of skeletal muscle damage. 
The overall effect within the Wound healing pathway does suggest a favourable condition for the 
application of intermittent hypoxia, albeit mild. However, in general, the addition of exercise does 
not seem to readily help the inflammation and in might cause some type of re-rupturing.  
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5.5 Adding the Secondary Measurements 
5.5.1 The Changes in the Body Weight 
The rat’s body weight could have been affected in many ways throughout the experimental 
procedure. Irrespective of any intentional physiological applications, stress related to running on 
the treadmill, in general, could always be the most uncontrollable factor reflected in a considerable 
body weight variability (Radahmadi et al., 2013). On top of that, the physiological applications could 
alter the body weight even further. Rats could become leaner with some weeks of exercise (Brown 
et al., 2007), and there is reported evidence of body weight loss in relation to hypoxia exposure as 
an indication of ineffective acclimatisation (Leal et al., 1995). 
Although the rats were not specifically checked for stress markers, other than their appearance, the 
overall body weight log (and the tracking of each rat in real time; data not shown here) does not 
indicate any unusual weight loss or weight gain. In fact, the regression in the body weight gain, 
from Week 1 to Week 6, shows that small variability that it is not until the very end of the recovery 
period some difference is noticeable; the [C]-group (sedentary trained rats) and the [E]-group (light 
exercise and hypoxia) show some significant difference (with the [H]-group non-significantly 
situated in between the two). From this weight perspective, the 98 rats used in the experiment 
demonstrate a fairly uniform group, with (at the very least) mild hypoxia sessions, and the light 
exercise during the recovery period was not strenuous. It is even more possible that the weight loss 
in the [E]-group is because of an exercise regimen stretching from Week 1 to Week 6, rather than 
just a product of the last two weeks. 
5.5.2 The Changes in the Weight Ratios and in the Fulton Index 
With a continuous exposure to environmental hypoxia, the heart rate increases and the stroke 
volume starts to decrease, as an adaptive process, mainly due to the volume reduction of the left 
ventricle of the heart (Siebenmann and Lundby, 2015), but also in the right ventricle. Still, there is 
some evidence suggesting that chronic hypoxia exposure leads to right ventricle hypertrophy 
(McGuire and Bradford, 1999).  Moreover, rapid exposure to high altitudes has been observed to 
cause the development of pulmonary oedema (West, 2004). However, the effects on 
cardiopulmonary parameters are still not well understood, although hypoxia exposure is common 
nowadays, e.g. altitude work shifts and in sports medicine.  
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In the experiment presented here, the focus is rather on a programme of intermittent hypoxia 
exposure accompanied with a low-intensity exercise and the physiological adaptations. The lung 
weight fraction in the hypoxic rats (the [H]-group) increased significantly at the same time the right 
ventricular weight decreased, suggesting a higher perfusion (or subclinical pulmonary oedema). 
The addition of exercise to hypoxia (the [E]-group) does not seem to for the [H]- group. However, 
this change in the weight is not evident for [E]-group. Our data support previous findings that 
hypoxia reduces both left and right ventricular volume (Naeije, 2010), reflected in the changed heart 
mass for the [H] group (Suarez, Alexander and Houston, 1987). However, we noted that the 
reduction of these two compartments seem to happen on distinct rates, faster for the right ventricle 
than the left.  
We also observed that the continuance of intermittent exposure strengthens the right ventricle on 
the expense of the left one, reflected in an increase (after the initial decrease) in the right ventricle's 
weight which remained that way throughout the rest of the sampling period. The addition of low 
intensity exercise seems to be sufficient enough to counteract the changes in rats solely exposed 
to hypoxia. This was reflected in an unchanged Fulton index as there was because of no regression 
of the left ventricle's muscle mass. It is therefore likely that the supplementary light aerobic exercise 
with intermittent altitude exposure could be beneficial for trained individuals in terms of minor 
physiological alterations on the cardiopulmonary system. However, the level and the nature of 
microstructural and functional alteration would need much support and refining than the 
gatherings from the result presented in this dissertation. 
5.6 Coda 
Upon drawing the results together, what sticks out is that despite the rigorous methodology and 
traceability, when at least to a good part can verify the validity of the result, despite what they 
convey, is that the key ingredient, the experimental critical point, perhaps was not effective to gain 
proper insight. However, that does not suggest that the model for this experimental setup is 
completely useless. There are indicators of muscle damage, although being week, in the majority 
of the results, however, they can only cover up to Day 1, Day 3 the most. Simultaneously, it raises 
the question of how easy the experimental version of recreational model is in reality, as it is difficult 
to define that group, to begin with. Still, as the rats were running to their exhaustion, and it is fairly 
clear that it was to exhaustion rather than stopping because of muscle damage per se, the rats 
would not have been pushed any further because of ethical reason. Therefore, even if the rat could, 
and perhaps would sustain more drastic protocol to induce the damage, than another application 
of measuring the rats wellbeing would be necessary. 
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The intention of this thesis was to investigate the effects of intermittent hypobaric hypoxia, alone 
or followed by a light exercise in normoxia, on the recovery of skeletal muscle damage induced 
with eccentric exercise-running on a treadmill, in trained laboratory rats; using plasma markers and 
differential gene expression of m. soleus for the evaluation, in conjunction with a running 
performance score and simple weight ratios to assess the level of homogeneity of the rat subject 
groups.  
 
The Weight Measurements 
(1)  The overall rat body weight with low variability monitored throughout the relatively long 
preconditioning, indicate a sufficiently uniform pool of rats prior to the point of their allocation 
to different subgroups. 
(2)  The gradual body weight changes with low variability throughout the muscle damage recovery 
period indicate a uniform group of rats, irrespective of being: sedentary, enduring intermittent 
hypoxia sessions alone or followed by light exercise, until at the end of the 14-day recovery; 
demonstrating the use of sustainable hypoxia sessions, and a light exercise schedule 
appropriate for a recovery. 
(3)   The lung weight fraction indicates a further induction of hypoxia on a systemic level with the 
addition of light exercise, immediately following a hypoxia session, when the sessions are not 
discontinued, hinting the possible effect of exercise being gradually more stable. 
(4)   The cardiac weight fractions in conjunction with the Fulton index are indicative of a mild 
longer-term effect of the intermittent hypoxia sessions affecting parts of the heart on a 
different rate. — Still, can be counteracted with a light addition of exercise. 
The AEY Running Performance Score 
(5)  The three-criteria qualitative running-style evaluation is sufficiently detailed to distinguish 
between rats that are running relatively differently, reflected in the score values; addressing the 
participation of running, an indication of gradual tiredness and the validity of objective 
monitoring via a treadmill apparatus. 
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(6)  The AEY score reflected on an acceptably equal training progress between the rats, suitable to 
consider them as the equivalent of recreational athletes, and a certain level of uniformity during 
the exercise session designed to induce muscle damage; although, simultaneously, suggesting 
a relatively low level of difficulty considering their training.  
The Plasma Markers 
(7)  The plasma markers are indicative of the existence of muscle damage, just after the induction, 
still, suggest a low impact of the damage induction itself.  
(8)  The application of intermittent hypoxia alone does not alter the recovery profile in comparison 
with passive recovery. However, the impact of the muscle damage seems sufficient to reflect 
on an altered profile in both cases, in comparison with the variability of the reference-sedentary 
rats.  
(9)  The addition of exercise following intermittent hypoxia sessions shows a different recovery 
profile, which slightly reduces and distributes the immediate impact of the muscle damage, 
however, indicates a slower recovery. 
The Differential Gene Expression of m. Soleus 
(10) The four pathways examined for m. soleus, indicate that the major effect took place one day 
after the induction of skeletal muscle damage, suggesting a low level of injury, probably due 
to the induction method of downhill running. However, the factor of exercise, in general, seems 
to affect the expression in relative negative controls more emphasised way. 
(11) Both the skeletal muscle pathway and the VEGF pathway demonstrated genes, which in 
general reflected damaged muscle tissue, regarding the expression of proteins that are 
structurally relevant to skeletal muscle tissue and angiogenesis. However, these trends were 
more evident in the group that carried out light exercise after a hypoxia exposure and even 
the trained reference group; suggesting a strong impact of exercise in the experimental 
process. 
(12) The analysis of both the hypoxia signalling pathway and the wound healing pathway, showed 
responses in genes expressing proteins partaking in inflammatory processes, still not to 
hypoxia specifically, thus suggesting that the level of atmospheric hypoxia was not a limiting 
factor at the muscle cellular level, probably due to the low energy muscle requirements by the 
activity depression manifested by the rats during the simulated altitude exposure.  
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Global points 
(13) The overall effects of the intermittent hypoxia sessions only suggest a mild implication, and 
although relatively ‘stronger’ effects detectable with the addition of light exercise, the recovery 
suggest pattern seem to be sensitive to breaks and need a higher frequency of sessions on a 
week-to-week basis. Although, seeming to have brought benefits to the table, the addition of 
exercise simultaneously provokes some other processes. 
(14) Preconditioning the rats with training indicates a level of resistance to experiencing exercise-
induced skeletal muscle damage, based on the performance evaluation, the overall low level 
of markers in plasma, and relatively low differential gene expression. However, the design of 
the exercise induction with trained rats on a treadmill, does demonstrate a limitation of the 
experimental model, regarding developing it to be more impactful on the trained rats, for 
ethical reasons. 
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Appendix A — Documents 
Appendix A.1 The Ethical Approval for Using Experimental Animals 
 
Fig. ApxA - 1. Scan of the ethical approval to use experimental animals for project in question which extends to all subprojects, 
including subproject DEP2010-22205-C02-01. 
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Appendix A.2 Janvier Lab’s Research Model Sheet for Rat Subjects 
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Appendix B — Operational Protocols 
Appendix B.1 Rat Handling Protocol 
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Appendix B.2 Treadmill Preparation Stage Protocol 
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Appendix B.3 Treadmill Training Stage Protocol 
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Appendix B.4 Treadmill Muscle Damage Induction Protocol 
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Appendix B.5 Recovery Period’s Intermittent Hypoxia Session Protocol 
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Appendix B.6 Treadmill Recovery Period Protocol 
 
 Appendices 
179 
  
 
  
 Appendices 
180 
 
Appendix B.7 ELISA Protocols from Life Diagnostics 
Appendix B.7.1 Creatine Kinase ELISA Protocol 
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Appendix B.7.2 Myoglobin ELISA Protocol 
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Appendix B.7.3 Troponin-I ELISA Protocol 
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Appendix B.8 Adapted RNA Extraction Protocol from Qiagen  
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Appendix C — Operational Diagrams 
Appendix C.1 The Experimental Setup (Detailed), The Rat Handling Phase 
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Appendix C.2 Overview of the S33+ Sampling Process 
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Appendix C.3 The AEY Rat-Performance Score (A-criteria) 
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Appendix C.4 The AEY Rat-Performance Score (E and Y-criteria) 
 
Appendix C.5 Representative AEY-Score Registry Notes with Calculations 
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Appendix C.6 Plasma Preparation Procedure 
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Appendix D — Supplementary Results 
Appendix D.1 FEH·lab’s In-house Haemolytic Scale with CMYK Colour 
Reference 
 
Fig. ApxD - 1. The in-house haemolytic evaluation key used to provide all fresh plasma samples with haemolytic status prior to 
freezing.  
 
Table ApxD - 1. The in-house haemolytic evaluation key referenced with the CMYK colour model. 
Order Plasma Code C M Y K 
1 - 0 0 20 0 
2 (-) 0 9 20 0 
3 (+) - - - - 
4 + 0 20 20 0 
5 (++) - - - - 
6 ++ 2 36 17 0 
7 (+++) - - - - 
8 +++ 0 60 33 0 
9 (++++) - - - - 
10 H 12-22 95 75 0-2 
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Appendix D.2 Full Gene List for False Discovery Rate Correction-Analysis 
 
 
C omple t e  Ge ne  Lis t  f o r  F a lse  Discove ry R a t e  C or re ct ion  A na lys is  (Pa r t  1 /4 )
C ode Symbo l C ode Symbo l C ode Symbo l C ode Symbo l
AY310138 Il6st NM_001012357 Ccl9 NM_001100834 Ppa1 NM_001107296 Ercc6
AY325159 Plg NM_001012359 Ang NM_001100895 Atf1 NM_001107330 Irx4
BC081950 Mapk12 NM_001013045 Ccl24 NM_001100984 Ncf2 NM_001107407 Cdh5
D87927 Cxcl3 NM_001013062 Thbs1 NM_001105713 Prkca NM_001107413 Irx3
NM_001002016 Lmna NM_001013145 Ccr6 NM_001105725 Ccng2 NM_001107425 Nfat5
NM_001003959 Dnmt3b NM_001013157 Nnt NM_001105727 Psmb5 NM_001107588 Chuk
NM_001004100 Klk10 NM_001013413 Als2 NM_001105737 Tek NM_001107737 Itga4
NM_001004202 Ccl6 NM_001013428 Pla2g2d NM_001105738 Gpx5 NM_001107764 Pla2g4b
NM_001004250 Uqcrc1 NM_001014166 Il33 NM_001105749 Il16 NM_001107787 Pax1
NM_001004263 Itgb6 NM_001014199 Atp6v1c2 NM_001105822 Ccl12 NM_001107805 Nfatc2
NM_001005246 Dmd NM_001014786 Ifna1 NM_001105829 Lpo NM_001107869 Dysf
NM_001005534 Sdhc NM_001015011 Il17f NM_001105885 Hoxd4 NM_001107874 Xpc
NM_001005550 Ndufs1 NM_001024751 Sox6 NM_001105991 Atp6v1g3 NM_001107902 Sox17
NM_001005765 Rap1a NM_001024897 Ehd2 NM_001105993 Glmn NM_001107956 Car9
NM_001006961 Osm NM_001025065 Angptl3 NM_001106007 Pgm2 NM_001108048 Rps6ka5
NM_001006970 Uqcrc2 NM_001025134 Uqcrq NM_001106015 Pla2g3 NM_001108065 Shc2
NM_001006972 Ndufv1 NM_001025146 Ndufs4 NM_001106041 Ctsg NM_001108069 Stk11
NM_001007612 Ccl7 NM_001025405 Ruvbl2 NM_001106148 Myot NM_001108116 Hoxc5
NM_001007666 Bcs1l NM_001025425 Map2k7 NM_001106153 Ndufa2 NM_001108118 Itga5
NM_001007684 Klf2 NM_001025695 Cops5 NM_001106259 Akt1s1 NM_001108216 Nck2
NM_001007729 Pf4 NM_001030023 Map2k4 NM_001106294 Ndufab1 NM_001108250 Foxp3
NM_001008324 Eif4b NM_001033069 Eif4ebp2 NM_001106322 Ndufs8 NM_001108341 Ulk1
NM_001008384 Rac2 NM_001033699 Cox15 NM_001106360 Ndufb8 NM_001108392 Zic2
NM_001008525 Ndufs7 NM_001033883 Cxcl12 NM_001106361 Pax2 NM_001108400 Ankrd37
NM_001008724 Fga NM_001034105 Tnnc1 NM_001106395 Foxo3 NM_001108442 Ndufb7
NM_001008767 Txnip NM_001034125 Per1 NM_001106426 Ndufb5 NM_001108444 Gab1
NM_001008802 Krt1 NM_001034131 Foxp1 NM_001106489 Ndufs3 NM_001108447 Nfatc3
NM_001008888 Uqcrfs1 NM_001034164 Stat1 NM_001106641 Rragd NM_001108517 Rps6ka4
NM_001009268 Actr2 NM_001037180 Fkbp8 NM_001106646 Ndufb6 NM_001108565 Pla2g12a
NM_001009290 Ndufc2 NM_001039539 Pax9 NM_001106673 Gpx7 NM_001108577 Ppp2r4
NM_001009480 Uqcrh NM_001039849 Gpx4 NM_001106696 Pla2g2e NM_001108604 Rbpjl
NM_001009623 Tnfsf13 NM_001044267 Mknk1 NM_001106704 Cox7a2l NM_001108624 Ndufb2
NM_001009706 Lhpp NM_001047858 Srxn1 NM_001106783 Myf5 NM_001108661 Ccl19
NM_001009964 Tbx5 NM_001047862 Ndufa8 NM_001106850 Sox14 NM_001108813 Ndufa1
NM_001010962 Rps6kb2 NM_001047880 Slc25a15 NM_001106897 Il17a NM_001108836 Ccr10
NM_001010968 Eng NM_001048184 Rragc NM_001106912 Ndufb3 NM_001108943 Il21
NM_001011907 Ndufs2 NM_001080148 Dhcr24 NM_001106921 Prkag3 NM_001108978 Pik3cd
NM_001011917 Cab39l NM_001082479 Igf1 NM_001106924 Cab39 NM_001108979 Atp6v1e2
NM_001011959 Ctsa NM_001083911 Sepp1 NM_001106943 Foxo4 NM_001109112 Tnfsf13b
NM_001011964 Mapkap1 NM_001098241 Hras NM_001106986 Noxo1 NM_001109181 Sox2
NM_001011972 Atp6v0d2 NM_001100171 Noxa1 NM_001107036 Mpo NM_001109233 Hoxa9
NM_001011991 Ndrg1 NM_001100528 Rag2 NM_001107037 Epx NM_001109269 Lin28a
NM_001012027 Serpinc1 NM_001100531 Dlx1 NM_001107039 Sgca NM_001109383 Angptl1
NM_001012066 Sphk2 NM_001100539 Sdhb NM_001107041 Hoxb13 NM_001109393 Timp4
NM_001012122 Tymp NM_001100557 Olig2 NM_001107042 Hoxb3 NM_001109532 Mapk11
NM_001012127 Mapkapk3 NM_001100648 Foxn1 NM_001107094 Hoxd10 NM_001109587 Pla2g2f
NM_001012143 Jmjd6 NM_001100752 Ndufa9 NM_001107159 Mmp19 NM_001109615 Gys1
NM_001012147 Pxn NM_001100781 Nanog NM_001107264 Nfatc4 NM_001109884 Hoxc4
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C omple t e  Ge ne  Lis t  f o r  F a lse  Discove ry R a t e  C or re ct ion  A na lys is  (Pa r t  2 /4 )
C ode Symbo l C ode Symbo l C ode Symbo l C ode Symbo l
NM_001110334 Vegfa NM_012628 Prkcg NM_012982 Msx2 NM_017051 Sod2
NM_001115021 Qk NM_012629 Prl NM_012985 Ndufa5 NM_017058 Vdr
NM_001127294 Ndufb9 NM_012631 Prnp NM_012998 P4hb NM_017061 Lox
NM_001127553 Uqcrb NM_012639 Raf1 NM_013001 Pax6 NM_017064 Stat5a
NM_001129878 Hoxa11 NM_012655 Sp1 NM_013005 Pik3r1 NM_017066 Ptn
NM_001130501 Zfpm2 NM_012671 Tgfa NM_013010 Prkag1 NM_017071 Insr
NM_001130505 Ndufa6 NM_012675 Tnf NM_013025 Ccl3 NM_017086 Egr3
NM_001130548 Col14a1 NM_012680 Tsc2 NM_013053 Ywhaq NM_017093 Akt2
NM_001134499 Rptor NM_012682 Ucp1 NM_013057 F3 NM_017102 Slc2a3
NM_001134530 Mmp1 NM_012689 Esr1 NM_013062 Kdr NM_017104 Csf3
NM_001134979 Ezh2 NM_012715 Adm NM_013070 Utrn NM_017113 Grn
NM_001135009 Col4a1 NM_012735 Hk2 NM_013075 Hoxa1 NM_017115 Myog
NM_001135157 Myh2 NM_012742 Foxa1 NM_013076 Lep NM_017116 Capn2
NM_001135158 Myh1 NM_012743 Foxa2 NM_013081 Ptk2 NM_017117 Capn3
NM_001135759 Col4a3 NM_012747 Stat3 NM_013085 Plau NM_017143 F10
NM_001145367 Pparg NM_012751 Slc2a4 NM_013096 Hba1 NM_017144 Tnni3
NM_001163168 Ntrk2 NM_012764 Gata1 NM_013102 Fkbp1a NM_017160 Rps6
NM_001164060 Shc1 NM_012775 Tgfbr1 NM_013110 Il7 NM_017161 Adora2b
NM_001168641 Wars2 NM_012780 Arnt NM_013123 Il1r1 NM_017168 Plcg2
NM_001170597 Bai1 NM_012797 Id1 NM_013129 Il15 NM_017169 Prdx2
NM_001172305 Prkcb NM_012801 Pdgfa NM_013135 Rasa1 NM_017171 Prkce
NM_001191052 Tcf7l2 NM_012802 Pdgfra NM_013151 Plat NM_017174 Pla2g5
NM_001191566 Mbnl1 NM_012806 Mapk10 NM_013156 Ctsl1 NM_017176 Pla2g10
NM_001191803 Tnfsf14 NM_012807 Smo NM_013160 Mxi1 NM_017178 Bmp2
NM_001191845 Hey1 NM_012812 Cox6a2 NM_013167 Ucp3 NM_017183 Cxcr2
NM_001191923 Pik3r5 NM_012814 Cox6a1 NM_013172 Myf6 NM_017185 Tnni2
NM_001270665 Tnnt3 NM_012815 Gclc NM_013174 Tgfb3 NM_017202 Cox4i1
NM_001270796 Pla2g6 NM_012817 Igfbp5 NM_013187 Plcg1 NM_017221 Shh
NM_001270931 Hnf4a NM_012827 Bmp4 NM_013190 Pfkl NM_017232 Ptgs2
NM_001276711 Nfkb1 NM_012842 Egf NM_013195 Il2rb NM_017256 Tgfbr3
NM_012492 Adrb2 NM_012846 Fgf1 NM_013199 Dnm2 NM_017258 Btg1
NM_012495 Aldoa NM_012848 Fth1 NM_013216 Rheb NM_017269 Ptprj
NM_012499 Apc NM_012854 Il10 NM_016993 Bcl2 NM_017301 S1pr1
NM_012509 Atp4a NM_012864 Mmp7 NM_017000 Nqo1 NM_017305 Gclm
NM_012510 Atp4b NM_012870 Tnfrsf11b NM_017001 Epo NM_017309 Ppp3r1
NM_012520 Cat NM_012880 Sod3 NM_017003 Erbb2 NM_017322 Mapk9
NM_012548 Edn1 NM_012881 Spp1 NM_017017 Hgf NM_017322 Mapk9
NM_012551 Egr1 NM_012886 Timp3 NM_017019 Il1a NM_017325 Runx1
NM_012557 Fancc NM_012908 Faslg NM_017020 Il6r NM_017339 Isl1
NM_012561 Fst NM_012922 Casp3 NM_017022 Itgb1 NM_017344 Gsk3a
NM_012580 Hmox1 NM_012925 Cd59 NM_017025 Ldha NM_017347 Mapk3
NM_012581 Hoxa2 NM_012931 Bcar1 NM_017034 Pim1 NM_019127 Ifnb1
NM_012588 Igfbp3 NM_012935 Cryab NM_017039 Ppp2ca NM_019130 Ins2
NM_012589 Il6 NM_012945 Hbegf NM_017041 Ppp3ca NM_019142 Prkaa1
NM_012603 Myc NM_012948 Emd NM_017042 Ppp3cb NM_019143 Fn1
NM_012611 Nos2 NM_012951 Fgf10 NM_017043 Ptgs1 NM_019147 Jag1
NM_012615 Odc1 NM_012953 Fosl1 NM_017045 Rb1 NM_019151 Mstn
NM_012620 Serpine1 NM_012969 Irs1 NM_017050 Sod1 NM_019155 Cav3
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C omple t e  Ge ne  Lis t  f o r  F a lse  Discove ry R a t e  C or re ct ion  A na lys is  (Pa r t  3 /4 )
C ode Symbo l C ode Symbo l C ode Symbo l C ode Symbo l
NM_019156 Vtn NM_022214 Cxcl5 NM_030989 Tp53 NM_031643 Map2k1
NM_019183 Actc1 NM_022266 Ctgf NM_030992 Pld1 NM_031716 Wisp1
NM_019185 Gata6 NM_022269 Cd55 NM_030994 Itga1 NM_031761 Figf
NM_019191 Smad2 NM_022381 Pcna NM_031004 Acta2 NM_031785 Atp6ap1
NM_019205 Ccl11 NM_022404 Mlst8 NM_031012 Anpep NM_031832 Lgals3
NM_019212 Acta1 NM_022503 Cox7a2 NM_031018 Atf2 NM_031970 Hspb1
NM_019218 Neurod1 NM_022525 Gpx3 NM_031020 Mapk14 NM_031976 Prkab1
NM_019223 Ndufs6 NM_022528 Hif3a NM_031021 Csnk2b NM_031977 Src
NM_019231 Mapk13 NM_022531 Des NM_031051 Mif NM_031985 Rps6kb1
NM_019232 Sgk1 NM_022532 Araf NM_031054 Mmp2 NM_032080 Gsk3b
NM_019233 Ccl20 NM_022540 Prdx3 NM_031055 Mmp9 NM_032085 Col3a1
NM_019247 Pitx3 NM_022542 Rhob NM_031056 Mmp14 NM_033230 Akt1
NM_019305 Fgf2 NM_022584 Txnrd2 NM_031061 Musk NM_033299 Pld2
NM_019306 Flt1 NM_022597 Ctsb NM_031064 Ndufv2 NM_033359 Ngb
NM_019310 Cxcr1 NM_022605 Hpse NM_031081 Pdpk1 NM_053290 Pgam1
NM_019333 Pfkfb4 NM_022611 Il12b NM_031107 Rps6ka1 NM_053291 Pgk1
NM_019334 Pitx2 NM_022627 Prkab2 NM_031116 Ccl5 NM_053295 Cast
NM_019353 Tpo NM_022631 Wnt5a NM_031131 Tgfb2 NM_053297 Pkm
NM_019354 Ucp2 NM_022677 Zic1 NM_031139 Usf2 NM_053303 Cxcr5
NM_019360 Cox6c NM_022698 Bad NM_031140 Vim NM_053304 Col1a1
NM_019363 Aox1 NM_022712 Tfrc NM_031317 Pdgfc NM_053328 Bhlhe40
NM_019371 Egln3 NM_022714 Crhr2 NM_031334 Cdh1 NM_053353 Cd40lg
NM_019383 Atp5h NM_022922 Tpi1 NM_031347 Ppargc1a NM_053355 Ikbkb
NM_019905 Anxa2 NM_022924 F2 NM_031353 Vdac1 NM_053356 Col1a2
NM_019906 Mtor NM_022938 Htr7 NM_031507 Egfr NM_053357 Ctnnb1
NM_020082 Rnase4 NM_022958 Pik3c3 NM_031507 Egfr NM_053364 Prl7d1
NM_020542 Ccr1 NM_023090 Epas1 NM_031510 Idh1 NM_053390 Il12a
NM_021578 Tgfb1 NM_023092 Myo1c NM_031511 Igf2 NM_053415 Cxcr3
NM_021588 Mb NM_023093 Atp5a1 NM_031512 Il1b NM_053420 Bnip3
NM_021592 Hand1 NM_023098 Nup62 NM_031513 Il3 NM_053423 Tert
NM_021655 Chga NM_023963 Cdx2 NM_031515 Kras NM_053425 Ccs
NM_021689 Ereg NM_023981 Csf1 NM_031517 Met NM_053429 Fgfr3
NM_021698 F13a1 NM_023991 Prkaa2 NM_031524 Pdgfb NM_053450 Hdac5
NM_021701 Ppp3r2 NM_024141 Duox2 NM_031530 Ccl2 NM_053472 Cox4i2
NM_021760 Col5a3 NM_024148 Apex1 NM_031534 Wt1 NM_053481 Pik3cb
NM_021834 Il5 NM_024160 Cyba NM_031534 Wt1 NM_053488 Col5a2
NM_021835 Jun NM_024161 Dnajc5 NM_031549 Tagln NM_053489 Col18a1
NM_021838 Nos3 NM_024358 Notch2 NM_031550 Cdkn2a NM_053512 Prdx4
NM_021854 Tsc1 NM_024359 Hif1a NM_031554 Acvr2b NM_053524 Nox4
NM_021866 Ccr2 NM_024400 Adamts1 NM_031560 Ctsk NM_053540 Cox17
NM_021989 Timp2 NM_030826 Gpx1 NM_031575 Akt3 NM_053545 Tie1
NM_022182 Fgf7 NM_030834 Slc16a3 NM_031585 Pla2g1b NM_053546 Angpt1
NM_022185 Pik3r2 NM_030836 Erap1 NM_031591 Pecam1 NM_053549 Vegfb
NM_022194 Il1rn NM_030845 Cxcl1 NM_031598 Pla2g2a NM_053551 Pdk4
NM_022196 Lif NM_030846 Grb2 NM_031606 Pten NM_053552 Tnfsf4
NM_022197 Fos NM_030854 Lect1 NM_031614 Txnrd1 NM_053576 Prdx6
NM_022209 Ppp2r2b NM_030859 Mdk NM_031632 Casp9 NM_053586 Cox5b
NM_022213 Pik3r3 NM_030869 Nrp2 NM_031633 Foxm1 NM_053595 Pgf
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C omple t e  Ge ne  Lis t  f o r  F a lse  Discove ry R a t e  C or re ct ion  A na lys is  (Pa r t  4 /4 )
C ode Symbo l C ode Symbo l C ode Symbo l C ode Symbo l
NM_053599 Efna1 NM_057149 Tnfsf11 NM_134454 Angpt2 NM_184051 Prkag2
NM_053602 Atp5j NM_057151 Ccl17 NM_134455 Cx3cl1 NM_198788 Sdhd
NM_053610 Prdx5 NM_057193 Il10ra NM_138503 Map3k2 NM_199115 Angptl4
NM_053645 Il5ra NM_057203 Ccl22 NM_138528 Ero1l NM_199495 Ndufa10
NM_053647 Cxcl2 NM_058213 Atp2a1 NM_138827 Slc2a1 NM_201270 Il4
NM_053652 Flt4 NM_080399 Ddit4l NM_138828 Apoe NM_206847 Pfkp
NM_053653 Vegfc NM_080481 Atp5i NM_138832 Slc38a1 NM_207592 Gpi
NM_053697 Dag1 NM_080766 Nras NM_138854 Slc38a5 NM_207605 Sh2d2a
NM_053708 Gbx2 NM_080769 Lta NM_138880 Ifng NM_212505 Ier3
NM_053710 Pax3 NM_080778 Nr2f2 NM_138883 Atp5o NM_212507 Ltb
NM_053713 Klf4 NM_080888 Bnip3l NM_139089 Cxcl10 NM_212516 Atp5l
NM_053725 Itga6 NM_080889 Il2rg NM_139104 Egfl7 NM_212517 Ndufa11
NM_053734 Ncf1 NM_080903 Trim63 NM_139105 Rnh1 X02610 Eno1
NM_053756 Atp5g3 NM_080906 Ddit4 NM_139106 Atp5d XM_001069410 Hoxc6
NM_053757 Aimp1 NM_130417 Hey2 NM_139192 Scd1 XM_001076610 Ep300
NM_053769 Dusp1 NM_130428 Sdha NM_144737 Fmo2 XM_001079130 RGD1561905
NM_053775 Atp6v0a2 NM_130744 Cygb NM_144744 Adipoq XM_003749164 Mef2c
NM_053789 Il17b NM_130755 Cs NM_145095 Kcnh8 XM_003750414 Hoxc10
NM_053792 Ift172 NM_131908 Fgf6 NM_145098 Nrp1 XM_235733 Amot
NM_053800 Txn1 NM_133386 Sphk1 NM_145672 Cxcl9 XM_575155 Ttn
NM_053819 Timp1 NM_133386 Sphk1 NM_145681 Tnfsf10
NM_053824 Csnk2a1 NM_133399 Pik3ca NM_145783 Cox5a
NM_053825 Atp5c1 NM_133409 Ilk NM_147139 Itgb5
NM_053826 Pdk1 NM_133418 Slc25a10 NM_147165 Gpx6
NM_053828 Il13 NM_133424 Actn3 NM_153629 Hspa4
NM_053829 Mapk8 NM_133517 Atp12a NM_153720 Itgb3
NM_053836 Il2 NM_133519 Il11 NM_153721 Ppbp
NM_053842 Mapk1 NM_133521 Fbxo32 NM_153739 Duox1
NM_053852 Csf2 NM_133523 Mmp3 NM_171992 Ccnd1
NM_053857 Eif4ebp1 NM_133524 Tcfe2a NM_171994 Cdc42
NM_053858 Ccl4 NM_133532 Ccr4 NM_172055 Cited1
NM_053883 Dusp6 NM_133551 Pla2g4a NM_172062 P4ha1
NM_053887 Map3k1 NM_133556 Atp5g2 NM_172068 Surf1
NM_053906 Gsr NM_133601 Cblb NM_173120 Vimp
NM_053918 Cga NM_133605 Camk2g NM_175754 Agrn
NM_053958 Ccr3 NM_133651 Cav1 NM_175761 Hsp90aa1
NM_053960 Ccr5 NM_134326 Alb NM_175843 Sqstm1
NM_053965 Slc25a20 NM_134345 Cox8a NM_176075 Ppargc1b
NM_053972 RragB NM_134352 Plaur NM_176079 Myod1
NM_053973 Rraga NM_134355 Pou4f2 NM_177927 Serpinf1
NM_053974 Eif4e NM_134364 Atp5b NM_177928 Nampt
NM_057108 Serpinb5 NM_134365 Atp5f1 NM_178102 Mapkapk2
NM_057114 Prdx1 NM_134366 Rac1 NM_181371 Gstk1
NM_057120 Nudt1 NM_134367 Ppp3cc NM_182667 Myocd
NM_057128 Rps6ka2 NM_134388 Tnnt1 NM_182819 Cox7b
NM_057132 Rhoa NM_134443 Creb1 NM_182952 Cxcl11
NM_057135 Pfkfb3 NM_134443 Creb1 NM_183055 Cox8c
NM_057143 Park7 NM_134452 Col5a1 NM_183403 Gpx2
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Appendix D.3 RNA Extraction Assessment (from m. Soleus Samples) 
Appendix D.3.1 RNA Quality and Quantity 
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Appendix D.3.2 Sample’s Dye-Proportions Prior to the Microarray Analysis Procedure   
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Appendix D.4 The Differential Gene Expression Profiles 
Appendix D.4.1 The Skeletal Muscle (Myogenesis & Myopathy) Pathway 
Table ApxD - 2. The Skeletal Muscle Contractility – Dystrophin-Glycoprotein Complex Gene Profile of Significant Differential Fold 
Changes (log2(FC)). 
 
Table ApxD - 3. The Skeletal Muscle Contractility – Titin Complex Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Capn3 Emd Lmna Cav3 Dmd Dysf Dag1 Camk2g
Day −1 A{−1} R{−1}
A{−1} −0.59* 0.28 0.57* −0.23  0.49*   
R{−1} −0.52* 0.24 0.48*   0.30   
A{−1} −0.56* 0.36* 0.72* −0.41* −0.39 0.50*   
R{−1} −0.49* 0.31* 0.64* −0.29 −0.44 0.31   
A{−1} −0.64* 0.32* 0.59* −0.39*  0.41 −0.26  
R{−1} −0.57* 0.27 0.50* −0.26   −0.24  
C{01}        −0.61
A{−1}   0.48   0.48   
R{−1}   0.39      
C{01} 0.52*        
A{−1}   0.36   0.33   
H{01} 0.44 −0.29 −0.36 0.30 0.53    
A{−1}   0.49   0.33   
R{−1}   0.41      
E{01} 0.39   0.28     
C{03} C{07}   −0.28      
A{−1}     0.44    
R{−1}     0.39    
H{01} 0.70* −0.42* −0.57* 0.36* 0.84*    
C{07}     0.38    
E{01} 0.61* −0.27 −0.40* 0.27  −0.38  0.46
E{03}   −0.30   −0.29   
H{07}     −0.37    
R{−1} C{14} 0.33       0.48
A{−1}       −0.24  
R{−1} 0.34      −0.23  
H{01} 0.84* −0.30* −0.52* 0.36* 0.71* −0.30   
H{03} 0.39        
E{01} 0.62* −0.35* −0.44* 0.21 0.37 −0.39   
E{03}   −0.34   −0.30   
Day 3
Day 14
C{03}
H{14}
E{14}
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value 
(false discovery rate corrected). Positive fold change values are in white letters on dark background. Genes within
this pathway line with no significant differential expression are: Mapk1, Sgca.
Day 7
Gene (Symbol)
Timing R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
E{07}
E{01}
H{07}
H{01}
E{03}
H{03}
Day 1
C{01}
Actn3 Capn3 Lmna Myot Cryab Tnnt3 Tnni2 Trim63 Acta1 Des Ttn Myh1 Myh2
Day −1 A{−1} R{−1}        −0.48 0.25     
A{−1} −3.10 −0.59* 0.57* −0.75*  −2.05 −2.78 −0.67*      
R{−1} −3.82 −0.52* 0.48* −0.62     −0.39     
A{−1}  −0.56* 0.72* −0.56* 0.42   −0.51    −2.40  
R{−1}  −0.49* 0.64* −0.43 0.43    −0.36   −2.11  
A{−1} −3.25 −0.64* 0.59* −0.68*       −0.51   
R{−1} −3.98* −0.57* 0.5* −0.56     −0.40     
C{01}      2.35 3.31 0.49   −0.51  2.72
A{−1} −2.54  0.48       0.38    
R{−1} −3.27  0.39       0.31    
C{01}  0.52*  0.59 −0.59 2.52* 3.33*   0.32   2.66
A{−1}   0.36           
R{−1}        0.49      
H{01}  0.44 −0.36 0.38 −0.64*   0.53    2.14  
C{03} 2.92             
A{−1}   0.49       0.27    
R{−1} −2.63  0.41     0.54      
E{01}  0.39  0.53     0.35     
C{03} C{07}   −0.28       −0.31    
R{−1}           0.64   
H{01}  0.70* −0.57* 0.54 −0.47    0.28  0.67   
H{03}           0.48   
R{−1} −3.14       0.83*      
E{01}  0.61* −0.40* 0.52    0.54      
E{03}   −0.30           
C{07}        0.56      
H{07}        0.51      
A{−1}            −2.16  
R{−1} −2.65 0.33         0.51   
A{−1}      −2.21 −2.31      −2.27
R{−1}  0.34            
H{01}  0.84* −0.52* 0.55*     0.31     
H{03}  0.39    −2.35 −2.64      −2.70
R{−1} −2.68       0.46      
E{01}  0.62* −0.44* 0.41   −1.97       
E{03}   −0.34       −0.25    
R
e
fe
re
n
c
e
H{01}
Day 3
C{03}
H{07}
E{07}
E{03}
H{03}
Day 1
C{01}
E{01}
Day 14
C{14}
H{14}
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false discovery
rate corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line with no significant
differential expression are: Mapk1, Mstn, Neb, Sgca, Tnnt1.
E{14}
O
b
je
c
ti
v
e
Timing
Day 7
Gene (Symbol)
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Table ApxD - 4. The Skeletal Muscle Contractility – Energy Metabolism Gene Profile of Significant Differential Fold Changes (log2(FC)).  
 
Table ApxD - 5. The Skeletal Muscle Contractility – Fast-Twitch Fibres Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 6. The Skeletal Muscle Contractility – Slow-Twitch Fibres Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Hk2 Slc2a4 Cs Pdk4
Day −1 A{−1} R{−1}
A{−1}  0.46 0.24  
R{−1}  0.47   
C{01} H{01}   −0.25  
A{−1} 0.54*   0.99
R{−1} 0.39   0.96
C{01} 0.67*    
H{01} 0.47    
C{01} C{03} 0.38 −0.53*   
H{01} H{03}  −0.33   
E{01} E{03} −0.49    
A{−1} −0.42    
R{−1} −0.57    
C{03} −0.67    
A{−1} −0.69    
R{−1} −0.85*    
H{01} −0.77*    
H{03} −0.70  −0.21  
A{−1}    0.87
R{−1}    0.84
E{01} −0.66*    
C{07}    0.89
H{07} 0.57    
A{−1}   −0.19  
R{−1} −0.37  −0.29  
H{01}   −0.19  
H{03}   −0.32  
H{07} 0.47    
A{−1} −0.39    
R{−1} −0.54  −0.20  
E{01} −0.93*  −0.29*  
E{03} −0.44  −0.26  
E{01}
Day 1
C{01}
Gene (Symbol)
Day 7
Day 14
H{07}
E{14}
Fold change values marked with an asterisk and in boldface letters
are significant (p≤0.05) with an adjusted p-value (false discovery
rate corrected). Positive fold change values are in white letters on
dark background. Genes within this pathway line with no significant 
differential expression are: none.
H{14}
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
C{07}
Day 3
Timing
E{07}
Atp2a1 Tnnt3 Tnni2 Myh1 Myh2
Day −1 A{−1} R{−1}
A{−1} C{01} −0.72* −2.05 −2.78   
A{−1} −0.60   −2.4  
R{−1}    −2.11  
C{01} 0.80* 2.35 3.31  2.72
H{01} 0.67     
R{−1} 0.54     
C{01} 0.93* 2.52* 3.33*  2.66
R{−1} 0.67     
H{01} 0.93*   2.14  
C{03} −0.46     
H{03} −0.59     
Day 7 H{03} H{07} −0.57     
A{−1} C{14}    −2.16  
A{−1} −0.51 −2.21 −2.31  −2.27
H{03} −0.85 −2.35 −2.64  −2.70
E{01} E{14} −0.44  −1.97   
Day 1
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
E{01}
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05)
with an adjusted p-value (false discovery rate corrected). Positive fold change values are in
white letters on dark background. Genes within this pathway line with no significant
differential expression are: none.
H{14}
Day 3
C{03}
Gene (Symbol)
Timing
H{01}
H{03}
Day 14
E{03}
Mb Myh1 Tnnc1
Day −1 A{−1} R{−1}
R{−1} C{01} −0.32   
A{−1}  −2.4  
R{−1} −0.29 −2.11  
Day 3 H{01} H{03}  2.14  
Day 7 H{03} H{07}   0.45
A{−1} C{14}  −2.16  
H{03} H{14}   0.43
E{01} E{14}   0.40
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
H{01}
Day 14
Day 1
Fold change values marked with an asterisk and in boldface
letters are significant (p≤0.05) with an adjusted p-value (false
discovery rate corrected). Positive fold change values are in
white letters on dark background. Genes within this pathway
line with no significant differential expression are: Tnnt1.
Timing
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Table ApxD - 7. The Skeletal Muscle Contractility – Other Genes Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 8. The Skeletal Myogenesis Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 9. The Skeletal Muscle Hypertrophy Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Gene (Symbol)
Rps6kb1
Day −1 A{−1} R{−1}
A{−1} −0.33
R{−1} −0.36
A{−1} −0.39*
R{−1} −0.42*
R{−1} E{01} −0.29
Day 3 E{01} E{03} 0.26
A{−1} −0.27
R{−1} −0.30
H{01} 0.30
E{01} 0.32
Day 14 H{14}
Day 1
H{07}
C{01}
Fold change values marked with an asterisk
and in boldface letters are significant (p≤0.05)
with an adjusted p-value (false discovery rate
corrected). Positive fold change values are in
white letters on dark background. Genes
within this pathway line with no significant
differential expression are: Dmpk, Ikbkb.
Timing
Day 7
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
H{01}
Myod1 Mef2c Hdac5 Myog Adrb2 Dmd Rps6kb1 Agrn Igfbp5 Cast Utrn Cav1 Bmp4 Capn2 Acta1 Myf5 Igfbp3 Igf1 Mbnl1 Myf6 Ppp3ca
Day −1 A{−1} R{−1}          0.44     0.25       
A{−1} 0.74 −0.48   −0.45  −0.33    0.24   −0.29        
R{−1} 0.88 −0.44     −0.36   −0.60*    −0.36 −0.39       
A{−1} 1.10* −0.55* −0.39 0.59 −0.57 −0.39 −0.39* −0.41* −0.81   −0.33         −0.33
R{−1} 1.24* −0.51* −0.46*  −0.53 −0.44 −0.42* −0.44*    −0.39   −0.36       
C{01}        −0.42 −0.96  −0.21 −0.39  0.34     −0.43   
A{−1} 1.32* −0.65* −0.6* 0.61 −0.48   −0.31 −0.96             
R{−1} 1.46* −0.61* −0.68*  −0.45  −0.29 −0.33    −0.31   −0.40       
C{01}   −0.45     −0.31 −1.12 0.46 −0.3 −0.31          
R{−1}                 −0.48     
C{01}  0.54*        0.33      0.24      
A{−1}           0.26           
R{−1}                 −0.51     
H{01} −0.88 0.70*  −0.72*  0.53  0.41*   0.24  0.34         
A{−1}                 −0.45     
R{−1}   −0.34              −0.52     
E{01} −1.04 0.75* 0.33 −0.48 0.66  0.26    0.22    0.35 0.27      
C{03}   −0.32                   
A{−1}             0.34         
R{−1}    −0.59      −0.44  −0.29  −0.30        
A{−1}      0.44 −0.27    0.31 −0.38 0.34         
R{−1}    −0.67  0.39 −0.30 −0.27  −0.47 0.26 −0.43    0.27      
H{01} −1.16* 0.45 0.34 −0.94* 0.42 0.84*   0.90  0.29*  0.39  0.28       
C{07}      0.38  −0.28   0.21     0.26      
A{−1}        −0.31    −0.50  −0.26        
R{−1}    −0.61    −0.34  −0.56  −0.56*  −0.33        
E{01} −1.65* 0.59* 0.44* −0.90* 0.74*    0.95 −0.43            
E{03}         0.68   −0.28          
C{07}        −0.35     −0.37         
H{07}      −0.37       −0.37         
A{−1}           0.26           
R{−1}    −0.57      −0.41    −0.24        
A{−1}           0.22           
R{−1}    −0.51      −0.37      0.26      
H{01} −1.52*  0.31 −0.78* 0.69* 0.71* 0.30 0.25 0.72    0.33  0.31       
H{03}  −0.42                    
C{14}                0.26      
A{−1}        −0.39    −0.36          
R{−1}    −0.66    −0.41  −0.41  −0.42 −0.38 −0.28    −0.57    
E{01} −1.53* 0.38 0.43* −0.95* 0.71* 0.37 0.32  1.00*    −0.32         
E{03}  −0.36  −0.47    −0.25 0.73    −0.31       −0.52  
C{14}        −0.28    −0.28 −0.48         
H{14}             −0.49   −0.24      
H{01}
Gene (Symbol)
Day 14
C{14}
H{07}
C{03}
E{07}
E{01}
Day 1
C{01}
Timing
E{03}
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false discovery rate corrected). Positive fold change values are in
white letters on dark background. Genes within this pathway line with no significant differential expression are:  Bcl2, Ctnnb1, Mstn, Musk, Pax3, Rhoa.
H{14}
Day 7
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
H{03}
Day 3
E{14}
C{07}
Myod1 Adrb2 Acvr2b Rps6kb1 Igfbp5 Acta1 Igf1 Myf6
Day −1 A{−1} R{−1}      0.25   
A{−1} 0.74 −0.45  −0.33     
R{−1} 0.88   −0.36  −0.39   
A{−1} 1.10* −0.57  −0.39* −0.81    
R{−1} 1.24* −0.53  −0.42*  −0.36   
C{01}     −0.96    
A{−1} 1.32* −0.48   −0.96    
R{−1} 1.46* −0.45  −0.29  −0.40   
C{01}     −1.12    
H{01} H{03} −0.88  0.62      
E{01} E{03} −1.04 0.66    0.35   
A{−1}    −0.27     
R{−1}    −0.30     
H{01} −1.16* 0.42 0.63  0.90 0.28   
E{01} −1.65* 0.74*  0.26 0.95    
E{03}     0.68    
H{01} H{14} −1.52* 0.69* 0.75* 0.30 0.72 0.31   
R{−1}       −0.57  
E{01} −1.53* 0.71* 0.50 0.32 1.00*    
E{03}     0.73   −0.52
H{01}
E{01}
H{07}
Day 1
C{01}
E{07}
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false
discovery rate corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line
with no significant differential expression are: Mstn.
Day 3
O
b
je
c
ti
v
e
Timing
Day 7
Day 14
E{14}
R
e
fe
re
n
c
e Gene (Symbol)
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Table ApxD - 10. The Skeletal Muscle Autocrine Signalling Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 11. The Diabetes/Metabolic Syndrome Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Il6 Tgfb1 Igf2 Adipoq Fgf2 Igf1
Day −1 A{−1} R{−1}    1.90   
A{−1}  0.71*     
R{−1}  0.49     
A{−1}  0.86*     
R{−1}  0.64*  −1.56   
A{−1} 1.06* 0.56 −0.53    
R{−1} 1.00*  −0.57  0.50  
C{01} 0.91      
H{01} 0.75      
A{−1}  0.70     
R{−1}  0.48     
C{01}   0.54    
A{−1}  0.55  1.92   
R{−1}     0.59  
H{01}   0.67 1.58   
A{−1}  0.61  1.79   
R{−1}     0.45  
E{01} −0.89  0.71    
A{−1}   0.66    
R{−1}   0.63    
H{01} H{07}  −0.65* 0.90*    
E{01} E{07} −0.98*  0.77*    
C{07} C{14}   −0.69    
H{07} H{14}  −0.58* −0.60    
R{−1}     0.50 −0.57
E{01} −1.04* −0.55     
E{03}  −0.60     
H{01}
E{01}
E{14}
Day 3
C{03}
E{03}
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with
an adjusted p-value (false discovery rate corrected). Positive fold change values are in white
letters on dark background. Genes within this pathway line with no significant differential
expression are: Lep, Mstn.
Day 1
C{01}
H{03}
R
e
fe
re
n
c
e
Timing
Day 14
Gene (Symbol)
Day 7
C{07}
O
b
je
c
ti
v
e
Ppargc1a Prkaa1 Slc2a4 Prkab2 Ppargc1b Adipoq Pparg
Day −1 A{−1} R{−1}    −0.64  1.90  
A{−1}   0.46     
R{−1}   0.47 0.80    
A{−1}  0.53*      
R{−1}      −1.56 −0.54
C{01}     −0.71  −0.55
A{−1} 1.65* 0.44   −0.71   
R{−1} 1.77*   0.89    
C{01} 1.27    −0.97   
H{01} 1.51       
A{−1}  0.52      
C{01}   −0.53* −0.71    
A{−1}    −0.71  1.92  
H{01}   −0.33 −0.68  1.58  
A{−1} 1.42 0.73*    1.79  
R{−1} 1.54 0.46      
C{03} 1.45       
H{03} 1.17       
C{03} C{07}  −0.38      
R{−1}       −0.53
H{01}     0.80   
A{−1} 2.18*       
R{−1} 2.30*       
E{01}     0.71   
E{03}  −0.56      
C{07} 2.16*       
H{07} 1.90*       
R{−1}    0.91    
H{01}  −0.43   0.88   
H{03}    0.98 0.65   
C{14}    0.78    
A{−1} 1.45       
R{−1} 1.56   0.79    
E{01}     0.63   
E{03}  −0.39      
C{14} 1.20       
H{14} 1.30       
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
H{01}
Gene (Symbol)
Day 1
C{01}
E{03}
Day 3
C{03}
H{07}
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected). Positive fold change values are in white letters on
dark background. Genes within this pathway line with no significant differential expression are: Lep,
Prkag1, Prkag3.
E{01}
H{03}
H{14}
E{14}
Day 14
Day 7
Timing
E{07}
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Table ApxD - 12. The Skeletal Muscle Wasting/Atrophy – Autophagy Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 13. The Skeletal Muscle Wasting/Atrophy – Dystrophy Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
  
Fbxo32 Casp3 Nos2 Rps6kb1 Ppargc1a Trim63 Foxo3 Capn2 Ppargc1b
Day −1 A{−1} R{−1} −0.58     −0.48    
A{−1} 0.42 0.52  −0.33  −0.67*  −0.29  
R{−1} 1.01*   −0.36  0.28 −0.36  
A{−1}  0.61 −0.36 −0.39* −0.51    
R{−1} 0.62* 0.42  −0.42  0.31   
C{01}        0.34 −0.71
A{−1}  0.64  1.65    −0.71
R{−1}  0.45 −0.29 1.77     
C{01} −0.66    1.27 0.49   −0.97
H{01}     1.51     
A{−1}  0.43* −0.33       
R{−1} 0.59         
C{01} −0.41      −0.33   
A{−1}  0.43*        
R{−1} 0.92*     0.49    
H{01}      0.53 −0.36   
A{−1}     1.42     
R{−1} 0.47    1.54 0.54    
E{01}    0.26      
C{03}     1.45     
H{03} −0.45    1.17     
R{−1} C{07} 0.66       −0.30  
A{−1} 0.46   −0.27      
R{−1} 1.05*   −0.3      
H{01} 0.42 −0.53* 0.26    −0.27  0.80
A{−1}    2.18   −0.26  
R{−1} 0.95*   2.30 0.83*  −0.33  
E{01} 0.61* −0.60*   0.54   0.71
E{03} 0.48     0.23   
C{07}    2.16 0.56    
H{07}    1.90 0.51    
R{−1} C{14} 0.92*       −0.24  
R{−1} 0.96*         
H{01}  −0.59  0.30     0.88
H{03}  −0.42*       0.65
A{−1} 0.50    1.45     
R{−1} 1.08*    1.56 0.46 0.31 −0.28  
E{01} 0.74* −0.70  0.32     0.63
E{03} 0.61      0.30   
C{14}     1.20  0.25   
H{14}     1.30     
E{01}
Day 1
C{01}
H{01}
E{07}
Day 7
H{14}
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false
discovery rate corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line with
no significant differential expression are: Mstn.
R
e
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n
c
e
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b
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c
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v
e
E{14}
Timing
Day 14
E{03}
Day 3
C{03}
H{03}
H{07}
Gene (Symbol)
Fbxo32 Akt2 Il1b Trim63 Mapk8 Utrn Mapk14 Tnf Akt1 Mapk3 Nfkb1
Day −1 A{−1} R{−1} −0.58   −0.48        
A{−1} 0.42 −0.45  −0.67* −0.38 0.24 −0.29 −0.64    
R{−1} 1.01* −0.50   −0.34   −0.78    
A{−1}  −0.51*  −0.51 −0.49*       
R{−1} 0.62* −0.55*   −0.45   −0.62    
C{01}      −0.21      
A{−1}  −0.44 1.18*  −0.39       
R{−1}  −0.48 0.76  −0.34    −0.43   
C{01} −0.66  0.84 0.49  −0.30  0.59    
A{−1}       −0.29     
R{−1} 0.59           
C{01} −0.41 0.55*      0.69    
A{−1}     −0.4 0.26 −0.27     
R{−1} 0.92*   0.49 −0.35       
C{01}            
H{01}    0.53  0.24      
A{−1}       −0.36     
R{−1} 0.47   0.54     −0.48  −0.30
E{01}   −0.83   0.22 −0.33     
C{03}  −0.36          
H{03} −0.45           
A{−1}     −0.39       
R{−1} 0.66    −0.34       
A{−1} 0.46     0.31 −0.32     
R{−1} 1.05*     0.26      
H{01} 0.42 0.49* −0.75   0.29*      
C{07}      0.21      
A{−1}       −0.33     
R{−1} 0.95*   0.83*        
E{01} 0.61*  −0.90 0.54   −0.29     
E{03} 0.48           
C{07}    0.56        
H{07}    0.51        
A{−1}      0.26      
R{−1} 0.92*           
A{−1}      0.22      
R{−1} 0.96*           
H{01}  0.44          
A{−1} 0.50           
R{−1} 1.08*   0.46        
E{01} 0.74*  −1.05*         
E{03} 0.61           
H{14}          −0.29  
R
e
fe
re
n
c
e
Day 1
O
b
je
c
ti
v
e
H{01}
C{01}
Gene (Symbol)
E{01}
E{07}
Day 3
H{03}
H{07}
C{03}
C{14}
Day 14
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false discovery rate corrected).
Positive fold change values are in white letters on dark background. Genes within this pathway line with no significant differential expression are:
Mapk1, Mmp9.
H{14}
E{14}
E{03}
Day 7
C{07}
Timing
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Appendix D.4.2 The Hypoxia Signalling Pathway 
Table ApxD - 14. The Hypoxia Signalling – Angiogenesis Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 15. The Hypoxia Signalling – HIF1 & Co-Transcription Factors Gene Profile of Significant Differential Fold Changes 
(log2(FC)). 
 
Hmox1 Btg1 Adora2b Anxa2 Plau Serpine1 Lox Pgf Vegfa Jmjd6 Angptl4 F3 Gpi
Day −1 A{−1} R{−1}
A{−1}     0.69 1.21 1.29       
R{−1}      1.16    −0.38    
A{−1} 1.26 0.57* 0.52 1.33* 1.05* 1.99* 2.03*  −1.11*     
R{−1} 1.23 0.46*  0.99 0.73 1.94* 1.46*  −0.62     
C{01}  0.35            
A{−1} 1.96* 0.89* 0.72* 1.09* 1.29* 2.24* 1.90*  −0.62     
R{−1} 1.93* 0.79* 0.50 0.76 0.97* 2.20* 1.34 0.74      
C{01} 1.59* 0.68*   0.60 1.03  0.59   2.92   
H{01}  0.32      0.56      
A{−1}    0.87  0.97 1.94       
R{−1}      0.92 1.38       
A{−1}    0.83 0.56  1.77  −1.02     
R{−1}       1.20   −0.33    
H{01} −0.98 −0.30 −0.45   −1.51*        
A{−1}    0.82 0.56 1.85* 1.59  −0.98     
R{−1}      1.80 1.02       
E{01} −1.51* −0.80* −0.72*  −0.72   −0.73   −2.49   
H{03}      1.37        
C{03} C{07}      −0.97 −1.04       
A{−1}        −0.63  −0.36    
R{−1}          −0.43    
H{01} −1.38* −0.69* −0.53 −1.32* −0.66 −1.59* −1.17       
H{03}  −0.39  −0.81          
A{−1}     0.57 1.14        
R{−1}      1.09        
E{01} −1.82* −1.07* −0.66* −1.12* −0.71 −1.10 −1.21 −0.73   −2.84   
E{03}    −0.84     0.91     
C{07}      1.14        
R{−1} C{14}            −0.74  
H{01} −1.39* −0.69* −0.62* −1.22* −0.81* −1.44* −1.46*  0.68     
H{03}  −0.39  −0.72   −1.20  0.59     
H{07}        0.55      
A{−1}      1.02       −0.29
R{−1}      0.97        
E{01} −1.84* −1.01* −0.79* −1.27* −0.94* −1.22 −1.84* −0.77*      
E{03}    −1.00   −1.52  0.62     
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false discovery rate
corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line with no significant differential
expression are: Egr1, Edn1, Epo, Mmp9.
Day 14
H{14}
E{14}
Day 1
C{01}
E{01}
Day 3
C{03}
E{07}
Day 7
H{07}
H{01}
E{03}
H{03}
Timing R
e
fe
re
n
c
e
O
b
je
c
ti
v
e Gene (Symbol)
Arnt Per1 Hif1a Cops5 Hif3a
Day −1 A{−1} R{−1}  −0.57    
A{−1} −0.30 −0.78 −1.11 −0.25  
R{−1} −0.22     
A{−1} H{01}  −0.64    
A{−1}  −0.58    
C{01} 0.37*  1.32   
R{−1}  0.52    
C{01} 0.22 0.72    
A{−1}  −0.66    
C{03}  −0.61    
A{−1} E{03}  −0.53    
A{−1} −0.23 −0.63    
C{03}  −0.57    
A{−1} −0.24 −0.53    
H{03} −0.20     
A{−1}  −0.69    
C{07} 0.26     
H{07} 0.27     
A{−1} −0.22 −0.66    
C{07}     0.24
A{−1} −0.36 −0.68    
R{−1} −0.28     
H{01} −0.23     
H{03} −0.31     
A{−1}  −0.56    
C{14} 0.25     
H{14} 0.38     
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e Gene (Symbol)
Timing
Fold change values marked with an asterisk and in boldface letters are significant
(p≤0.05) with an adjusted p-value (false discovery rate corrected). Positive fold change
values are in white letters on dark background. Genes within this pathway line with no
significant differential expression are: Hnf4a.
Day 1
C{01}
E{01}
Day 3
C{03}
H{03}
H{07}
E{07}
Day 7
C{07}
E{14}
Day 14
C{14}
H{14}
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Table ApxD - 16. The Hypoxia Signalling – Other HIF1 Interactors Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 17. The Hypoxia Signalling – Coagulation Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 18. The Hypoxia Signalling – DNA Damage Signalling & Repair Gene Profile of Significant Differential Fold Changes 
(log2(FC)). 
 
Egln3 P4hb Tp53 Apex1 P4ha1 Nfkb1
Day −1 A{−1} R{−1}
A{−1} −1.98* 0.51   −0.83  
R{−1} −2.10*    −0.95  
A{−1} −1.49* 0.80* 0.44* 0.30   
R{−1} −1.62* 0.61* 0.44* 0.27   
A{−1} −0.88* 0.50     
R{−1} −1.00*      
C{01} 1.09*    0.96  
H{01} 0.61      
A{−1}  0.60 0.36    
R{−1}  0.41 0.36    
C{01} 2.18*      
A{−1}  0.49     
H{01} 1.33*  −0.39 −0.37*   
C{03}   −0.31    
R{−1}      −0.30
E{01} 0.88   −0.29   
C{07}   −0.37    
A{−1} C{07}  0.36     
A{−1}     −0.80  
R{−1} −0.64    −0.92  
H{01} 0.97* −0.73* −0.31    
H{03}  −0.42   −0.67  
E{01} 0.78 −0.39     
H{07}     0.89  
R{−1} C{14} −0.61    −0.64  
R{−1} −0.66      
H{01} 0.95* −0.55* −0.28    
E{01} 0.68 −0.45 −0.42*    
E{07}   −0.28    
C{14}     0.65  
H{14}   −0.34    
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected). Positive fold change values are in white letters on
dark background. Genes within this pathway line with no significant differential expression are:
Cdkn2a, Egln1.
Day 1
C{01}
Day 3
C{03}
Day 7
E{07}
H{01}
E{01}
E{03}
H{03}
Day 14
H{14}
H{07}
E{14}
Timing R
e
fe
re
n
c
e
O
b
je
c
ti
v
e Gene (Symbol)
Anxa2 Plau Serpine1 Aldoa F10 F3
Day −1 A{−1} R{−1}
A{−1}  0.69 1.21  0.27  
R{−1}   1.16    
A{−1} 1.33* 1.05* 1.99*    
R{−1} 0.99 0.73 1.94* −0.45   
A{−1} 1.09* 1.29* 2.24*    
R{−1} 0.76 0.97* 2.20*    
C{01}  0.60 1.03    
A{−1} 0.87  0.97    
R{−1}   0.92    
C{01}    0.54   
A{−1} 0.83 0.56  0.41   
H{01}   −1.51* 0.68*   
A{−1} 0.82 0.56 1.85*    
R{−1}   1.80    
E{01}  −0.72     
H{03}   1.37    
C{03} C{07}   −0.97    
H{01} −1.32* −0.66 −1.59*    
H{03} −0.81   −0.44   
A{−1}  0.57 1.14    
R{−1}   1.09    
E{01} −1.12* −0.71 −1.1    
E{03} −0.84      
C{07}   1.14    
R{−1} C{14}      −0.74
H{01} −1.22* −0.81* −1.44*    
H{03} −0.72   −0.49   
A{−1}   1.02    
R{−1}   0.97    
E{01} −1.27* −0.94* −1.22    
E{03} −1.00   −0.41 −0.26  
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected). Positive fold change values are in white letters on
dark background. Genes within this pathway line with no significant differential expression are:
Slc16a.
Day 14
H{01}
Day 1
C{01}
E{01}
Day 3
C{03}
H{03}
E{07}
Day 7
E{03}
H{07}
H{14}
E{14}
Timing R
e
fe
re
n
c
e
O
b
je
c
ti
v
e Gene (Symbol)
Mif Ndrg1 Ruvbl2
Day −1 A{−1} R{−1}
R{−1} C{01} −0.27   
A{−1} −0.32   
R{−1} −0.42*   
C{01}  0.48  
A{−1}   −0.23
R{−1} −0.30   
R{−1} −0.25   
H{01}  −0.52  
H{03}  −0.46  
E{01} E{07} 0.23 −0.55  
H{07} 0.22   
R{−1} −0.23   
E{01}  −0.60  
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
E{01}
Day 1
Day 3 E{03}
Day 7
H{07}
Day 14 H{14}
Fold change values marked with an asterisk and in boldface
letters are significant (p≤0.05) with an adjusted p-value (false 
discovery rate corrected). Positive fold change values are in
white letters on dark background. Genes within this pathway
line with no significant differential expression are:
LOC367198.
Timing
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Table ApxD - 19. The Hypoxia Signalling – Metabolism Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 20. The Hypoxia Signalling – Regulation of Apoptosis Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Pdk1 Pfkl Ero1l Hk2 Pgam1 Slc2a1 Aldoa Ldha Pkm Ddit4 Pgm2 Pfkp Gpi Gys1 Tpi1
Day −1 A{−1} R{−1}
A{−1} −0.39 −0.84*    −0.67  −0.5 −0.54 1.18*     −0.28
R{−1} −0.60* −0.62*    −0.85  −0.49 −0.39 0.72      
A{−1} −0.58* −0.43*       −0.54*       
R{−1} −0.78*      −0.45  −0.39       
C{01}  0.41   0.61 0.70    −0.70      
A{−1} −0.72* −0.48*  0.54*  0.75   −0.41       
R{−1} −0.93*   0.39            
C{01}  0.36  0.67* 0.60 1.42*    −0.91      
H{01}    0.47  0.72          
R{−1} −0.40               
C{01}  0.57*  0.38  0.61 0.54 0.79* 0.56 −0.74    0.40  
A{−1}       0.41         
H{01} 0.6*    −0.51  0.68* 0.42 0.41       
A{−1}  −0.34        0.83      
E{01} 0.59*   −0.49  −1.23*    0.57 −0.40     
A{−1}  −0.40  −0.42            
R{−1}    −0.57  −0.62          
C{03} 0.34   −0.67            
A{−1}  −0.42  −0.69  −0.58          
R{−1}    −0.85*  −0.77     −0.43     
H{01} 0.58*  −0.60* −0.77* −0.66* −0.62     −0.39     
C{07}   −0.40             
A{−1}          0.60      
R{−1}      −0.65     −0.48     
E{01} 0.85*   −0.66*            
H{03}   −0.49 −0.70   −0.44 −0.40        
E{03}      −0.70          
H{07}    0.57            
A{−1}  −0.35              
R{−1}      −0.61     −0.37     
A{−1}  −0.43       −0.40       
R{−1}   −0.40 −0.37  −0.70     −0.36 −0.54    
H{01} 0.83*  −0.62*        −0.32     
H{07}    0.47            
A{−1}  −0.39  −0.39    −0.41  0.73 −0.35  −0.29   
R{−1}    −0.54  −0.70  −0.39   −0.54 −0.55    
E{01} 0.86*   −0.93* −0.58 −1.27*     −0.46* −0.49    
H{03}   −0.51    −0.49         
E{03}    −0.44  −0.74 −0.41 −0.41   −0.37     
Gene (Symbol)
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false discovery rate corrected).
Positive fold change values are in white letters on dark background. Genes within this pathway line with no significant differential expression are: Eno1,
Pfkfb3, Pfkfb4, Pfkl, Slc2a3.
E{14}
H{01}
Day 1
C{01}
E{01}
Day 3
C{03}
E{07}
H{07}
E{03}
Day 7
C{07}
H{03}
Day 14
C{14}
H{14}
Timing R
e
fe
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n
c
e
O
b
je
c
ti
v
e
Bnip3 Btg1 Pim1 Mif Ddit4 Ier3 Bnip3l Adm Nos3
Day −1 A{−1} R{−1}
A{−1} −1.52*  0.38  1.18* 1.23    
R{−1} −1.53*  0.36 −0.27 0.72 1.21    
A{−1} −1.40* 0.57* 0.94*       
R{−1} −1.41* 0.46* 0.92*    −0.37   
C{01}  0.35 0.56  −0.7     
A{−1} −1.18* 0.89* 0.99* −0.32  1.01    
R{−1} −1.19* 0.79* 0.98* −0.42*  1.00    
C{01}  0.68* 0.61*  −0.91    0.42
H{01}  0.32       0.36
R{−1}       −0.31   
C{01} 1.26*    −0.74 −0.98    
A{−1}   0.33   0.90    
R{−1}   0.31   0.88    
H{01} 1.12* −0.30 −0.61*    0.30   
A{−1}   0.59*  0.83     
R{−1}   0.58 −0.30      
E{01} 0.79* −0.8* −0.4  0.57    −0.45
C{03}   0.41       
R{−1}    −0.25   −0.34   
H{01} 1.36* −0.69* −0.83*       
H{03}  −0.39     −0.27   
A{−1}   0.43  0.60     
R{−1}   0.41    −0.31 −0.55  
E{01} 1.00* −1.07* −0.56* 0.23    −0.61  
H{07}   0.33     −0.59  
R{−1}       −0.35   
C{07}   −0.41       
A{−1}      0.93    
R{−1}      0.91    
H{01} 1.35* −0.69* −0.8*       
H{03}  −0.39        
H{07}    0.22      
C{14}      0.90    
A{−1}     0.73     
R{−1}    −0.23   −0.32   
E{01} 1.07* −1.01* −0.96*       
E{03}   −0.56       
E{07}   −0.40       
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false
discovery rate corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line
with no significant differential expression are: none.
Day 14
C{14}
E{07}
E{14}
Day 1
C{01}
E{01}
Day 3
C{03}
H{01}
E{03}
H{03}
Day 7
H{07}
H{14}
Timing R
e
fe
re
n
c
e
O
b
je
c
ti
v
e Gene (Symbol)
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Table ApxD - 21. The Hypoxia Signalling – Regulation of Cell Proliferation Gene Profile of Significant Differential Fold Changes 
(log2(FC)). 
 
Table ApxD - 22. The Hypoxia Signalling – Transcription Factors Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Btg1 Pim1 Mxi1 Ccng2 Mif Pgf Odc1 Igfbp3 Met Adm Nampt Nos3
Day −1 A{−1} R{−1}
A{−1}  0.38 −0.37 0.37   −0.73      
R{−1}  0.36 −0.40 0.56* −0.27  −0.77      
A{−1} 0.57* 0.94* −0.47*    −0.68      
R{−1} 0.46* 0.92* −0.50*    −0.72      
C{01} 0.35 0.56  −0.38         
A{−1} 0.89* 0.99* −0.39  −0.32      0.42  
R{−1} 0.79* 0.98* −0.42  −0.42* 0.74       
C{01} 0.68* 0.61*  −0.47  0.59     0.51 0.42
H{01} 0.32 0.56    0.56      0.36
R{−1}        −0.48     
C{01}   0.29          
A{−1}  0.33     −0.58      
R{−1}  0.31     −0.62 −0.51     
H{01} −0.30 −0.61* 0.42          
A{−1}  0.59*     −0.61 −0.45 0.22  0.45  
R{−1}  0.58   −0.30  −0.65 −0.52 0.22    
E{01} −0.80* −0.40    −0.73      −0.45
C{03}  0.41           
A{−1}      −0.63       
R{−1}    0.35 −0.25        
H{01} −0.69* −0.83*       −0.24    
H{03} −0.39            
C{07}  −0.25       −0.25    
A{−1}  0.43           
R{−1}  0.41  0.36      −0.55   
E{01} −1.07* −0.56* 0.31  0.23 −0.73    −0.61   
E{03}         −0.22    
H{07}  0.33        −0.59   
R{−1}    0.41         
C{07}  −0.41           
H{01} −0.69* −0.80* 0.38    0.68      
H{03} −0.39      0.57      
H{07}     0.22 0.55       
A{−1}    0.38         
R{−1}    0.56 −0.23        
E{01} −1.01* −0.96* 0.44* 0.48*  −0.77* 0.65      
E{03}  −0.56  0.41   0.82      
E{07}  −0.40     0.58      
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false discovery rate
corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line with no significant
differential expression are: Blm, Egr1, Txnip.
E{14}
Day 1
C{01}
H{01}
E{01}
Day 3
C{03}
Day 7
H{07}
E{03}
H{03}
E{07}
Day 14
C{14}
H{14}
Timing
Usf2 Bhlhe40 Fos
Day −1 A{−1} R{−1}
A{−1} −0.26   
R{−1} −0.26   
C{01}  0.60  
Day 3 C{01} C{03} 0.28   
R{−1}  0.62  
H{01}   −1.42
E{01} 0.34* −0.62  
E{03} 0.23   
H{07}  −0.67  
H{01} 0.30   
H{03} 0.27   
H{07}  −0.67  
E{01} 0.31   
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e Gene (Symbol)
Timing
E{01}Day 1
Day 7
H{07}
E{07}
Day 14 H{14}
Fold change values marked with an asterisk and in boldface
letters are significant (p≤0.05) with an adjusted p-value (false 
discovery rate corrected). Positive fold change values are in
white letters on dark background. Genes within this pathway
line with no significant differential expression are: Rbpjl.
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Table ApxD - 23. The Hypoxia Signalling – Transporters, Channels & Receptors Gene Profile of Significant Differential Fold Changes 
(log2(FC)). 
 
Table ApxD - 24. The Hypoxia Signalling – Other Responsive Genes Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
  
Tfrc Slc16a3 Slc2a1 Vdac1
Day −1 A{−1} R{−1}
A{−1}  −0.94 −0.67  
R{−1}   −0.85  
A{−1}  −1.78*  −0.40
R{−1}  −1.57*  −0.43
C{01}  −0.83 0.70  
A{−1}  −0.88 0.75  
C{01}   1.42*  
H{01}  0.89 0.72 0.31
A{−1} −1.10   −0.34
R{−1} −0.85   −0.37
C{01} −0.85 0.98 0.61  
A{−1} −1.54*   −0.31
R{−1} −1.29*   −0.34
H{01} −1.12* 1.67*   
A{−1} −0.60    
H{03} 0.94    
A{−1} −0.97    
R{−1} −0.72  −0.62  
A{−1} −1.23  −0.58  
R{−1} −0.98  −0.77  
H{01} −0.81* 1.09* −0.62  
A{−1} −1.34* −0.87   
R{−1} −1.09  −0.65  
E{01} −1.10*  −1.23*  
E{03} −0.74  −0.70  
A{−1} −0.98 −0.97   
R{−1} −0.73  −0.61  
A{−1} −1.19 −1.00   
R{−1} −0.93 −0.79 −0.70  
H{01} −0.77 0.77  0.31
H{03}  −0.89   
A{−1} −1.20 −1.18   
R{−1} −0.94 −0.97 −0.7  
E{01} −0.95*  −1.27*  
E{03} −0.60  −0.74 0.29
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Fold change values marked with an asterisk and in boldface letters are
significant (p≤0.05) with an adjusted p-value (false discovery rate
corrected). Positive fold change values are in white letters on dark
background. Genes within this pathway line with no significant differential
expression are: Slc2a3.
E{07}
Day 1
C{01}
H{01}
Day 3
E{01}
Day 7
C{03}
Day 14
C{14}
H{07}
E{03}
H{03}
C{07}
H{14}
E{14}
Timing
Lgals3 Ctsa Ankrd37 Car9 Dnajc5 Eif4ebp1 Map3k1
Day −1 A{−1} R{−1}
A{−1} 1.79* 1.02* −1. 20* −0.25    
R{−1} 1.17 0.75 −1.03*     
A{−1} 2.51* 1.10* −0.82 −0.24    
R{−1} 1.88* 0.84* −0.64     
A{−1} 2.10* 0.77      
R{−1} 1.47*       
C{01}   0.60     
A{−1} 1.31 0.66      
C{01}   0.72 0.23    
A{−1} 1.49 0.75 −0.65   0.57  
R{−1} 0.87       
H{01} −1.01   0.21    
A{−1} 1.79* 0.55      
R{−1} 1.16       
E{01}     0.31   
C{03} C{07} −0.94       
A{−1} 0.86      −0.49
H{01} −1.64* −0.81*  0.24    
H{03}     −0.26 −0.58  
E{01} −1.47* −0.57      
E{03} −1.16       
A{−1} 1.26       
H{01} −1.24* −0.79*  0.23    
E{01} −1.48* −0.54      
E{03} −1.17    −0.31 −0.45  
O
b
je
c
ti
v
e Gene (Symbol)
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected). Positive fold change values are in white letters on
dark background. Genes within this pathway line with no significant differential expression are: none.
H{14}
H{01}
E{01}
Day 1
C{01}
Day 3
C{03}
E{03}
Day 7
H{07}
E{07}
Day 14
H{03}
E{14}
Timing R
e
fe
re
n
c
e
 Appendices 
211 
  
Appendix D.4.3 The VEGF Pathway 
Table ApxD - 25. The VEGF – Small G-Protein Signalling Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 26. The VEGF – Growth Factors & Receptors Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Nras Raf1 Rac1 Rac2 Shc2 Src Hras
Day −1 A{−1} R{−1}
A{−1} 0.40 −0.52*      
R{−1}  −0.6*      
A{−1} 0.53* −0.39 0.43* 1.14* 0.33   
R{−1} 0.36 −0.47* 0.37 0.92 0.29   
A{−1} 0.53* −0.51* 0.28 1.16*    
R{−1} 0.37 −0.6*  0.94    
A{−1} 0.44  0.29  0.41 0.37  
R{−1}     0.38 0.27  
C{01}  0.45*   0.33   
A{−1}     0.38  −0.51
R{−1}     0.35  −0.38
H{01}  0.32      
E{01} E{03}  0.34  −0.82    
A{−1} C{07}      0.24  
H{01} −0.64* 0.42* −0.40* −1.08*    
H{03} −0.38       
E{01} −0.67* 0.44*  −1.27*    
E{03} −0.46       
A{−1}     0.30   
R{−1}     0.26   
C{14}     0.29   
H{01} −0.53* 0.46* −0.31 −1.22*    
R{−1} −0.36       
E{01} −0.74* 0.39* −0.31 −1.28*    
E{03} −0.52       
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected). Positive fold change values are in white letters on dark
background. Genes within this pathway line with no significant differential expression are: Kras.
Day 1
C{01}
H{01}
Day 3
C{03}
E{01}
H{03}
H{07}
E{07}
Day 7
Day 14
H{14}
E{14}
Timing
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Vegfc Kdr Flt1 Pgf Vegfa Vegfb Pdgfc Figf Nrp1
Day −1 A{−1} R{−1}
A{−1}  −0.70        
R{−1}  −0.49        
A{−1} −0.47 −1.11*   −1.11*     
R{−1} −0.65* −0.90*   −0.62     
C{01} −0.38        −0.37
A{−1} −0.57* −0.59   −0.62     
R{−1} −0.76*  0.39 0.74      
C{01} −0.49   0.59     −0.47
H{01}  0.51 0.41 0.56      
A{−1}  −0.72        
R{−1}  −0.51    2.18    
A{−1}  −0.85 −0.38  −1.02 2.19    
R{−1}  −0.64    2.43    
H{01} 0.36         
A{−1}  −0.76   −0.98     
R{−1} −0.39 −0.55        
C{03}      −3.18    
H{03}      −3.43    
E{01} 0.36  −0.45 −0.73  −2.91    
A{−1}  −0.56 −0.33 −0.63  2.20    
R{−1} −0.46     2.44    
H{01}  0.55        
A{−1} −0.61         
R{−1} −0.80*         
C{07} −0.64         
E{01}   −0.37 −0.73      
E{03} −0.40    0.91 3.07    
R{−1} C{14}       −0.25   
R{−1}      2.31    
C{14}       0.24   
H{01} 0.51* 0.88*   0.68   −0.34  
H{03}  0.62   0.59     
H{07}    0.55    −0.37  
R{−1} −0.52         
C{14}       0.26   
H{14} −0.38         
E{01}   −0.52* −0.77*      
E{03}     0.62 3.15    
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false
discovery rate corrected). Positive fold change values are in white letters on dark background. Genes within this pathway
line with no significant differential expression are: Flt4, Nrp2.
E{03}
H{03}
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Day 1
C{01}
H{01}
E{01}
Day 3
C{03}
E{07}
Day 7
H{07}
Day 14
H{14}
E{14}
Timing
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Table ApxD - 27. The VEGF – Akt & PI-3-Kinase Signalling Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 28. The VEGF – Heat Shock Proteins Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Pik3r1 Pik3ca Akt2 Pik3r3 Pik3r2 Akt3 Pik3r5 Akt1 Pik3cb Pik3cd
Day −1 A{−1} R{−1}
A{−1} 0.92* −0.79* −0.45    −0.41    
R{−1} 0.84* −0.67* −0.5    −0.38    
A{−1}  −0.79* −0.51*        
R{−1}  −0.67* −0.55*        
C{01}       0.34    
A{−1} 1.18* −0.63* −0.44  −0.44      
R{−1} 1.09* −0.51* −0.48  −0.33   −0.43   
C{01}    −0.59 −0.58*      
H{01} 0.67    −0.38      
C{01} C{03} −0.82* 0.52* 0.55*        
A{−1}  −0.41         
H{01} −0.60 0.38         
A{−1}  −0.34         
R{−1}        −0.48   
C{03}   −0.36  −0.43      
H{03}     −0.34      
E{01} −1.00*          
A{−1}  −0.30  0.50       
R{−1}      −0.34     
H{01}  0.49* 0.49* 0.63*  −0.36   −0.29  
H{03}    0.53  −0.35    −0.31
C{07} 0.52    −0.38      
H{07}    −0.52       
E{01} −0.85* 0.34         
A{−1}  −0.34         
R{−1}      −0.31     
A{−1}  −0.40         
R{−1}      −0.33     
H{01} −0.76* 0.39 0.44 0.47  −0.34     
H{03}      −0.34     
H{07} −0.49          
A{−1}  −0.34         
H{14} 0.59          
E{01} −0.85*          
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false
discovery rate corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line with
no significant differential expression are: Pik3cg.
E{03}
E{07}
Day 1
C{01}
H{01}
E{01}
H{03}
Day 3
Day 7
H{07}
C{14}
H{14}
Day 14
E{14}
Timing
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Hspb1 Hsp90aa1
Day −1 A{−1} R{−1}
A{−1} 0.84*  
R{−1} 0.70  
C{01}  0.89
A{−1} 0.72 1.08*
R{−1} 0.58 0.93
C{01}  1.35*
H{01} H{03} −0.58  
A{−1} 0.64 0.80
C{03}  0.94
H{03}  0.83
C{03} C{07} −0.64  
A{−1}  −0.91
R{−1}  −1.06
H{01} −1.01* −1.54*
H{03}  −0.88
H{07}  1.04
E{01} −0.91* −0.95
E{03} −0.84  
H{01} −1.24* −1.15*
H{03} −0.65  
A{−1} −0.68  
R{−1} −0.82  
E{01} −1.41* −0.93
E{03} −1.33*  
Gene (Symbol)
Day 14
Fold change values marked with an asterisk and in
boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected).
Positive fold change values are in white letters on
dark background. Genes within this pathway line
with no significant differential expression are: none.
Day 1
H{01}
E{01}
E{03}
Day 7
H{07}
Day 3
E{07}
E{14}
H{14}
Timing R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
 Appendices 
213 
  
Table ApxD - 29. The VEGF – MAP Kinase Signalling Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 30. The VEGF – Nfat Signalling Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 31. The VEGF – Phospholipase A2 & C Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Map2k1 Mapk11 Mapk14 Mapkapk3 Mapk3
Day −1 A{−1} R{−1}
A{−1}  −0.52* −0.29   
R{−1}  −0.40    
A{−1} 0.53* −0.67*    
R{−1} 0.47* −0.55*    
C{01} 0.49     
A{−1}  −0.70*    
R{−1}  −0.58*    
H{01} −0.29     
A{−1}  −0.70* −0.29   
R{−1}  −0.58  0.45  
A{−1}  −0.62 −0.27   
R{−1}  −0.50    
H{01} −0.36     
A{−1}  −0.62* −0.36   
R{−1}  −0.50    
C{03}    −0.43  
E{01}   −0.33   
A{−1}  −0.46    
R{−1}  −0.35    
A{−1}  −0.48 −0.32   
R{−1}  −0.36    
H{01} −0.46*     
A{−1}  −0.55 −0.33   
R{−1}  −0.44    
E{01}   −0.29   
A{−1}  −0.64  −0.51  
R{−1}  −0.53    
C{14}  −0.33    
H{01} −0.39*     
H{03}    −0.46  
A{−1}  −0.56    
R{−1}  −0.44    
H{14}     −0.29
E{01} −0.29     
E{03} −0.28     
Fold change values marked with an asterisk and in boldface letters are significant
(p≤0.05) with an adjusted p-value (false discovery rate corrected). Positive fold change
values are in white letters on dark background. Genes within this pathway line with no
significant differential expression are:  Map2k2, Mapk11, Mapk12, Mapk13, Mapkapk2.
H{07}
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Day 1
C{01}
H{01}
E{01}
Day 3
C{03}
H{03}
Day 7
C{07}
E{03}
Day 14
H{14}
E{07}
E{14}
Timing
Gene (Symbol)
Nfatc2 Nfatc3 Nfatc4
Day −1A{−1}R{−1}
A{−1} C{01} −0.36   
A{−1}H{01}   0.38
C{01} 0.46   
H{01} 0.33   
A{−1} C{03}   0.42
A{−1}H{03}   0.52
A{−1}   0.50
C{03} 0.38   
Day 7 H{03} H{07}  −0.35  
E{01} −0.39   
E{03} −0.36  −0.56
Fold change values marked with an asterisk and in boldface letters 
are significant (p≤0.05) with an adjusted p-value (false discovery
rate corrected). Positive fold change values are in white letters on
dark background. Genes within this pathway line with no
significant differential expression are: Nfat5, RGD1560225.
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e Gene (Symbol)
Timing
Day 1
E{01}
Day 3
E{03}
Day 14 E{14}
Pla2g2d Pla2g2e Pla2g1b Pla2g6 Pla2g12a Pla2g2a Pla2g4a Pla2g3 Pla2g5 Pla2g2f Pla2g10
Day −1 A{−1} R{−1} 0.85           
A{−1} 1.33*  −0.39*     −0.36    
R{−1}   −0.34     −0.29    
A{−1} 2.05*  −0.37*  −0.92 1.29  −0.33    
R{−1} 1.20  −0.32     −0.26    
C{01}            
A{−1} 1.53*  −0.26 −0.2 −1.10* 1.30 0.53     
R{−1}     −0.71       
C{01}    −0.2        
A{−1} 1.67  −0.29 0.22 −0.77   −0.33    
R{−1}    0.33    −0.26    
C{01}    0.22        
A{−1} 1.98*   0.19 −0.93   −0.26    
R{−1} 1.13   0.31        
C{03}          0.50  
H{01}    0.34*        
A{−1} 1.65*     1.33 0.53     
R{−1}           −0.23
C{03}    −0.22  1.20      
H{03}    −0.19        
E{01}    0.20        
A{−1} 0.85           
R{−1}    0.24        
C{03} −0.82           
A{−1} 0.94    −0.83       
R{−1}    0.24     −0.26   
C{07}         −0.33   
H{01} −1.11  0.22 0.27*  −1.42 −0.65     
H{03} −1.03      −0.55   −0.33  
R{−1}    0.20        
C{07}         −0.29   
E{01}  0.34*  0.29*  −1.27 −0.58     
E{03} −0.84 0.28    −1.30 −0.58     
A{−1} 0.99  −0.24         
R{−1}    0.21        
C{07}         −0.30   
A{−1} 1.05           
R{−1}           −0.23
H{01} −1.00 0.22 0.26 0.21  −1.08 −0.62     
H{03} −0.92 0.23     −0.52   −0.42  
E{01} −0.95   0.20 0.80 −1.14      
E{03} −1.07     −1.17      
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false discovery
rate corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line with no significant
differential expression are: Pla2g12b, Pla2g4b, Plcg1, Plcg2.
H{03}
Gene (Symbol)
Timing R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Day 1
C{01}
H{01}
Day 3
C{03}
E{01}
E{03}
Day 7
C{07}
H{07}
E{07}
Day 14
C{14}
H{14}
E{14}
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Table ApxD - 32. The VEGF – Protein Kinase C Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 33. The VEGF – Protein Phosphatases Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 34. The VEGF – Transcription Factors Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Prkca Prkcb
Day −1 A{−1} R{−1}
A{−1} −0.58* 0.89
R{−1} −0.70*  
A{−1} −0.68* 0.92
R{−1} −0.81*  
A{−1} −0.47* 0.86
R{−1} −0.59*  
C{01} C{03} 0.45  
R{−1} −0.39  
H{01} 0.41  
R{−1} −0.31  
E{01} 0.28  
A{−1} −0.3  
R{−1} −0.43  
R{−1} −0.35  
H{01} 0.45* −0.95
H{03}  −0.82
R{−1} −0.36  
E{01}  −0.90
R{−1} C{14} −0.38  
A{−1} −0.36  
R{−1} −0.48  
H{01} 0.32  
A{−1} −0.52  
R{−1} −0.64  
E{01}  −1.07
E{03} −0.33 −0.94
Fold change values marked with an asterisk and in
boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected).
Positive fold change values are in white letters on
dark background. Genes within this pathway line
with no significant differential expression are: Prkcg.
H{14}
O
b
je
c
ti
v
e
Day 1
C{01}
H{01}
Day 3
E{01}
H{03}
Day 7
C{07}
E{03}
E{07}
H{07}
Day 14
E{14}
Timing
Gene (Symbol)
R
e
fe
re
n
c
e
Ppp3cc Ppp3r1 Ppp3cb Ppp3ca Ppp3r2
Day −1 A{−1} R{−1}
A{−1}   −0.55   
R{−1}  0.50    
A{−1}   −0.49 −0.33  
C{01}  −0.44    
R{−1} −0.25     
C{01}  −0.46    
C{01} C{03}  −0.45    
C{03} H{03}     −0.25
A{−1} −0.32     
R{−1} −0.34     
H{03} −0.26     
H{07} E{07} 0.22     
Fold change values marked with an asterisk and in boldface letters are significant
(p≤0.05) with an adjusted p-value (false discovery rate corrected). Positive fold change
values are in white letters on dark background. Genes within this pathway line with no
significant differential expression are: none.
O
b
je
c
ti
v
e Gene (Symbol)
Timing R
e
fe
re
n
c
e
Day 1
C{01}
H{01}
E{01}
Day 3
Day 7
H{07}
Arnt Nfatc2 Nfatc4 Hif1a Nfatc3
Day −1 A{−1} R{−1}
A{−1} −0.30 −0.36  −1.11  
R{−1} −0.22     
A{−1} H{01}   0.38   
C{01} 0.37* 0.46  1.32  
H{01}  0.33    
A{−1}   0.42   
C{01} 0.22     
A{−1} H{03}   0.52   
A{−1}   0.50   
C{03}  0.38    
A{−1} C{07} −0.23     
A{−1} −0.24     
H{03} −0.20    −0.35
C{07} 0.26     
H{07} 0.27     
A{−1} C{14} −0.22     
A{−1} −0.36     
R{−1} −0.28     
H{01} −0.23     
H{03} −0.31     
C{14} 0.25     
H{14} 0.38     
E{01}  −0.39    
E{03}  −0.36 −0.56   
Fold change values marked with an asterisk and in boldface letters are significant
(p≤0.05) with an adjusted p-value (false discovery rate corrected). Positive fold change
values are in white letters on dark background. Genes within this pathway line with no
significant differential expression are:  Nfat5, RGD1560225.
H{14}
H{07}
E{14}
Gene (Symbol)
Timing R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Day 1
C{01}
C{03}
E{01}
Day 3
Day 7
E{03}
E{07}
Day 14
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Table ApxD - 35. The VEGF – Apoptosis & Cell Cycle Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 36. The VEGF – Cell Motility, Migration & Morphology Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 37. The VEGF – Other Related Genes Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
  
Bad Casp9
Day −1 A{−1} R{−1}
A{−1} 0.24 0.30
R{−1} 0.30  
A{−1} 0.35* 0.26
R{−1} 0.41*  
R{−1} E{01} 0.24  
R{−1} C{03} 0.21  
A{−1} 0.21  
R{−1} 0.27  
R{−1} C{07} 0.24  
H{01} H{07} −0.23  
A{−1} C{14}  0.22
A{−1} 0.29  
R{−1} 0.35  
C{14} 0.19  
R{−1} E{14} 0.24  
Fold change values marked with an asterisk and in
boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected).
Positive fold change values are in white letters on
dark background. Genes within this pathway line
with no significant differential expression are:
Cdc42.
H{14}
Gene (Symbol)
Timing R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
C{01}
H{01}
Day 1
H{03}
Day 7
Day 3
Day 14
Ptk2 Pxn
Day −1 A{−1} R{−1}
C{01}  −0.23
−0.33*  
−0.28  
−0.31*  
−0.25  
Day 3 H{01} H{03} 0.20  
H{01} 0.28*  
H{07}  0.24
Day 1
H{01}
Day 14 H{14}
Fold change values marked with an asterisk and in
boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected).
Positive fold change values are in white letters on
dark background. Genes within this pathway line
with no significant differential expression are: none.
E{01}
Timing
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Grb2 Sh2d2a Cav1 Sphk2 Nos3 Ptgs2
Day −1 A{−1} R{−1}
A{−1} 0.42* 0.30     
R{−1} 0.37* 0.25     
A{−1} 0.35* 0.47* −0.33    
R{−1} 0.29 0.42* −0.39    
C{01}   −0.39    
A{−1} 0.31 0.26     
R{−1} 0.26  −0.31    
C{01}   −0.31  0.42  
H{01}     0.36  
A{−1} 0.24      
R{−1}    0.24   
A{−1}  0.34     
R{−1}  0.30  0.24   
E{01} E{03} −0.23    −0.45  
R{−1}   −0.29    
C{03} −0.21      
A{−1}   −0.38    
R{−1}   −0.43    
H{01} −0.28 −0.35*     
A{−1}   −0.50    
R{−1}   −0.56* 0.29   
E{03}   −0.28    
R{−1} C{14}    0.37   
A{−1}  0.39     
R{−1}  0.35  0.37   
C{14}  0.38     
H{01} −0.30*      
H{07}  0.27     
A{−1}   −0.36    
R{−1}   −0.42 0.34   
C{14}   −0.28   0.22
H{14}  −0.35     
E{01} −0.32*      
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected). Positive fold change values are in white letters on
dark background. Genes within this pathway line with no significant differential expression are: Sphk1.
C{07}
H{03}
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Day 1
C{01}
H{01}
E{01}
Day 3
C{03}
Day 7
H{07}
Day 14
H{14}
E{07}
E{14}
Timing
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Appendix D.4.4 The Wound Healing Pathway 
Table ApxD - 38. The Wound Healing Extracellular Matrix & Cell Adhesion – Remodelling Enzymes Gene Profile of Significant 
Differential Fold Changes (log2(FC)). 
 
 
Table ApxD - 39. The Wound Healing Extracellular Matrix & Cell Adhesion – ECM Components Gene Profile of Significant 
Differential Fold Changes (log2(FC)). 
 
Plaur Ctsl1 F13a1 Plau Mmp7 Fga Ctsk Mmp2 Ctsg F3 Plg
Day −1 A{−1} R{−1}   1.08  0.92       
A{−1}   1.49* 0.69        
R{−1}     −0.84*       
A{−1} 0.96* 0.90* 1.81* 1.05*        
R{−1} 0.90* 0.60  0.73 −0.76*       
C{01} 0.51 0.54          
A{−1} 1.38* 0.75 1.54* 1.29*  0.45      
R{−1} 1.33*   0.97* −0.79* 0.48      
C{01} 0.93*   0.60  0.54      
H{01}      0.55      
A{−1}   1.07         
R{−1}     −1.05       
A{−1}   1.50 0.56   0.76 0.87    
R{−1}     −1.06*       
H{01} −0.70 −0.50     0.67     
A{−1} 0.71  1.44 0.56        
R{−1} 0.66    −0.57       
C{03}     0.48       
H{03}     0.48       
E{01} −0.66   −0.72  −0.39      
A{−1}       0.80 0.83    
R{−1}     −1.07*       
C{03}            
R{−1}     −0.84       
H{01} −1.12* −0.98* −1.42* −0.66        
H{03}   −1.11         
A{−1}    0.57        
R{−1}     −0.78       
C{07}            
E{01} −1.14* −0.88* −1.12 −0.71  −0.41      
E{03}   −1.02         
A{−1}     0.58       
R{−1}          −0.74  
C{07}     0.73  −0.83     
R{−1}     −0.48       
C{14}         −0.25   
H{01} −0.88* −0.96* −1.20* −0.81*        
H{03}   −0.89  0.57       
A{−1}      0.51      
R{−1}  −0.58   −0.59 0.54      
C{14}      0.54      
H{14}      0.55     −0.63
E{01} −1.27* −1.04* −1.30* −0.94*        
E{03} −0.60 −0.58 −1.21   0.45 −0.64     
E{07}      0.47      
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false discovery rate
corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line with no significant differential
expression are: Mmp1, Mmp9, Plat, Serpine1, Timp1.
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
H{01}
C{01}
E{01}
H{03}
Day 3
C{03}
Day 7
Day 14
C{14}
H{14}
E{14}
Day 1
Timing
H{07}
E{03}
C{07}
E{07}
Col14a1 Col4a1 Col1a2 Col5a2 Col5a1 Col3a1 Col1a1 Col5a3 Col4a3 Vtn
Day −1 A{−1} R{−1}   0.87        
A{−1} C{01}  0.41         
A{−1}         −0.22  
R{−1}          −0.43
C{01}          −0.49
A{−1} 0.79  1.04 1.12 0.97 1.07 1.17    
R{−1}    0.82 0.71   0.72   
C{01} 0.57    0.60   0.87   
A{−1} 0.95  1.38 1.21 0.93 1.19 1.48    
R{−1} 0.59   0.91 0.68      
H{01} 0.86*  1.09   0.76 1.05    
A{−1} 0.62  1.45 0.99  1.07 1.12    
C{03}        −0.81   
E{01} 0.62  0.98        
A{−1} C{07} 0.75    0.66  1.15    
A{−1} 0.59          
H{01}  −0.52         
H{03}    −0.77       
C{07}         0.22  
E{01}  −0.63*         
E{03}  −0.37 −1.25 −0.81  −0.85     
R{−1}   −0.96        
C{07} −0.53  −0.99  −0.61      
A{−1}  −0.39         
R{−1}  −0.44         
H{01}  −0.66*         
H{03} −0.58   −1.02 −0.77 −1.00     
A{−1}  −0.56         
R{−1}  −0.61         
E{01}  −0.86*  −0.77       
E{03} −0.59 −0.60 −1.37 −1.18 −0.77 −1.06 −0.97    
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false
discovery rate corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line with
no significant differential expression are: none.
H{03}Day 3
C{03}
H{01}
Day 1
E{03}
E{07}
E{14}
Timing
Day 14
C{14}
H{14}
Day 7
H{07}
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Table ApxD - 40. The Wound Healing Extracellular Matrix & Cell Adhesion – Cellular Adhesion Gene Profile of Significant 
Differential Fold Changes (log2(FC)). 
 
Table ApxD - 41. The Wound Healing Extracellular Matrix & Cell Adhesion – Cytoskeleton Gene Profile of Significant Differential 
Fold Changes (log2(FC)). 
 
Table ApxD - 42. The Wound Healing – Inflammatory Cytokines & Chemokines Gene Profile of Significant Differential Fold 
Changes (log2(FC)). 
 
Itga1 Itgb1 Itga6 Cdh1 Itga5 Itgb5 Itga4 Itgb3
Day −1 A{−1} R{−1}      1.44   
A{−1}  2.91*   1.75 1.94   
R{−1}  2.59*  −2.23     
A{−1} −1.62* 2.33* −1.67* −2.36 2.00    
R{−1} −1.97* 2.01  −2.68 1.58    
C{01} −1.41  −1.66      
A{−1}  1.64 −1.62*  1.96  4.79 1.05
R{−1}    −2.13   5.33  
C{01}   −1.61   −1.67   
H{01} 1.35        
A{−1}  2.25   2.70 2.36   
R{−1}  1.93   2.28    
C{01}    1.92     
A{−1}  1.62 −1.68 −2.69 1.79 2.67  1.21
R{−1}    −3.01     
C{03}    −2.71     
H{01} 1.60     1.51   
A{−1}   −1.81 −2.4 2.24 1.77  1.16
R{−1}    −2.73 1.82    
C{03}    −2.42     
E{01}      1.51 −3.93  
A{−1}      2.08   
R{−1}    −2.21     
C{03}    −1.90 −1.61    
A{−1}   −1.45 −2.41     
R{−1}    −2.74     
H{01} 1.43        
R{−1} −1.29        
C{07}      −1.51   
E{01}       −4.08 −1.08
E{03}   0.97     −1.18
A{−1} C{14}   −1.13      
A{−1}   −1.17 −2.97    1.05
R{−1}    −3.3     
H{01} 1.66*        
H{03}      −1.59   
A{−1}   −1.21      
R{−1}    −2.12     
C{14}       4.33  
E{01}  −1.49   −1.90    
E{03}     −2.18   −0.94
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false 
discovery rate corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line 
with no significant differential expression are: Itga2, Itga3, Itgav, Itgb6.
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e Gene (Symbol)
H{01}
Day 1
C{01}
E{01}
E{03}
Day 3
C{03}
H{03}
H{07}
E{07}
Day 14
H{14}
E{14}
Timing
Day 7
C{07}
Rac1 Actc1 Tagln
Day −1 A{−1} R{−1}  4.76 1.53
A{−1} C{01}  4.92  
A{−1} 1.74* 5.03  
R{−1} 1.51  −1.59
A{−1} 1.14   
R{−1}   −1.64
A{−1} C{03} 1.17 4.21 1.84
A{−1}  5.07 1.42
H{01}   1.48
A{−1}  7.09  
E{01}  4.34  
H{01} H{07} −1.63*   
R{−1}   −1.68
E{03}  −5.44  
R{−1} C{14}  −5.58  
H{01} −1.25 −4.21  
H{03}  −4.25  
E{01} −1.26   
E{03}  −5.82  
Fold change values marked with an asterisk and in boldface letters
are significant (p≤0.05) with an adjusted p-value (false discovery rate 
corrected). Positive fold change values are in white letters on dark
background. Genes within this pathway line with no significant
differential expression are: Acta2, Rhoa.
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e Gene (Symbol)
Day 1
E{01}
Day 3
H{03}
H{01}
Day 7
E{14}
E{07}
E{03}
Timing
Day 14
H{14}
Ccl7 Ccl12 Il6 Il1b Cxcl3 Il10 Cxcl1 Ifng Il4
Day −1 A{−1} R{−1}
A{−1} 10.47* 5.27        
R{−1} 8.04         
C{01} 6.90 4.92        
A{−1} 13.85* 7.40* 4.25* 4.74* 3.51 1.18    
R{−1} 11.42* 6.07 4.02* 3.07 3.83     
C{01} 10.28* 7.05* 3.64 3.36 3.47 1.26    
H{01}   3.00       
C{03}         −0.72
H{01} −8.69*         
C{03}       4.07 0.72  
H{03}        0.65  
E{01} −11.41* −7.60* −3.59 −3.35 −3.13     
C{03} C{07}         −0.72
H{01} H{07} −11.58* −6.21*  −3.02 −2.54     
E{01} E{07} −13.44* −8.73* −3.93* −3.63 −3.86* −1.12 −4.21   
H{01} H{14} −11.03* −6.73*        
E{01} −13.40* −9.21* −4.18* −4.21* −3.29 −1.22 −4.13   
E{03}        −0.66  
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false
discovery rate corrected). Positive fold change values are in white letters on dark background. Genes within this pathway
line with no significant differential expression are:  Cd40lg,  Cxcl11, Cxcl5, Il2.
E{01}
E{03}
E{14}
Day 7
Day 3
H{03}
Day 1
H{01}
Timing
Day 14
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Table ApxD - 43. The Wound Healing – Growth Factors Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 44. The Wound Healing Signal Transduction – TGF Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Table ApxD - 45. The Wound Healing Signal Transduction – WNT Gene Profile of Significant Differential Fold Changes (log2(FC)). 
 
Pdgfa Csf3 Hbegf Mif Fgf7 Hgf Angpt1 Fgf2 Fgf10 Ctgf Igf1
Day −1 A{−1} R{−1}
A{−1} −1.49 −3.12*    1.25      
R{−1} −1.26 −2.47*  −1.09  1.10 2.28     
A{−1}            
R{−1}            
C{01}  1.99 3.96    −1.80  1.06   
A{−1} 1.34   −1.29        
R{−1} 1.56   −1.70*    2.01    
C{01} 2.83* 3.14* 4.20         
H{01} 2.04           
A{−1}  −2.22    1.09      
R{−1}  −1.57    0.93      
C{01}            
A{−1}            
R{−1}        2.36    
H{01}         −0.97   
A{−1}            
R{−1}    −1.22    1.80    
C{03}  2.07          
E{01} −2.18*           
A{−1}  −2.33   1.50       
R{−1}  −1.68   1.51       
A{−1}     1.58       
R{−1}   −4.18 −1.02 1.58       
H{01}   −4.44         
H{03}      −0.95      
R{−1}   −4.36    2.11     
C{07}  1.92          
E{01} −2.45*  −4.86 0.93        
E{03}   −4.57         
A{−1}  −2.01   1.62       
R{−1}     1.62  2.08     
A{−1}     1.76       
R{−1}   −5.21  1.77       
H{01}   −5.47*       4.48  
H{03}      −1.04      
H{07}    0.91        
A{−1}     2.66       
R{−1}   −5.52 −0.93 2.67  2.28 2.01   −2.30
C{14}  1.58          
E{01} −1.69*  −6.02*  1.95       
E{03}   −5.74  1.79       
E{07}     1.83       
Fold change values marked with an asterisk and in boldface letters are significant (p≤0.05) with an adjusted p-value (false discovery rate
corrected). Positive fold change values are in white letters on dark background. Genes within this pathway line with no significant differential
expression are: Csf2, Egf, Tgfa, Tgfb1, Tnf, Vegfa.
R
e
fe
re
n
c
e Gene (Symbol)
O
b
je
c
ti
v
e
H{01}
E{01}
E{03}
Day 3
C{03}
C{01}
Day 14
C{14}
H{14}
Day 7
C{07}
E{14}
E{07}
H{07}
H{03}
Timing
Day 1
Tgfb1 Stat3
Day −1 A{−1} R{−1}
A{−1} 2.87*  
R{−1} 1.99  
A{−1} 3.46*  
R{−1} 2.58* 1.94
A{−1} 2.25 2.14*
R{−1}  2.69*
C{01}  1.87
A{−1} 2.80  
R{−1} 1.92  
A{−1} 2.22  
H{01}  −1.68
A{−1} 2.45  
E{01}  −1.61
H{01} H{07} −2.61* −1.81
E{01} E{07}  −2.00
H{01} H{14} −2.33* −1.54
E{01} −2.21 −2.62*
E{03} −2.42  
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
H{03}
Fold change values marked with an asterisk and in
boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected).
Positive fold change values are in white letters on
dark background. Genes within this pathway line
with no significant differential expression are: Tgfbr3.
Day 3
C{03}
Day 1
C{01}
H{01}
E{01}
E{03}
E{14}
Day 7
Timing
Day 14
Wnt5a Wisp1
Day −1 A{−1} R{−1}
A{−1} −1.91*  
R{−1} −1.81*  
C{01} −1.68  
A{−1} −1.38  
R{−1} −1.29  
C{01} −1.15  
A{−1} C{03}  3.82
A{−1} H{03} −1.11  
A{−1} −1.33  
R{−1} −1.23  
Day 7 A{−1} H{07} −1.07  
C{07} C{14}  −3.06
A{−1} H{14} −1.06  
Fold change values marked with an asterisk and in
boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected).
Positive fold change values are in white letters on
dark background. Genes within this pathway line
with no significant differential expression are:
Ctnnb1.
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e Gene (Symbol)
Day 3
Day 1
H{01}
E{01}
E{03}
Day 14
Timing
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Table ApxD - 46. The Wound Healing Signal Transduction – Phosphorylation Gene Profile of Significant Differential Fold Changes 
(log2(FC)). 
 
Table ApxD - 47. The Wound Healing Signal Transduction – Receptors Gene Profile of Significant Differential Fold Changes 
(log2(FC)). 
 
The Wound Healing Signal Transduction – Other Related Gene Profile of Ptgs2 did not demonstrate any 
significant differential fold changes. 
Pten Mapk3
Day −1 A{−1} R{−1}
Day 3 C{01} C{03} −1.24  
R{−1} −1.19  
H{01} −1.13  
R{−1} C{14} −1.07  
H{14} E{14}  −1.16
Fold change values marked with an asterisk and in
boldface letters are significant (p≤0.05) with an
adjusted p-value (false discovery rate corrected).
Positive fold change values are in white letters on
dark background. Genes within this pathway line
with no significant differential expression are:
Mapk1.
Gene (Symbol)
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Timing
H{07}
Day 14
Day 7
Gene (Symbol)
Il6st
Day −1 A{−1} R{−1}
Day 7 R{−1} H{07} −1.23
Fold change values marked with an asterisk
and in boldface letters are significant
(p≤0.05) with an adjusted p-value (false
discovery rate corrected). Positive fold
change values are in white letters on dark
background. Genes within this pathway line
with no significant differential expression
are: Egfr.
R
e
fe
re
n
c
e
O
b
je
c
ti
v
e
Timing
